WO2002046189A2 - Aryl ether substituted imidazoquinolines - Google Patents

Aryl ether substituted imidazoquinolines Download PDF

Info

Publication number
WO2002046189A2
WO2002046189A2 PCT/US2001/046581 US0146581W WO0246189A2 WO 2002046189 A2 WO2002046189 A2 WO 2002046189A2 US 0146581 W US0146581 W US 0146581W WO 0246189 A2 WO0246189 A2 WO 0246189A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
imidazo
aryl
alkenyl
quinolin
Prior art date
Application number
PCT/US2001/046581
Other languages
French (fr)
Other versions
WO2002046189A3 (en
Inventor
Leslie J. Charles
Joseph F. Dellaria
Philip D. Heppner
Bryon A. Merrill
John W. Mickelson
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2003065277A priority Critical patent/UA75622C2/en
Priority to PL01366115A priority patent/PL366115A1/en
Priority to EP01987282A priority patent/EP1341789A2/en
Priority to EEP200300270A priority patent/EE200300270A/en
Priority to AU3951602A priority patent/AU3951602A/en
Priority to BRPI0116052-4A priority patent/BR0116052A/en
Priority to AU2002239516A priority patent/AU2002239516B2/en
Priority to CA002430844A priority patent/CA2430844A1/en
Priority to JP2002547926A priority patent/JP2004523498A/en
Priority to NZ526105A priority patent/NZ526105A/en
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to SK684-2003A priority patent/SK6842003A3/en
Priority to KR10-2003-7007538A priority patent/KR20040028691A/en
Priority to IL15604301A priority patent/IL156043A0/en
Priority to HU0700062A priority patent/HUP0700062A2/en
Priority to MXPA03004973A priority patent/MXPA03004973A/en
Publication of WO2002046189A2 publication Critical patent/WO2002046189A2/en
Publication of WO2002046189A3 publication Critical patent/WO2002046189A3/en
Priority to NO20032452A priority patent/NO20032452L/en
Priority to HR20030462A priority patent/HRP20030462A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to imidazoquinoline compounds that have a 1 -substituent that contains ether and aryl or alkenyl functionality, and to pharmaceutical compositions containing such compounds.
  • a further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.
  • this invention provides imidazo[4, 5-c]quinoline-4- amine and tetrahydroimidazo[4, 5-c]quinoline-4-amine compounds that have an ether containing substituent at the 1 -position.
  • the compounds are described by Formulas (I), (II), (III) and (IV), which are defined in more detail infra. These compounds share the general structural formula:
  • X, R l9 R 2 , and R are as defined herein for each class of compounds having Formulas (I), (II), (III) and (IV).
  • the compounds of Formulas (I), (II), (III), and (IV) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
  • the invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I), (II), (III), or (IV) to the animal.
  • the invention provides methods of synthesizing the compounds of the invention and intermediates useful in the synthesis of these compounds.
  • Imidazoquinoline compounds of the invention which have ether and aryl or alkenyl functionality at the 1 -position are represented by Formula (I):
  • X is -CHR 3 -, -CHR 3 -alkyl-, or-CHR 3 -alkenyl-;
  • Ri is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • R4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R 3 is independently H or C ⁇ - 10 alkyl; each Y is independently -O- or -S(O) 0 - 2 -; n is 0 to 4; and each R present is independently selected from the group consisting of C-- 10 alkyl, C ⁇ - 1 0 alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • the invention also provides imidazoquinoline compounds that contain ether functionality at the 1 -position, where the ether containing substituent also contains an alkynyl group.
  • These compounds are represented by structural formula (II):
  • X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-; Rio is selected from the group consisting of: -H; -alkyl;
  • R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
  • the invention also includes tetrahydroimidazoquinoline compounds that bear an ether and aryl or alkenyl containing substituent at the 1 -position.
  • tetrahydroimidazoquinoline compounds are represented by Formula (III):
  • X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-;
  • Ri is selected from the group consisting of: aryl; alkenyl; and R 4 -aryl;
  • R 2 is selected from the group consisting of:
  • R 4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R 3 is independently H or Ci-io alkyl; each Y is independently -O- or -S(0)o- 2 -; n is 0 to 4; and each R present is independently selected from the group consisting of Ci-io alkyl, Ci-io alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • An additional class of immune response modifying compounds of the invention are tetrahydroimidazoquinoline compounds that have an ether containing substituent at the 1- position, where the ether containing substituent also contains an alkynyl group. These compounds are represented by structural formula (IV):
  • X is -CHR 3 -, -CHR 3 -alkyl-, or-CHR 3 -alkenyl-; Rio is selected from the group consisting of: -H; -alkyl;
  • R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
  • each R 3 is independently H or C MO alkyl; each Y is independently -O- or - S(0)o- 2 -; n is ⁇ to 4; and each R present is independently selected from the group consisting of C MO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • a 4-amino-lH-imidazo[4,5-c]quinolin- 1-yl alcohol of Formula X is alkylated with a halide of Formula XI to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XII which is a subgenus of Formula I.
  • the alcohol of Formula X is reacted with sodium hydride in a suitable solvent such as N,N- dimethylformamide to form an alkoxide.
  • the halide is then added to the reaction mixture.
  • the reaction can be carried out at ambient temperature or with gentle heating ( ⁇ 50°C) if desired.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XIII is alkylated with a halide of Formula XI to provide a lH-imidazo[4,5- c]quinolin- 1 -yl ether of Formula XIV.
  • the alcohol of Formula XIII is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide or tetrahydrofuran to form an alkoxide.
  • the alcohol and the halide can be combined in a biphasic mixture of aqueous 50% sodium hydroxide and an inert solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethylammonium chloride.
  • the reaction can be carried out at ambient temperature.
  • Many compounds of Formula XIII are known, see for example, Gerster, U.S. Patent 4,689,338; others can readily be prepared using known synthetic routes, see for example, Gerster et al., U.S. Patent No. 5,605,899 and Gerster, U.S. Patent No. 5,175,296.
  • step (2) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl ether of
  • Formula XIV is oxidized to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV using a conventional oxidizing agent capable of forming N-oxides.
  • a solution of a compound of Formula XIV in a suitable solvent such as chloroform or dichloromethane is oxidized using 3-chloroperoxybenzoic acid at ambient temperature.
  • Step (3) involves (i) reacting a compound of Formula XV with an acylating agent and then (ii) reacting the product with an animating agent. Part (i) of step (3) involves reacting an N-oxide of Formula XV with an acylating agent.
  • Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride).
  • Part (ii) of step (3) involves reacting the product of part (i) with an excess of an aminating agent.
  • Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate).
  • Ammonium hydroxide is preferred.
  • the reaction is preferably carried out by dissolving the N-oxide of Formula XV in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (3) may be carried out by (i) reacting an N-oxide of Formula XV with an isocyanate and then (ii) hydrolyzing the resulting product.
  • Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group.
  • Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate.
  • the reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane.
  • Part (ii) involves hydrolysis of the product from part (i).
  • the hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
  • a catalyst such as an alkali metal hydroxide or lower alkoxide.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Reaction Scheme III a 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula X is condensed with a phenol of Formula XVI to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XVII which is a subgenus of Formula I.
  • a solution of a compound of Formula X and the phenol in a suitable solvent such as N,N- dimethylformamide is treated with diethyl azodicarboxylate and triphenylphosphine at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme IV the hydroxy group of a lH-imidazo[4,5- c]quinolin-l-yl alcohol of Formula XIII is protected with a benzyl group.
  • the alcohol of Formula XIII is reacted with sodium hydride in a suitable solvent such as N,N- dimethylformamide to form an alkoxide.
  • the alkoxide is then alkylated with benzyl bromide to provide a compound of Formula XVIII.
  • the reaction can be carried out at ambient temperature.
  • step (2) of Reaction Scheme IV a compound of Formula XVIII is oxidized using the method of step (2) of Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline- 5N-oxide of Formula XIX.
  • step (3) of Reaction Scheme IV a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XIX is chlorinated to provide a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XX.
  • a solution of a compound of Formula XIX in a suitable solvent such as toluene is treated with phosphorous oxychloride at ambient temperature.
  • step (4) of Reaction Scheme IV a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XX is reacted with phenol to provide a 4-phenoxy-lH-imidazo[4,5-c]quinoline of Formula XXI.
  • the phenol is reacted with sodium hydride in a suitable solvent such as diglyme to form a phenoxide.
  • the phenoxide is then reacted at an elevated temperature with a compound of Formula XX.
  • step (5) of Reaction Scheme IV the benzyl protecting group is removed from a compound of Formula XXI to provide a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXII.
  • the reaction is preferably carried out by adding triflic acid in a controlled fashion to a solution of a compound of Formula XXI in a suitable solvent such as dichloromethane at ambient temperature.
  • step (6) of Reaction Scheme IV a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXII is alkylated with a halide of ⁇ al-Rn to provide a 4-phenoxy-lH- imidazo[4,5-c]quinolin-l-yl ether of Formula XXIII.
  • Formula XXII is formed by adding the alcohol to a biphasic mixture of aqueous 50% sodium hydroxide and an inert solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethlammonium chloride. The alkoxide is then alkylated. The reaction can be carried out at ambient temperature.
  • a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yI ether of Formula XXIII is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XII which is a subgenus of Formula I.
  • the reaction can be carried out by combining a compound of Formula XXIII with ammonium acetate and heating the resulting mixture at ⁇ 150°C.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme V where R, R 2 , Rn, X and n are as defined above.
  • a 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l- yl alcohol of Formula XXIV is alkylated with a halide of Formula XI to provide a 6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XXV which is a subgenus of Formula III.
  • the alcohol of Formula XXIV is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide to form an alkoxide.
  • the alkoxide is then combined with the halide.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme VI a 4-chloro-3-nitroquinoline of Formula XXVI is reacted with an amine of Formula R ⁇ -0-X-NH 2 to provide a 3-nitroquinolin-4-amine of Formula XXVII.
  • the reaction can be carried out by adding the amine to a solution of a compound of Formula XXVI in a suitable solvent such as chloroform or dichloromethane and optionally heating.
  • a suitable solvent such as chloroform or dichloromethane
  • step (2) of Reaction Scheme VI a 3-nitroquinolin-4-amine of Formula XXVII is reduced to provide a quinoline-3,4-diamine of Formula XXVIII.
  • the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
  • the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl alcohol or preferably toluene.
  • step (3) of Reaction Scheme VI a quinoline-3,4-diamine of Formula XXVIII is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5- c]quinoline of Formula XXIX.
  • Suitable equivalents to carboxylic acid include orthoesters, and 1,1-dialkoxyalkyl alkanoates.
  • the carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula XXIX.
  • triethyl orthoformate will provide a compound where R 2 is hydrogen and triethyl orthoacetate will provide a compound where R 2 is methyl.
  • the reaction can be run in the absence of solvent or in an inert solvent such as toluene.
  • the reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • a catalyst such as pyridine hydrochloride can be included.
  • step (3) can be carried out by (i) reacting the diamine of Formula XXVIII with an acyl halide of Formula R 2 C(0)C1 and then (ii) cyclizing.
  • the acyl halide is added to a solution of the diamine in a suitable solvent such as acetonitrile, pyridine or dichloromethane.
  • the reaction can be carried out at ambient temperature.
  • the product of part (i) is heated in an alcoholic solvent in the presence of a base.
  • step (i) is refluxed in ethanol in the presence of an excess of triethylamine or heated with methanolic ammonia.
  • step (ii) can be carried out by heating the reaction mixture after analysis indicates that step (i) is complete.
  • step (4) of Reaction Scheme VI a lH-imidazo[4,5-c]quinoline of Formula XXIX is oxidized using the method of step (2) of Reaction Scheme II to provide a 1H- imidazo[4,5-c]quinoline-5N-oxide of Formula XXX
  • step (5) of Reaction Scheme VI a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XXX is aminated using the method of step (3) of Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula I.
  • step (1) of Reaction Scheme VII a lH-imidazo[4,5-c]quinolin-l-yl alcohol of
  • Formula XIII is alkylated with a halide of Formula XXXI to provide a lH-imidazo[4,5- c]quinolin-l-yl ether of Formula XXXII.
  • the compound of Formula XIII and the halide of Formula XXXI are combined in a biphasic mixture of 50% aqueous sodium hydroxide and a suitable solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethylammonium chloride.
  • the reaction can be run at ambient temperature.
  • step (2) of Reaction Scheme VII a lH-imidazo[4,5-c]quinoline of Formula
  • XXXII is oxidized using the method of step (2) of Reaction Scheme II to provide a 1H- imidazo[4,5-c]quinoline-5N-oxide of Formula XXXIII.
  • step (3) of Reaction Scheme VII a lH-imidazo[4,5-c]quinoline-5N-oxide of
  • Formula XXXIII is reacted with trichloroacetyl isocyanate to provide a lH-imidazo[4,5- e]quinolin-4-yl trichloroacetamide of Formula XXXIV.
  • the isocyanate is added in a controlled fashion at ambient temperature to a solution of the 5N-oxide in a suitable solvent such as dichloromethane.
  • step (4) of Reaction Scheme VII a lH-imidazo[4,5-c]quinolin-4-yl trichloroacetamide of Formula XXXIV is hydrolyzed to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV which is a subgenus of Formula II.
  • the hydrolysis can be carried out by conventional methods, preferably by treating a solution of a compound of Formula XXXIV in methanol with sodium methoxide.
  • step (5) of Reaction Scheme VII lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXV is coupled with a halide of formula ⁇ al-R ⁇ 2 using a transition metal catalyst to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVT which is a subgenus of Formula II.
  • a compound of Formula XXXV is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)paIladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile.
  • the reaction is preferably carried out at an elevated temperature (60-80°C).
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Step (1) of Reaction Scheme VIII the amino group of a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV is protected with two tert-butoxycarbonyl groups.
  • a compound of Formula XXXV is combined with di-tert-butyl dicarbonate in a suitable solvent such as N,N-dimethylformamide in the presence of 4-(dimethylamino)pyridine and triethylamine. The reaction is carried out at an elevated temperature (80-85°C).
  • a protected lH-imidazo[4,5-c]quinolin-4- amine of Formula XXXVII is coupled with a halide of formula ⁇ al-R ⁇ 2 using a transition metal catalyst to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVIII.
  • a compound of Formula XXXVII is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)palladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile.
  • the reaction can be carried out at ambient temperature or at an elevated temperature (40-80°C).
  • step (3) of Reaction Scheme VIII the protecting groups are removed by hydrolysis under acidic conditions to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II.
  • a compound of Formula XXXVIII is treated with trifluoroacetic acid in a suitable solvent such as dichloromethane.
  • the reaction can be run at ambient temperature or at a reduced temperature (0°C).
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (4) of Reaction Scheme VIII the alkyne bond of a protected ⁇ H- imidazo[4,5-c]quinolin-4-amine of Formula XXXVIII is reduced to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXIX.
  • the reduction is carried out using a conventional heterogeneous hydrogentation catalyst such as platinum oxide, platinum on carbon or palladium on carbon.
  • the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as methanol.
  • step (5) of Reaction Scheme VIII the protecting groups of a compound of Formula XXXIX are removed in the same manner as in step (3) to provide a 1H- imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme IX the amino group of a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV is protected with benzyloxycarbonyl groups.
  • a compound of Formula XXXV is combined with dibenzyl dicarbonate in a suitable solvent such as N,N-dimethylformamide. The reaction can be carried out at ambient temperature or with mild heating (40°C).
  • a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XLI is coupled with a halide of formula ⁇ al-Rj 2 using a transition metal catalyst to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XLII.
  • a compound of Formula XLI is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)palladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile.
  • the reaction can be carried out at ambient temperature or at an elevated temperature (40-80°C).
  • step (3) of Reaction Scheme IX the protecting groups are removed by hydrolysis to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II.
  • a compound of Formula XLII is treated with sodium methoxide in a suitable solvent such as methanol.
  • the reaction can be run at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (4) of Reaction Scheme IX the protecting groups of a compound of Formula XLII are removed by hydrogenolysis and the alkyne bond is reduced to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I.
  • the hydrogenolysis/reduction is carried out using palladium hydroxide on carbon.
  • the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as methanol.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme X a 2,4-dichloro-3-nitroquinoline of Formula XLIII is reacted with an amine of Formula R ⁇ -0-X-NH 2 to provide a 2-chloro-3-nitroquinolin-4- amine of Formula XLIV.
  • the reaction can be carried out by adding the amine to a solution of a compound of Formula XLIII in a suitable solvent such as chloroform or dichloromethane and optionally heating.
  • a suitable solvent such as chloroform or dichloromethane
  • step (2) of Reaction Scheme X a 2-chloro-3-nitroquinolin-4-amine of Formula XLIV is reduced using the method of step (2) in Reaction Scheme VI to provide a 2- chloroquinoline-3,4-diamine of Formula XLV.
  • step (3) of Reaction Scheme X a 2-chloroquinoline-3,4-diamine of Formula XLV is cyclized using the method of step (3) in Reaction Scheme VI to provide a 4- chloro-lH-imidazo[4,5-c]quinoline of Formula XL VI.
  • step (4) of Reaction Scheme X a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XL VI is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula I.
  • the reaction is carried out by heating (e.g.,125-175°C) a compound of Formula XL VI under pressure in a sealed reactor in the presence of a solution of ammonia in an alkanol.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Reaction Scheme XI where- R, R], R 2 , X and n are as defined above.
  • a lH-imidazo[4,5-c]quinolin-4-amine of Formula XLVII is alkylated with a halide of Formula XLVIII to provide a lH-imidazo[4,5-c]quinolin-4- amine of Formula I.
  • the compound of Formula XLVII is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide.
  • the halide is then added to the reaction mixture.
  • the reaction can be carried out at an elevated temperature ( ⁇ 100°C). Alkylation occurs at both the Nl and the N3 nitrogens; however, the desired 1-isomer can be readily separated from the 3-isomer using conventional techniques such as column chromatography and recrystallization.
  • step (1) of Reaction Scheme XII a 4-nitrotetrazolo[l,5-a]quinolin-5-ol of Formula XLIX is chlorinated to provide a 5-chloro-4-nitrotetrazolo[l,5-a]quinoIine of
  • step (2) of Reaction Scheme XII a 5-chloro-4-nitrotetrazolo[l,5-a]quinoline of Formula L is reacted with an amine of Formula R ⁇ -0-X-N ⁇ 2 to provide a 4- nitrotetrazolo[l,5-a]quinolin-5-amine of Formula LI.
  • the reaction can be carried out by adding the amine to a solution of a compound of Formula L in a suitable solvent such as dichloromethane in the presence of triethylamine.
  • step (3) of Reaction Scheme XII a 4-nitrotetrazolo[l,5-a]quinolin-5-amine of Formula LI is reduced using the method of step (2) in Reaction Scheme VI to provide a tetrazolo[l,5-a]quinolin-4,5-diamine of Formula LII.
  • step (4 ) of Reaction Scheme XII a tetrazolo[l,5-a]quinolin-4,5-diamine of Formula LII is cyclized using the method of step (3) in Reaction Scheme VI to provide a 6H-imidazo[4,5-c]tetrazolo[l,5- ]quinoline of Formula LIII.
  • step (5) of Reaction Scheme XII a 6H-imidazo[4,5-c]tetrazolo[l,5- ⁇ ]quinoline of Formula LIII is reduced to provide a lH-imidazo[4,5-c]quinolin- 4-amine of Formula I.
  • Step (5) involves (i) reacting a compound of Formula LIII with triphenylphosphine and then (ii) hydrolyzing.
  • Part (i) can be carried out by combining a compound of Formula LIII with triphenylphosphine in a suitable solvent such as 1,2-dichlorobenzene and heating.
  • Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Formula XXXII is coupled with a halide of Formula ⁇ al-Rj 2 using the method of step (5) in Reaction Scheme VII to provide a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LIV.
  • step (2) of Reaction Scheme XIII a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LIV is oxidized using the method of step (2) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LV.
  • step (3) of Reaction Scheme XIII a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LV is aminated using the method of step (3) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme XIV the alkyne bond of a lH-imidazo[4,5- c]quinolin-l-yl ether of Fonnula LIV is reduced using the method of step (4) of Reaction Scheme VIII to provide a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LVI.
  • step (2) of Reaction Scheme XIV a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LVI is oxidized using the method of step (2) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline-5 ⁇ -oxide of Formula LVII.
  • step (3) of Reaction Scheme XIV a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LVII is aminated using the method of step (3) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme XV where R, R 2 , R 12 , X and n are as defined above.
  • step (1) of Reaction Scheme XV a 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-l-yl alcohol of Formula XXIV is alkylated using the method described in Reaction Scheme V with a halide of Formula ⁇ al-(C ⁇ 2 ) ⁇ - ⁇ 0 -C ⁇ C ⁇ to provide a 6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula LVIII which is a subgenus of Formula IV.
  • step (2) of Reaction Scheme XV a 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-4-amine of Formula LVIII is coupled using the method of step (5) of Reaction Scheme VII with a halide of Formula ⁇ al-R ⁇ 2 to provide a 6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-4-amine of Formula LIX which is a subgenus of Formula IV.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Step (1) of Reaction Scheme XVI a 2,4-dihydroxy-3-nitro-6,7,8,9- tetrayhydroquinoline of Formula LX is chlorinated to provide a 2,4-dichloro-3-nitro- 6,7,8,9-tetrayhydroquinoline of Formula LXI.
  • Conventional chlorinating agents can be used.
  • the reaction is carried out by combining a compound of Formula LX with phosphorous oxychloride and then heating (55-65°C).
  • Compounds of Formula LX are known or can be prepared using known synthetic methods (see for example Nikolaides et al,. U.S. Patent 5,352,784 and references cited therein).
  • step (2) of Reaction Scheme XVI a 2,4-dichloro-3-nitro-6,7,8,9- tetrayhydroquinoline of Formula LXI is reacted with an amine of Formula R ⁇ -0-X-NH 2 to provide a 2-chloro-3-nitro-6,7,8,9-tetrahydroquinolin-4-amine of Formula LXII.
  • the reaction can be carried out by adding the amine to a solution of a compound of Formula
  • step (3) of Reaction Scheme XVI a 2-chloro-3-nitro-6,7,8,9-tetrahydroquinolin- 4-amine of Formula LXII is reacted with phenol using the method of step (4) of Reaction Scheme IV to provide a 2-phenoxy-3-nitro-6,7,8,9-tetrahydroquinolin-4-amine of Formula LXIII.
  • step (4) of Reaction Scheme XVI a 2-phenoxy-3-nitro-6,7,8,9- tetrahydroquinolin-4-amine of Formula LXIII is reduced using the method of step (2) of Reaction Scheme VI to provide a 2-phenoxy-6,7,8,9-tetrahydroquinolin-3,4-diamine of Formula LXIV.
  • step (5) of Reaction Scheme XVI a 2-phenoxy-6,7,8,9-tetrahydroquinolin-3,4- diamine of Formula LXIV is cyclized using the method of step (3) of Reaction Scheme VI to provide a 4-phenoxy-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline of Formula LXV.
  • step (6) of Reaction Scheme XVI a 4-phenoxy-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinoline of Formula LXV is aminated using the method of step (7) of Reaction Scheme IV to provide a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula III.
  • the invention also provides novel compounds useful as intermediates in the synthesis of the compounds of Formulas (I), (II), (III), and (IV). These intermediate compounds have the structural Formulas (V) - (IX), described in more detail below.
  • One class of intermediate compounds has formula (V):
  • V wherein X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-; Ri is selected from the group consisting of: -aryl; -alkenyl; -I ⁇ -aryl; and -(CH 2 )M 0 -C ⁇ C-R 10 ; R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
  • R-t is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 3 is independently H or C O alkyl;
  • Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or-S(0)o- 2 S n is 0 to 4; and each R present is independently selected from the group consisting of C MO alkyl, C MO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • X is -CHR 3 -, -CHR 3 -alkyI-, or -CHR 3 -aIkenyl-;
  • Ri is selected from the group consisting of: -aryl; -alkenyl; -J r-aryl; and -(CH 2 ) O -C ⁇ C-R ⁇ o ;
  • R 2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -heteroaryl;
  • R 4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R3 is independently H or C O alkyl;
  • Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(0)o- 2 -; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CM O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • intennediate compounds are the imidazoquinoline-N-oxide compounds of formula (VII):
  • X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-;
  • Ri is selected from the group consisting of: -aryl; -alkenyl;
  • -R-r-aiyl is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R 3 is independently H or C MO alkyl;
  • Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; n is 0 to 4; and each R present is independently selected from the group consisting of C MO alkyl, C MO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-;
  • Ri is selected from the group consisting of: -aryl; -alkenyl;
  • R 2 is selected from the group consisting of: -hydrogen; -alkyl;
  • K is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 3 is independently H or CM O alkyl;
  • R 10 is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(O) 0 - 2 -; n is 0 to 4; each R present is independently selected from the group consisting of CM O alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; and R 7 is tert-butyl or benzyl; or a pharmaceutically acceptable salt thereof.
  • a further class of intermediates are imidazoquinoline-4-chloro compounds of the formula (IX)
  • X is -CHR 3 -, -CHR 3 -alkyl-, or -CHR 3 -alkenyl-;
  • Ri is selected from the group consisting of: aryl; alkenyl; R-v-aryl; and -(CH 2 )M O -C ⁇ CH R 2 is selected from the group consisting of:
  • . is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 3 is independently H or CM O alkyl; each Y is independently -O- or -S(0)o- 2 -; n is 0 to 4; and each R present is independently selected from the group consisting of C MO alkyl, CM O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • alkyl As used herein, the terms "alkyl”, “alkenyl” and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, and adamantyl.
  • alkyl and alkenyl portions of -X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the group consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo-”. Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N).
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
  • Heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of any of the above mentioned heteroaryl groups.
  • exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, tliiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
  • the aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbon
  • R- t -aryl is a preferred Rj group and preferred Rio groups are alkyl and aryl, with phenyl or substituted phenyl being a preferred aryl group.
  • Preferred R 2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), methoxyethyl, and ethoxymethyl.
  • substituted groups such as substituted alkyl or substituted aryl groups
  • preferred substituents include halogen, nitrile, nitro, carboxy, methoxy, methylthio, trifluoromethyl, and trifluoromethoxy.
  • One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination.
  • the invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like.
  • the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
  • compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
  • a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity.
  • a therapeutic effect such as cytokine induction, antitumor activity, and/or antiviral activity.
  • the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg, of the compound to the subject.
  • Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
  • the compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
  • the compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
  • Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon- (IFN- ⁇ ) and/or tumor necrosis factor- ⁇ (TNF- ⁇ ) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN- ⁇ , TNF- ⁇ , IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
  • Certain compounds of the invention have been found to preferentially induce the expression of IFN- ⁇ in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
  • PBMCs peripheral blood mononuclear cells
  • pDC2 cells precursor dendritic cell-type 2
  • the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.
  • the compounds may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
  • Compounds of the invention also have an effect on the acquired immune response.
  • the production of the T helper type 1 (Thl) cytokine IFN- ⁇ is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds.
  • This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired.
  • the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
  • atopic diseases e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
  • the immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN- ⁇ and/or TNF- ⁇ , the compounds are particularly useful in the treatment of viral diseases and tumors.
  • This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; variola, particularly variola major; rhinovirus; adenovirus; influenza; para-influenza; HIV;
  • diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; variola, particularly variola major; rhinovirus; adenovirus; influenza; para-influenza; HIV;
  • CMV CMV
  • VZV intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
  • Candida aspergillus, and cryptococcal meningitis
  • neoplastic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g.
  • Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of keloid formation after surgery and other types of post-surgical scars.
  • these compounds could enhance or stimulate the healing of wounds, including chronic wounds.
  • the compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients
  • An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- ⁇ , TNF- ⁇ , IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
  • the invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
  • An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
  • An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
  • aqueous fraction was then extracted multiple times with dichloromethane.
  • the organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide 18.5 g of l-[2-(2-pro ⁇ ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N- oxide as a yellow oil.
  • Trifluoroacetic acid (20 mL) was added to a solution of the material from Part B in dichloromethane (20 mL). After 4 hours the reaction mixture was diluted with dichloromethane containing a small amount of methanol and 20% sodium hydroxide. The layers were separated. The aqueous fraction was extracted with dichloromethane. The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a yellow powder. This material was purified by flash chromatography eluting with 9/1 dichloromethane/methanol to provide
  • reaction mixture (0.05 g, 0.26 mmol) were added and the reaction mixture was stirred for 1 hour at ambient temperature at which time analysis by ⁇ PLC (reverse phase, acetonitrile/water) indicated that the reaction was complete.
  • ⁇ PLC reverse phase, acetonitrile/water
  • the aqueous fraction was extracted with dichloromethane. The organic fractions were combined, dried over magnesium sulfate and then concentrated to a volume of ⁇ 10 mL. The concentrate was allowed to stand over the weekend and then it was diluted with toluene. The resulting precipitate was isolated by filtration and identified as starting material. The filtrate was diluted with diethyl ether. The resulting precipitate was isolated by filtration to provide 1.1 g of benzyl N- ⁇ l-[2- (propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-yl ⁇ carbamate as a white solid.
  • This material was further purified by column chromatography eluting with 99/1 ethyl acetate/methanol to provide 24 mg of 1 -(2- ⁇ [3-(4-phenoxyphenyl)-2-propynyl]oxy ⁇ ethyl)-lH-imidazo[4,5- c]quinolin-4-amine as a solid, m.p. 146-148°C.
  • This material was partially dissolved in a mixture of dichloromethane (17 mL) and methanol (17 mL). Hydrogen chloride/diethyl ether (3.24 L of 1.0 M) was added and the mixture turned homogeneous. The mixture was concentrated under reduced pressure to provide a brown crystalline residue. The residue was combined with 50/50 acetonitrile/ethyl acetate containing a small amount of methanol. Sodium hydroxide (0.5 mL of 20%) was added. The mixture was concentrated under reduced pressure to provide a glassy solid.
  • dibenzyl dicarbonate 50 g, 174 mmol was added to a mixture of l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (16.4 g, 61.6 mmol) and anhydrous N,N-dimethylformamide (200 mL).
  • the reaction mixture was allowed to stir at ambient temperature for 16 hours and the reaction mixture turned homogeneous.
  • the reaction mixture was partitioned between ethyl acetate and water. The layers were separated. The aqueous layer was extracted with ethyl acetate.
  • N,N-(bis benzyloxycarbonyl)- 1-[2-(2- propynyloxy)ethylj-lH-imidazo[4,5-c]quinolin-4-amine 0.5 g, 0.94 mmol
  • anhydrous acetonitrile 5 mL
  • triethylamine 0.34 mL, 2.43 mmol
  • l-(4-iodophenyl)pyrrole (0.28 g, 1.03 mmol) were combined and the resulting homogeneous mixture was heated to
  • This material was purified on a second column using 9/1 hexane/ethyl acetate to provide 0.229 g of N,N-(bis benzyloxycarbonyl)- l-[2-( ⁇ 3-[4-(lH-pyrrol-l-yl)phenyl]prop-2- ynyl ⁇ oxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine.
  • N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (2.82 g g, 6.04 mmol)
  • benzyl 3- iodobenzoate 2.245 g, 6.64 mmol
  • triethylamine 2.2 mL, 15.7 mmol
  • anhydrous acetonitrile (20 mL) were combined and the resulting mixture was heated to 60°C.
  • Copper (I) iodide (0.05 g) and dichlorobis(triphenylphosphine)palladium(II) (0.0.08 g) were added.
  • Example 13 2- ⁇ 3 -[2-(4-Amino- 1 H-imidazo [4, 5 -cjquinolin- 1 -yl)ethoxy]propyl ⁇ benzoic acid trifluoroacetate
  • Example 12 Part B Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide 0.041 g of a mixture of mono-and di-BOC protected 2- ⁇ 3-[2-(4- amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl ⁇ benzoic acid.
  • Example 12 Part C the material from Part B was hydrolyzed to provide 0.28 g of 2- ⁇ 3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]propyl ⁇ benzoic acid as a solid, m.p. 186-188°C. Analysis. Calculated for C 22 ⁇ 2 2N 4 03»C 2 ⁇ F 3 0 2 : %C, 57.14; %H, 4.59; %N, 11.11.
  • Example 12 Part B Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide 1.86 g of a mixture of mono-and di-BOC protected 4- ⁇ 3-[2-(4- amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl ⁇ benzoic acid.
  • Example 12 Part C Using the general method of Example 12 Part C, the material from Part B was hydrolyzed to provide 0.96 g of 4- ⁇ 3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]propyl ⁇ benzoic acid trifluoroacetate, m.p. 235-237°C.
  • Example 12 Part B Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide -2.9 g of a mixture of mono Boc protected and unprotected l-(2- ⁇ 3-[3-(dimethylamino)phenyl]propoxy ⁇ ethyl)-lH-imidazo[4,5-c]quinolin-4-amine.
  • the material from Part B was combined with hydrogen chloride/methanol (30 mL of 3 M) and stirred at ambient temperature for 19 hours. A precipitate was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was dissolved in a small amount of methanol and then neutralized with concentrated ammonium hydroxide to p ⁇ ⁇ 11. The resulting precipitate was purified by column chromatography eluting with 95/5/1 dichloromethane/methanol/ammonium hydroxide. This material was combined with hydrogen chloride/diethyl ether. The resulting solution was concentrated under reduced pressure. The residue was triturated with diethyl ether.
  • the resulting solution was heated to 80°C.
  • 2-iodoaniline (0.26 mL, 1.18 mmol
  • copper (I) iodide 0.012 g
  • dichlorobis(triphenylphosphine)palladium(II) 0.023 g
  • Catalyst (5% platinum on carbon) was added to a solution of N,N-(bis tert- butoxycarbonyl)-! -(2- ⁇ [3-(2-aminophenyl)prop-2-ynyl]oxy ⁇ ethyl)-lH-imidazo[4,5- c]quinolin-4-amine in methanol.
  • the mixture was hydrogenated on a Parr apparatus at 50 psi (3.5 Kg.cm 2 ) overnight.
  • the reaction mixture was filtered through a layer of Celite® filter aid and the filter cake was washed with additional methanol. The filtrate was concentrated under reduced pressure to provide an off-white solid.
  • Examples 24 - 27 The compounds in the table below were prepared according to the synthetic method of Reaction Scheme I above using the following general method. 2-(4-Amino-lH ⁇ imidazo[4,5-c]quinolin-l-yl)-2-ethylethanol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.75 eq of 60% in mineral oil) and N,N- dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 10 minutes at ambient temperature to allow the alkoxide to form. The halide (1.75 eq) was added and the vial was placed back on the sonicator for about 30 to 60 minutes at ambient temperature.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the reaction mixture was purified by semi-preparative ⁇ PLC.
  • the semi-prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
  • the 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol (25 mg) was placed in a 2 dram (7.4 mL) vial.
  • the vial was placed on a sonicator for about 1 hour at 50°C to allow the alkoxide to form.
  • the halide (1.2 eq) was added and the vial was placed back on the sonicator for about 1 to 2 hours at 50°C.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the reaction mixture was purified by semi-preparative ⁇ PLC.
  • the semi-prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
  • the 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol (25 mg) was placed in a 2 dram (7.4 mL) vial.
  • the vial was placed on a sonicator for about 15 to 30 minutes at ambient temperature to allow the alkoxide to form.
  • the halide (1.2 eq) was added and the vial was placed back on the sonicator for about 15 to 120 minutes at ambient temperature.
  • the reaction mixture was analyzed by LC/MS to confirm the formation of the desired product.
  • the reaction mixture was purified by semi-preparative ⁇ PLC.
  • the semi-prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM) or nominal mass (NM).
  • the reaction mixture was purified by semi-preparative ⁇ PLC.
  • the semi-prep ⁇ PLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product , which was confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
  • the reaction mixture was sonicated for about 30 minutes and then shaken overnight at ambient temperature.
  • the reaction mixture was purified by semi-preparative ⁇ PLC using Method A.
  • the compounds of Examples 99 and 100 were provided as the trifluoroacetate salts
  • the products were confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the nominal mass (NM).
  • (2R)-2-[(3-Aminoquinolin-4-yl)amino]butan-l-ol (416.0 g, 1 eq.) and triethylorthoformate (1.2 L, 4 eq.) were combined and slowly heated to 145°C. Ethanol was distilled off as it formed during the reaction. After -500 mL of ethanol had been distilled off, the reaction mixture was allowed to cool to 50°C under a nitrogen atmosphere. Excess triethyLorthoformate was removed under reduced pressure to provide crude (2R)-2-( 1 H-imidazo [4, 5-c] quinolin- 1 -yl)butan- 1 -ol .
  • 3-Chloroperoxybenzoic acid (15.0 g of 57-86%) was added to a chilled (0°) mixture of the material from Part F and chloroform (250 mL). After 0.5 hour the reaction mixture was allowed to warm to ambient temperature. The progress of the reaction was monitored by TLC and two additional portions of 3-chloroperoxybenzoic acid (3.75 g) were added. When the reaction was complete, it was washed with sodium bicarbonate. The aqueous fraction was extracted with ethyl acetate.
  • Trichloroacetyl isocyanate (10.7 mL) was added dropwise to a mixture of the material from Part G and anhydrous dichloromethane (300 mL). After 1 hour analysis by TLC indicated that the reaction was not complete so more trichloroacetyl isocyanate (2 mL) was added. After 1 hour the reaction mixture was concentrated under reduced pressure to provide 2,2,2-trichloro-N-(l- ⁇ (lR)-l-[(2-propynyloxy)methyl]propyl ⁇ -lH- imidazo[4,5-c]quinolin-4-yl)acetamide as a yellow solid.
  • Examples 110 - 112 Part A Triethylamine (15 mL) and R-3-amino-2-methylpropan-l-ol (about 0.1 mole of crude) were added to a solution of 2,4-dichloro-3-nitroquinoline (24.3 g, 0.1 mole) in dichloromethane (250 mL). The reaction mixture was refluxed until analysis by TLC showed no change. The reaction mixture was evaporated to dryness. The solid yellow- brown residue was crushed and then extracted repeatedly with hexane containing a small amount of dichloromethane in order to remove the starting quinoline.
  • the reaction mixture was purified by semi-preparative HPLC.
  • the semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and ⁇ NMR.
  • the table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
  • This material was slurried with refluxing ethyl acetate (-5 mL). The mixture was cooled and a precipitate was isolated by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was slurried twice with ethyl acetate and then combined with the precipitate to provide 0.8 g of solid. This solid was recrystallized from ethanol ( ⁇ 5 mL) to provide 0.6 g of l-[(benzyloxy)methyl]-lH-imidazo[4,5-c]quinolin-4- amine, m.p. 168-172°C.
  • 3-methoxypropanoyl chloride (0.86 ml, 7.9 mmol) was added dropwise over a 30 minute period to a chilled (ice bath) solution of N 4 -(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) in dichloromethane (100 ml). After a few hours, a precipitate formed. The solvent volume was reduced under vacuum to near dryness and hexane (100 ml) was added. Vacuum filtration provided 2.9 g of 3-methoxy-N- ⁇ 4-[(2- phenoxyethyl)amino]quinolin-3-yl ⁇ propanamide as a hydrochloride salt.
  • 3-Chloroperoxybenzoic acid (1.5 g, 8.7 mmol, 60% by weight) was added in three portions over a period of 20 minutes to 2-(2-methoxyethyl)-l-(2-phenoxyethyl)-lH- imidazo[4,5-c]quinoline (1.8 g, 5.2 mmol) in chloroform (100 ml).
  • the reaction mixture was maintained at ambient temperature overnight and then washed with saturated sodium bicarbonate followed by water.
  • the organic fraction was dried (MgS0 4 ) and concentrated under vacuum to near dryness.
  • N 4 -(2-Phenoxyethyl)quinoline-3,4-diamine (1.5 g, 5.4 mmol) and isovaleryl chloride (0.8 ml, 6.4 mmol) were combined and treated according to the general procedures of Parts C-E of Example 129.
  • the reaction was chilled (ice bath) and -toluenesulfonyl chloride (0.85 g, 4.5 mmol) was slowly added over a period of 20 minutes. The cooling bath was removed and the reaction was maintained at ambient temperature overnight. The phases were separated and the organic phase was sequentially washed with 1% aqueous sodium carbonate (3X), water, brine; dried (Na 2 S0 ); and concentrated to near dryness in vacuo. Hexane was added to provide a precipitate.
  • N 4 -(2-Phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and isobutyryl chloride (0.9 ml, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 0.82 g of 2- isopropyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 229-231°C.
  • N 4 -(2-Phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol), xylenes (150 ml), and trimethylorthovalerate (2.5 ml, 14.3 mmol) were combined under an atmosphere of nitrogen and heated at reflux temperature for 4 days. The external heat was increased and approximately 35 ml of xylenes was removed by distillation. The reaction was slowly cooled to room temperature and a precipitate formed. The solid was recovered by vacuum filtration to yield 2.4 g of 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinoline as a light tan crystalline solid.
  • N 4 -(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and cyclopentanecarbonyl chloride (1.1 ml, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 1.4 g of 2-cyclopentyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 216.0-217.9°C.
  • N 4 -(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and 2-(2- methoxyethoxy)acetyl chloride (1.3 g, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from methanol provided 1.6 g of 2-[(2-methoxyethoxy)methyl]-l-(2-phenoxyethyl)-lH-imidazo[4,5- c]quinolin-4-amine as white needles, m.p. 170.0-171.5°C.
  • N 4 -(2-phenoxyethyl)quinolme-3,4-diamine (1.7 g, 6.1 mmol) and cyclopropylacetyl chloride (0.86 ml, 7.3 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from methanol provided 0.86 g of 2-(cyclopropylmethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin- 4-amine as a white solid, m.p. 191.7-192.6°C.
  • N 4 -(2-phenoxyethyl)quinoline-3,4-diamine (1.6 g, 5.7 mmol) and tetrahydrofuran- 3-carbonyl chloride (0.98 ml, 7.3 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 0.3 g of l-(2-phenoxyethyl)-2-tetrahydrofuran-3-yl-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 235.9-236.3°C.
  • reaction became a dark orange solution. After 1.5 hours the reaction was quenched by the slow addition of saturated ammonium chloride solution (10 ml). The methanol was removed in vacuo. The aqueous residue was extracted with dichloromethane (3 x 10 ml) and the organic fractions were combined and washed with water (10 ml) and brine (10 ml). The solution was dried (Na 2 S0 4 ), filtered and concentrated in vacuo to yield the crude product as an orange solid.
  • Example 115 Part C Using the general method of Example 115 Part C, the 4-amino group was introduced to 2-(2-methyl-5-oxido-lH-imidazo[4,5-c]quinolin-l-yl)ethyl acetate (8.47 g, 29.71 mmol). The resulting brown oil was purified by trituration with acetonitrile and dried to yield 3.583 g of 2-(4-amino-2-methyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl acetate as a tan solid.
  • the resulting oil was partitioned between dichloromethane and 4% aqueous sodium carbonate and the organic layer removed.
  • the aqueous layer was extracted with dichloromethane (3x).
  • the organic fractions were combined, dried with anhydrous sodium sulfate and the volatiles were removed under reduced pressure.
  • the resulting oil was purified by chromatography over silica gel (95/5 dichloromethane/methanol).
  • the resulting white solid was dissolved in dichloromethane (2 mL) and reacted with IM HCl in ether (2 mL).
  • the volatiles were removed under reduced pressure and the resulting solids recrystallized from methanol to provide 0.1089 g of 2-methyl-l- ⁇ 2-[(3-phenylprop-2-ynyl)oxy]ethyl ⁇ -
  • cytokine induction An in vitro human blood cell system is used to assess cytokine induction. Activity is based on the measurement of interferon and tumor necrosis factor ( ⁇ ) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In “Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995).
  • ⁇ interferon and tumor necrosis factor
  • PBMCs Peripheral blood mononuclear cells
  • Histopaque®-1077 The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 10 6 cells/mL in RPMI complete.
  • the PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park,
  • the compounds are solubilized in dimethyl sulfoxide (DMSO).
  • DMSO dimethyl sulfoxide
  • the DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells.
  • test compound is added at 60 ⁇ M to the first well containing RPMI complete and serial 3 fold dilutions are made in the wells.
  • the PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (0.12 to 30 ⁇ M).
  • the final concentration of PBMC suspension is 1.5-2 X
  • Interferon ( ⁇ ) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
  • Tumor necrosis factor ( ⁇ ) concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San
  • the table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound. A "*" indicates that no induction was seen at any of the tested concentrations; generally the highest concentration tested was 10 or 30 ⁇ M.

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Description

Aryl Ether Substituted I idazoquinolmes
Field of the Invention
This invention relates to imidazoquinoline compounds that have a 1 -substituent that contains ether and aryl or alkenyl functionality, and to pharmaceutical compositions containing such compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.
Background of the Invention
The first reliable report on the lH-imidazo[4,5-c]quinoline ring system, Backman et al., J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of l-(6-methoxy-8- quinolinyl)-2-methyl-lH-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted lH-imidazo[4,5-c] quinolines were reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound l-[2-(4-piperidyl)ethyl]-lH-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J. Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5- cjquinolines.
Certain lH-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos. 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference.
There continues to be interest in the imidazoquinoline ring system. Certain 1Η- imidazo[4,5-c] naphthyridine-4-amines, lΗ-imidazo [4,5-c] pyridin-4-amines, and 1Η- imidazo[4,5-c] quinolin-4-amines having an ether containing substituent at the 1 position are known. These are described in U.S. Patent Nos. 5,268,376; 5,389,640; 5,494,916; and
WO 99/29693. There is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
Summary of the Invention We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazo[4, 5-c]quinoline-4- amine and tetrahydroimidazo[4, 5-c]quinoline-4-amine compounds that have an ether containing substituent at the 1 -position. The compounds are described by Formulas (I), (II), (III) and (IV), which are defined in more detail infra. These compounds share the general structural formula:
Figure imgf000003_0001
wherein X, Rl9 R2, and R are as defined herein for each class of compounds having Formulas (I), (II), (III) and (IV). The compounds of Formulas (I), (II), (III), and (IV) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response. The invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I), (II), (III), or (IV) to the animal. In addition, the invention provides methods of synthesizing the compounds of the invention and intermediates useful in the synthesis of these compounds. Detailed Description of the Invention
As mentioned earlier, we have found certain compounds that induce cytokine biosynthesis and modify the immune response in animals. Such compounds are represented by Formulas (I), (II), (III), and (IV), as shown below.
Imidazoquinoline compounds of the invention, which have ether and aryl or alkenyl functionality at the 1 -position are represented by Formula (I):
Figure imgf000004_0001
wherein: X is -CHR3-, -CHR3-alkyl-, or-CHR3-alkenyl-; Ri is selected from the group consisting of:
-alkenyl;
-aryl;
Figure imgf000004_0002
R2 is selected from the group consisting of:
-hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y- alkenyl;
-alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2;
-CO-Ci-io alkyl;
-CO-0-Cι-ιo alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; R4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R3 is independently H or Cι-10 alkyl; each Y is independently -O- or -S(O)0-2-; n is 0 to 4; and each R present is independently selected from the group consisting of C--10 alkyl, Cι-10 alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
The invention also provides imidazoquinoline compounds that contain ether functionality at the 1 -position, where the ether containing substituent also contains an alkynyl group. These compounds are represented by structural formula (II):
Figure imgf000005_0001
(II)
wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-; Rio is selected from the group consisting of: -H; -alkyl;
-alkenyl; and -aryl;
R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl- Y- alkenyl; -alkyl- Y-aryl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3) ; -CO-Ci-io alkyl; -CO-O-Ci-,0 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; n is 0 to 4; each Y is independently -O- or -S(0)o-2-; each R3 is independently H or Ci-io alkyl; and each R present is independently selected from the group consisting of Ci-io alkyl, Ci-io alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
The invention also includes tetrahydroimidazoquinoline compounds that bear an ether and aryl or alkenyl containing substituent at the 1 -position. Such tetrahydroimidazoquinoline compounds are represented by Formula (III):
Figure imgf000007_0001
(III) wherein:
X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-; Ri is selected from the group consisting of: aryl; alkenyl; and R4-aryl;
R2 is selected from the group consisting of:
-hydrogen;
-alkyl;
-alkenyl; -aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl- Y-aryl; - alkyl- Y- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH;
-halogen;
-N(R3)2;
-CO-N(R3)2; -CO-Ci-io alkyl;
-CO-0-Cι-ιo alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; R4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R3 is independently H or Ci-io alkyl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of Ci-io alkyl, Ci-io alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
An additional class of immune response modifying compounds of the invention are tetrahydroimidazoquinoline compounds that have an ether containing substituent at the 1- position, where the ether containing substituent also contains an alkynyl group. These compounds are represented by structural formula (IV):
Figure imgf000009_0001
(IV) wherein
X is -CHR3-, -CHR3-alkyl-, or-CHR3-alkenyl-; Rio is selected from the group consisting of: -H; -alkyl;
-alkenyl; and -aryl; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl- Y-aryl; -alkyl-Y- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-Ci-io alkyl;
-CO-0-Cι-ιo alkyl; -N3;
-aryl;
-heteroaryl;
-heterocyclyl; -CO-aryl; and
-CO-heteroaryl; each R3 is independently H or CMO alkyl; each Y is independently -O- or - S(0)o-2-; n is ϋ to 4; and each R present is independently selected from the group consisting of CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
Preparation of the Compounds Compounds of the invention can be prepared according to Reaction Scheme I where R, R2, X and n are as defined above and Rn is alkyl substituted by an aryl group wherein the aryl group may be unsubstituted or may be substituted or Rn is substituted aryl with the proviso that if R] i is substituted aryl at least one substituent is a strong electron withdrawing group located ortho ox para to the ether bond. Reaction Scheme I
Figure imgf000010_0001
In Reaction Scheme I a 4-amino-lH-imidazo[4,5-c]quinolin- 1-yl alcohol of Formula X is alkylated with a halide of Formula XI to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XII which is a subgenus of Formula I. The alcohol of Formula X is reacted with sodium hydride in a suitable solvent such as N,N- dimethylformamide to form an alkoxide. The halide is then added to the reaction mixture. The reaction can be carried out at ambient temperature or with gentle heating (~50°C) if desired. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Many compounds of Formula X are known, see for example Gerster, U.S. Patent No. 4,689,338 and Gerster et. al., U.S. Patent No. 5,605,899, the disclosures of which are incorporated by reference herein; others can readily be prepared using known synthetic routes, see for example, Andre et. al, U.S. Patent No. 5,578,727; Gerster, U.S. Patent No. 5,175,296; Nikolaides et al., U.S. Patent No. 5,395,937; and Gerster et. al., U.S. Patent No. 5,741,908, the disclosures of which are incorporated by reference herein. Many halides of Formula XI are commercially available; others can be readily prepared using known synthetic methods.
Compounds of the invention can be prepared according to Reaction Scheme II where R, R2, Rn, X and n are as defined above.
In step (1) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XIII is alkylated with a halide of Formula XI to provide a lH-imidazo[4,5- c]quinolin- 1 -yl ether of Formula XIV. The alcohol of Formula XIII is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide or tetrahydrofuran to form an alkoxide. The alkoxide is then combined with the halide Alternatively, the alcohol and the halide can be combined in a biphasic mixture of aqueous 50% sodium hydroxide and an inert solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethylammonium chloride.. The reaction can be carried out at ambient temperature. Many compounds of Formula XIII are known, see for example, Gerster, U.S. Patent 4,689,338; others can readily be prepared using known synthetic routes, see for example, Gerster et al., U.S. Patent No. 5,605,899 and Gerster, U.S. Patent No. 5,175,296. In step (2) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl ether of
Formula XIV is oxidized to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV using a conventional oxidizing agent capable of forming N-oxides. Preferably a solution of a compound of Formula XIV in a suitable solvent such as chloroform or dichloromethane is oxidized using 3-chloroperoxybenzoic acid at ambient temperature. In step (3) of Reaction Scheme II a lH-imidazo[4,5-c]quinoline-5N-oxide of
Formula XV is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XII which is a subgenus of Formula I. Step (3) involves (i) reacting a compound of Formula XV with an acylating agent and then (ii) reacting the product with an animating agent. Part (i) of step (3) involves reacting an N-oxide of Formula XV with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. Eαra-toluenesulfonyl chloride is most preferred. Part (ii) of step (3) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula XV in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Alternatively, step (3) may be carried out by (i) reacting an N-oxide of Formula XV with an isocyanate and then (ii) hydrolyzing the resulting product. Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group. Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane. Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme II
Figure imgf000013_0001
(2)
Figure imgf000013_0002
Compounds of Formula I wherem R, R2, X and n are as defined above and Ri is an optionally substituted phenyl can be prepared according to Reaction Scheme III where m is 0 to 3 and each R' is independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, aryloxycarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, aroyloxy and aroylamino. In Reaction Scheme III a 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula X is condensed with a phenol of Formula XVI to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XVII which is a subgenus of Formula I. Preferably, a solution of a compound of Formula X and the phenol in a suitable solvent such as N,N- dimethylformamide is treated with diethyl azodicarboxylate and triphenylphosphine at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme III
Figure imgf000014_0001
Compounds of the invention can also be prepared according to Reaction Scheme IV where R, R2, Rn, X and n are as defined above.
In step (1) of Reaction Scheme IV the hydroxy group of a lH-imidazo[4,5- c]quinolin-l-yl alcohol of Formula XIII is protected with a benzyl group. The alcohol of Formula XIII is reacted with sodium hydride in a suitable solvent such as N,N- dimethylformamide to form an alkoxide. The alkoxide is then alkylated with benzyl bromide to provide a compound of Formula XVIII. The reaction can be carried out at ambient temperature.
In step (2) of Reaction Scheme IV a compound of Formula XVIII is oxidized using the method of step (2) of Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline- 5N-oxide of Formula XIX.
In step (3) of Reaction Scheme IV a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XIX is chlorinated to provide a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XX. Preferably a solution of a compound of Formula XIX in a suitable solvent such as toluene is treated with phosphorous oxychloride at ambient temperature.
In step (4) of Reaction Scheme IV a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XX is reacted with phenol to provide a 4-phenoxy-lH-imidazo[4,5-c]quinoline of Formula XXI. The phenol is reacted with sodium hydride in a suitable solvent such as diglyme to form a phenoxide. The phenoxide is then reacted at an elevated temperature with a compound of Formula XX.
In step (5) of Reaction Scheme IV the benzyl protecting group is removed from a compound of Formula XXI to provide a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXII. The reaction is preferably carried out by adding triflic acid in a controlled fashion to a solution of a compound of Formula XXI in a suitable solvent such as dichloromethane at ambient temperature.
In step (6) of Reaction Scheme IV a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXII is alkylated with a halide of Ηal-Rn to provide a 4-phenoxy-lH- imidazo[4,5-c]quinolin-l-yl ether of Formula XXIII. The alkoxide of a compound of
Formula XXII is formed by adding the alcohol to a biphasic mixture of aqueous 50% sodium hydroxide and an inert solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethlammonium chloride. The alkoxide is then alkylated. The reaction can be carried out at ambient temperature. In step (7) of Reaction Scheme IV a 4-phenoxy-lH-imidazo[4,5-c]quinolin-l-yI ether of Formula XXIII is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XII which is a subgenus of Formula I. The reaction can be carried out by combining a compound of Formula XXIII with ammonium acetate and heating the resulting mixture at ~150°C. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme IN
Figure imgf000016_0001
Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme V where R, R2, Rn, X and n are as defined above.
In Reaction Scheme V a 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l- yl alcohol of Formula XXIV is alkylated with a halide of Formula XI to provide a 6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula XXV which is a subgenus of Formula III. The alcohol of Formula XXIV is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide to form an alkoxide. The alkoxide is then combined with the halide. The reaction can be carried out at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Many tetrahydro-lH-imidazo[4,5-c]quinolines of Formula XXIV are known, see for example, Nikolaides et al., U.S. Patent No. 5,352,784; others can be prepared using known synthetic methods, see for example, Lindstrom, U.S. Patent No. 5,693,811 ; the disclosures of which are incorporated by reference herein.
Reaction Scheme V
Figure imgf000017_0001
Compounds of the invention can also be prepared according to Reaction Scheme VI where R, Ri , R2, X and n are as defined above.
In step (1) of Reaction Scheme VI a 4-chloro-3-nitroquinoline of Formula XXVI is reacted with an amine of Formula Rι-0-X-NH2 to provide a 3-nitroquinolin-4-amine of Formula XXVII. The reaction can be carried out by adding the amine to a solution of a compound of Formula XXVI in a suitable solvent such as chloroform or dichloromethane and optionally heating. Many quinolines of Formula XXVI are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).
In step (2) of Reaction Scheme VI a 3-nitroquinolin-4-amine of Formula XXVII is reduced to provide a quinoline-3,4-diamine of Formula XXVIII. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl alcohol or preferably toluene. In step (3) of Reaction Scheme VI a quinoline-3,4-diamine of Formula XXVIII is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5- c]quinoline of Formula XXIX. Suitable equivalents to carboxylic acid include orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula XXIX. For example, triethyl orthoformate will provide a compound where R2 is hydrogen and triethyl orthoacetate will provide a compound where R2 is methyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction. Optionally a catalyst such as pyridine hydrochloride can be included.
Alternatively, step (3) can be carried out by (i) reacting the diamine of Formula XXVIII with an acyl halide of Formula R2C(0)C1 and then (ii) cyclizing. In part (i) the acyl halide is added to a solution of the diamine in a suitable solvent such as acetonitrile, pyridine or dichloromethane. The reaction can be carried out at ambient temperature. In part (ii) the product of part (i) is heated in an alcoholic solvent in the presence of a base.
Preferably the product of part (i) is refluxed in ethanol in the presence of an excess of triethylamine or heated with methanolic ammonia. Alternatively, if step (i) has been run in pyridine, step (ii) can be carried out by heating the reaction mixture after analysis indicates that step (i) is complete. In step (4) of Reaction Scheme VI a lH-imidazo[4,5-c]quinoline of Formula XXIX is oxidized using the method of step (2) of Reaction Scheme II to provide a 1H- imidazo[4,5-c]quinoline-5N-oxide of Formula XXX
In step (5) of Reaction Scheme VI a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XXX is aminated using the method of step (3) of Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula I.
Reaction Scheme VT
Figure imgf000019_0001
(3)
Figure imgf000019_0002
Compounds of the invention can be prepared according to Reaction Scheme VII where R, R2, X and n are as defined above and Rι2 is an aryl group which may be unsubstituted or substituted as defined above.
In step (1) of Reaction Scheme VII a lH-imidazo[4,5-c]quinolin-l-yl alcohol of
Formula XIII is alkylated with a halide of Formula XXXI to provide a lH-imidazo[4,5- c]quinolin-l-yl ether of Formula XXXII. The compound of Formula XIII and the halide of Formula XXXI are combined in a biphasic mixture of 50% aqueous sodium hydroxide and a suitable solvent such as dichloromethane in the presence of a phase transfer catalyst such as benzyltrimethylammonium chloride. The reaction can be run at ambient temperature. In step (2) of Reaction Scheme VII a lH-imidazo[4,5-c]quinoline of Formula
XXXII is oxidized using the method of step (2) of Reaction Scheme II to provide a 1H- imidazo[4,5-c]quinoline-5N-oxide of Formula XXXIII.
In step (3) of Reaction Scheme VII a lH-imidazo[4,5-c]quinoline-5N-oxide of
Formula XXXIII is reacted with trichloroacetyl isocyanate to provide a lH-imidazo[4,5- e]quinolin-4-yl trichloroacetamide of Formula XXXIV. Preferably the isocyanate is added in a controlled fashion at ambient temperature to a solution of the 5N-oxide in a suitable solvent such as dichloromethane.
In step (4) of Reaction Scheme VII a lH-imidazo[4,5-c]quinolin-4-yl trichloroacetamide of Formula XXXIV is hydrolyzed to provide a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV which is a subgenus of Formula II. The hydrolysis can be carried out by conventional methods, preferably by treating a solution of a compound of Formula XXXIV in methanol with sodium methoxide.
In step (5) of Reaction Scheme VII lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXV is coupled with a halide of formula Ηal-Rι2 using a transition metal catalyst to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVT which is a subgenus of Formula II. Preferably a compound of Formula XXXV is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)paIladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile. The reaction is preferably carried out at an elevated temperature (60-80°C). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme VII
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000021_0003
XXXVI
Figure imgf000021_0004
Compounds of the invention can be prepared according to Reaction Scheme VIII where R, R2, R-2, X and n are as defined above and BOC is tert-butoxycarbonyl. In step (1) of Reaction Scheme VIII the amino group of a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV is protected with two tert-butoxycarbonyl groups. A compound of Formula XXXV is combined with di-tert-butyl dicarbonate in a suitable solvent such as N,N-dimethylformamide in the presence of 4-(dimethylamino)pyridine and triethylamine. The reaction is carried out at an elevated temperature (80-85°C). In step (2) of Reaction Scheme VIII a protected lH-imidazo[4,5-c]quinolin-4- amine of Formula XXXVII is coupled with a halide of formula Ηal-Rι2 using a transition metal catalyst to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVIII. Preferably a compound of Formula XXXVII is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)palladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile. The reaction can be carried out at ambient temperature or at an elevated temperature (40-80°C).
In step (3) of Reaction Scheme VIII the protecting groups are removed by hydrolysis under acidic conditions to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II. Preferably a compound of Formula XXXVIII is treated with trifluoroacetic acid in a suitable solvent such as dichloromethane. The reaction can be run at ambient temperature or at a reduced temperature (0°C). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. In step (4) of Reaction Scheme VIII the alkyne bond of a protected \H- imidazo[4,5-c]quinolin-4-amine of Formula XXXVIII is reduced to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXIX. Preferably, the reduction is carried out using a conventional heterogeneous hydrogentation catalyst such as platinum oxide, platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as methanol.
In step (5) of Reaction Scheme VIII the protecting groups of a compound of Formula XXXIX are removed in the same manner as in step (3) to provide a 1H- imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme VIII
Figure imgf000023_0001
Compounds of the invention can be prepared according to Reaction Scheme IX where R, R , Rι2, X and n are as defined above and CBZ is benzyloxycarbonyl.
In step (1) of Reaction Scheme IX the amino group of a lH-imidazo[4,5- c]quinolin-4-amine of Formula XXXV is protected with benzyloxycarbonyl groups. A compound of Formula XXXV is combined with dibenzyl dicarbonate in a suitable solvent such as N,N-dimethylformamide. The reaction can be carried out at ambient temperature or with mild heating (40°C).
In step (2) of Reaction Scheme IX a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XLI is coupled with a halide of formula Ηal-Rj2 using a transition metal catalyst to provide a protected lH-imidazo[4,5-c]quinolin-4-amine of Formula XLII. Preferably a compound of Formula XLI is combined with the halide in the presence of copper (I) iodide, dichlorobis(triphenylphosphine)palladium(II), and excess triethylamine in a suitable solvent such as N,N-dimethylformamide or acetonitrile. The reaction can be carried out at ambient temperature or at an elevated temperature (40-80°C). In step (3) of Reaction Scheme IX the protecting groups are removed by hydrolysis to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II. Preferably a compound of Formula XLII is treated with sodium methoxide in a suitable solvent such as methanol. The reaction can be run at ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (4) of Reaction Scheme IX the protecting groups of a compound of Formula XLII are removed by hydrogenolysis and the alkyne bond is reduced to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I. Preferably, the hydrogenolysis/reduction is carried out using palladium hydroxide on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as methanol. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme IX
Figure imgf000025_0001
Compounds of the invention can be prepared according to Reaction Scheme X where R, Ri, R2, X and n are as defined above.
In step (1) of Reaction Scheme X a 2,4-dichloro-3-nitroquinoline of Formula XLIII is reacted with an amine of Formula Rι-0-X-NH2 to provide a 2-chloro-3-nitroquinolin-4- amine of Formula XLIV. The reaction can be carried out by adding the amine to a solution of a compound of Formula XLIII in a suitable solvent such as chloroform or dichloromethane and optionally heating. Many quinolines of Formula XLIII are known or can be prepared using known synthetic methods (see for example, Andre et al., U.S. Patent No. 4,988,815 and references cited therein). In step (2) of Reaction Scheme X a 2-chloro-3-nitroquinolin-4-amine of Formula XLIV is reduced using the method of step (2) in Reaction Scheme VI to provide a 2- chloroquinoline-3,4-diamine of Formula XLV.
In step (3) of Reaction Scheme X a 2-chloroquinoline-3,4-diamine of Formula XLV is cyclized using the method of step (3) in Reaction Scheme VI to provide a 4- chloro-lH-imidazo[4,5-c]quinoline of Formula XL VI.
In step (4) of Reaction Scheme X a 4-chloro-lH-imidazo[4,5-c]quinoline of Formula XL VI is aminated to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula I. The reaction is carried out by heating (e.g.,125-175°C) a compound of Formula XL VI under pressure in a sealed reactor in the presence of a solution of ammonia in an alkanol. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme X
Figure imgf000026_0001
(3)
Figure imgf000026_0002
Compounds of the invention can be prepared according to Reaction Scheme XI where- R, R], R2, X and n are as defined above. In Reaction Scheme XI a lH-imidazo[4,5-c]quinolin-4-amine of Formula XLVII is alkylated with a halide of Formula XLVIII to provide a lH-imidazo[4,5-c]quinolin-4- amine of Formula I. The compound of Formula XLVII is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide. The halide is then added to the reaction mixture. The reaction can be carried out at an elevated temperature (~100°C). Alkylation occurs at both the Nl and the N3 nitrogens; however, the desired 1-isomer can be readily separated from the 3-isomer using conventional techniques such as column chromatography and recrystallization.
Many lH-imidazo[4,5-c]quinolin-4-amines of Formula XLVII are known; others may be prepared using known synthetic methods, see for example, Gerster, U.S. Patent No. 5,756,747 and the references cited therein.
Reaction Scheme XI
Figure imgf000027_0001
XLVII XLVIII
Figure imgf000027_0002
Compounds of the invention can be prepared according to Reaction Scheme XII where R, Ri R2, X and n are as defined above.
In step (1) of Reaction Scheme XII a 4-nitrotetrazolo[l,5-a]quinolin-5-ol of Formula XLIX is chlorinated to provide a 5-chloro-4-nitrotetrazolo[l,5-a]quinoIine of
Formula L. Conventional chlorinating agents can be used. Preferably the reaction is carried out using phosphorus oxychloride in a suitable solvent such as N,N- dimethylformamide. 4-Nitrotetrazolo[l,5-a]quinolin-5-ols of Formula XLIX are known or can be prepared using known synthetic methods (see for example, Gerster, et al., U.S. Patent No. 5,741 ,908 and references cited therein).
In step (2) of Reaction Scheme XII a 5-chloro-4-nitrotetrazolo[l,5-a]quinoline of Formula L is reacted with an amine of Formula Rι-0-X-NΗ2 to provide a 4- nitrotetrazolo[l,5-a]quinolin-5-amine of Formula LI. The reaction can be carried out by adding the amine to a solution of a compound of Formula L in a suitable solvent such as dichloromethane in the presence of triethylamine.
In step (3) of Reaction Scheme XII a 4-nitrotetrazolo[l,5-a]quinolin-5-amine of Formula LI is reduced using the method of step (2) in Reaction Scheme VI to provide a tetrazolo[l,5-a]quinolin-4,5-diamine of Formula LII.
In step (4 ) of Reaction Scheme XII a tetrazolo[l,5-a]quinolin-4,5-diamine of Formula LII is cyclized using the method of step (3) in Reaction Scheme VI to provide a 6H-imidazo[4,5-c]tetrazolo[l,5- ]quinoline of Formula LIII. In step (5) of Reaction Scheme XII a 6H-imidazo[4,5-c]tetrazolo[l,5-α]quinoline of Formula LIII is reduced to provide a lH-imidazo[4,5-c]quinolin- 4-amine of Formula I. Step (5) involves (i) reacting a compound of Formula LIII with triphenylphosphine and then (ii) hydrolyzing. Part (i) can be carried out by combining a compound of Formula LIII with triphenylphosphine in a suitable solvent such as 1,2-dichlorobenzene and heating. Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme XII
Figure imgf000029_0001
Compounds of the invention can be prepared according to Reaction Scheme XIII where R, R2, Rι2, X and n are as defined above. In step (1) of Reaction Scheme XIII a lH-imidazo[4,5-c]quinolin-l-yl ether of
Formula XXXII is coupled with a halide of Formula Ηal-Rj2 using the method of step (5) in Reaction Scheme VII to provide a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LIV.
In step (2) of Reaction Scheme XIII a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LIV is oxidized using the method of step (2) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LV.
In step (3) of Reaction Scheme XIII a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LV is aminated using the method of step (3) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme XIII
Figure imgf000030_0001
Compounds of the invention can be prepared according to Reaction Scheme XIN where R, R2, Rι2, X and n are as defined above.
In step (1) of Reaction Scheme XIV the alkyne bond of a lH-imidazo[4,5- c]quinolin-l-yl ether of Fonnula LIV is reduced using the method of step (4) of Reaction Scheme VIII to provide a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LVI.
In step (2) of Reaction Scheme XIV a lH-imidazo[4,5-c]quinolin-l-yl ether of Formula LVI is oxidized using the method of step (2) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinoline-5Ν-oxide of Formula LVII.
In step (3) of Reaction Scheme XIV a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula LVII is aminated using the method of step (3) in Reaction Scheme II to provide a lH-imidazo[4,5-c]quinolin-4-amine of Formula XL which is a subgenus of Formula I. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme XIV
Figure imgf000031_0001
Tetrahydroimidazoquinolines of the invention can be prepared according to Reaction Scheme XV where R, R2, R12, X and n are as defined above.
In step (1) of Reaction Scheme XV a 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-l-yl alcohol of Formula XXIV is alkylated using the method described in Reaction Scheme V with a halide of Formula Ηal-(CΗ2)ι-ι0-CΗ≡CΗ to provide a 6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula LVIII which is a subgenus of Formula IV.
In step (2) of Reaction Scheme XV a 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinolin-4-amine of Formula LVIII is coupled using the method of step (5) of Reaction Scheme VII with a halide of Formula Ηal-Rι2 to provide a 6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-4-amine of Formula LIX which is a subgenus of Formula IV. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme XV
Figure imgf000032_0001
Compounds of the invention can be prepared according to Reaction Scheme XVI where R, Rls R2, X and n are as defined above. In step (1) of Reaction Scheme XVI a 2,4-dihydroxy-3-nitro-6,7,8,9- tetrayhydroquinoline of Formula LX is chlorinated to provide a 2,4-dichloro-3-nitro- 6,7,8,9-tetrayhydroquinoline of Formula LXI. Conventional chlorinating agents can be used. Preferably the reaction is carried out by combining a compound of Formula LX with phosphorous oxychloride and then heating (55-65°C). Compounds of Formula LX are known or can be prepared using known synthetic methods (see for example Nikolaides et al,. U.S. Patent 5,352,784 and references cited therein).
In step (2) of Reaction Scheme XVI a 2,4-dichloro-3-nitro-6,7,8,9- tetrayhydroquinoline of Formula LXI is reacted with an amine of Formula Rι-0-X-NH2 to provide a 2-chloro-3-nitro-6,7,8,9-tetrahydroquinolin-4-amine of Formula LXII. The reaction can be carried out by adding the amine to a solution of a compound of Formula
LXI in a suitable solvent such as N,N-dimethylformamide and heating (55-65°C).
In step (3) of Reaction Scheme XVI a 2-chloro-3-nitro-6,7,8,9-tetrahydroquinolin- 4-amine of Formula LXII is reacted with phenol using the method of step (4) of Reaction Scheme IV to provide a 2-phenoxy-3-nitro-6,7,8,9-tetrahydroquinolin-4-amine of Formula LXIII. In step (4) of Reaction Scheme XVI a 2-phenoxy-3-nitro-6,7,8,9- tetrahydroquinolin-4-amine of Formula LXIII is reduced using the method of step (2) of Reaction Scheme VI to provide a 2-phenoxy-6,7,8,9-tetrahydroquinolin-3,4-diamine of Formula LXIV. In step (5) of Reaction Scheme XVI a 2-phenoxy-6,7,8,9-tetrahydroquinolin-3,4- diamine of Formula LXIV is cyclized using the method of step (3) of Reaction Scheme VI to provide a 4-phenoxy-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline of Formula LXV.
In step (6) of Reaction Scheme XVI a 4-phenoxy-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinoline of Formula LXV is aminated using the method of step (7) of Reaction Scheme IV to provide a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine of Formula III.
Reaction Scheme XVI
Figure imgf000034_0001
The invention also provides novel compounds useful as intermediates in the synthesis of the compounds of Formulas (I), (II), (III), and (IV). These intermediate compounds have the structural Formulas (V) - (IX), described in more detail below. One class of intermediate compounds has formula (V):
Figure imgf000035_0001
(V) wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-; Ri is selected from the group consisting of: -aryl; -alkenyl; -I^-aryl; and -(CH2)M0-C≡C-R10 ; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl- Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-Ci-io alkyl;
-CO-O-CMO alkyl;
-N3;
-aryl; -heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; R-t is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or C O alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or-S(0)o-2S n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
Another class of intermediates are imidazoquinoline-4-phenoxy compounds of formula (VI):
Figure imgf000036_0001
(VI)
wherein X is -CHR3-, -CHR3-alkyI-, or -CHR3-aIkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl; -J r-aryl; and -(CH2) O-C≡C-Rιo ;
R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -heteroaryl;
-heterocyclyl; -alkyl-Y-alkyl; alkyl- Y- alkenyl; alkyl-Y-aryl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2; -CO-N(R3)2;
-CO-CMO alkyl; -CO-O-CMO alkyl; -N3; -aryl; -heteroaryl;
-heterocyclyl; -CO-aryl; and -CO-heteroaryl; R4 is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R3 is independently H or C O alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof. Another class of intennediate compounds are the imidazoquinoline-N-oxide compounds of formula (VII):
Figure imgf000038_0001
(VII)
wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl;
-R-r-aiyl; and -(CH2)MO-C≡C-R10; is alkyl or alkenyl, both of which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
An additional class of intermediate compounds has the formula (VIII):
Figure imgf000039_0001
(VIII)
wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl;
-R-t-aryl; and -(CH2) i -l o— * C≡C-Ri o; R2 is selected from the group consisting of: -hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl;
-alkyl- Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH;
-halogen; -N(R3)2; -CO-N(R3)2;
-CO-Ci-io alkyl;
-CO-O-CMO alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; K is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl;
R10 is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(O)0-2-; n is 0 to 4; each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; and R7 is tert-butyl or benzyl; or a pharmaceutically acceptable salt thereof.
A further class of intermediates are imidazoquinoline-4-chloro compounds of the formula (IX)
Figure imgf000040_0001
(IX)
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-; Ri is selected from the group consisting of: aryl; alkenyl; R-v-aryl; and -(CH2)MO-C≡CH R2 is selected from the group consisting of:
-hydrogen; -alkyl; -alkenyl; -aryl; -heteroaryl;
-heterocyclyl; -alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aiyl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2; -CO-N(R3)2;
-CO-CMO alkyl; -CO-O-CMO alkyl; -N3; -aryl; -heteroaryl;
-heterocyclyl; -CO-aryl; and -CO-heteroaryl; . is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
As used herein, the terms "alkyl", "alkenyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, and adamantyl.
In addition, the alkyl and alkenyl portions of -X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the group consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of any of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, tliiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
The aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, aroyloxy, aroylthio, aroylamino, alkylaminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, arylalkylcarbonylamino, heteroarylcarbonylamino, heteroarylalkylcarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, heteroarylsulfonylamino, heteroarylalkylsulfonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, arylaminocarbonylamino, arylalkylaminocarbonylamino, heteroarylaminocarbonylamino, heteroarylalkylaminocarbonylamino, and, in the case of heterocyclyl, oxo. If any other groups are identified as being "substituted" or "optionally substituted", then those groups can also be substituted by one or more of the above enumerated substituents.
Certain substituents are generally preferred. For example, R-t-aryl is a preferred Rj group and preferred Rio groups are alkyl and aryl, with phenyl or substituted phenyl being a preferred aryl group. Preferably no R substituents are present (i.e., n is 0). Preferred R2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), methoxyethyl, and ethoxymethyl. For substituted groups such as substituted alkyl or substituted aryl groups, preferred substituents include halogen, nitrile, nitro, carboxy, methoxy, methylthio, trifluoromethyl, and trifluoromethoxy. One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination. The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
Pharmaceutical Compositions and Biological Activity
Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
The term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg, of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
The compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon- (IFN-α) and/or tumor necrosis factor-α (TNF-α) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-α, TNF-α, IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
Certain compounds of the invention have been found to preferentially induce the expression of IFN-α in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response. For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-γ is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of the invention to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia. The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-α and/or TNF-α, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; variola, particularly variola major; rhinovirus; adenovirus; influenza; para-influenza; HIV;
CMV; VZV; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g. Candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g. pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis; and bacterial infections, e.g., tuberculosis, and mycobacterium avium. Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of keloid formation after surgery and other types of post-surgical scars. In addition, these compounds could enhance or stimulate the healing of wounds, including chronic wounds. The compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.
An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-α, TNF-α, IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg.
The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μg/kg to about 5 mg/kg.
The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
EXAMPLES
In the examples below some of the compounds were purified using semi- preparative HPLC. Two different methods were used and they are described below. Both methods used a A-100 Gilson-6 equipped with 900 Series Intelligent Interface. The semi- prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired compound. Method A
Column: column Microsorb C 18, 21.4 x 250 mm, 8 micron particle size, 60Apore; flow rate: 10 mL/min.; gradient elution from 2-95% B in 25 min., hold at 95% B for 5 min., where A=0.1 % trifluoroacetic acid/water and B=0.1% trifluoroacetic acid/acetonitrile; peak detection at 254 nm for triggering fraction collection. Method B
Column: Phenomenex Capcell PakClδ, 35 x 20 mm, 5 micron particle size; flow rate: 20 mL/min.; gradient elution from 5-95% B in 10 min., hold at 95% B for 2 min., where A=0.1 % trifluoroacetic acid/water and B=0.1% trifluoroacetic acid/acetonitrile; peak detection at 254 nm for triggering fraction collection.
Example 1 l-[2-(2-Propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000048_0001
Part A 2-(lH-Imidazo[4,5-c]quinolin-l-yl)-l-ethanol (28.5 g, 0.133 mol) was added in portions over a period of 1 hour to a mixture of sodium hydroxide (240 mL of 50%), dichloromethane (240 mL), propargyl bromide (39.6 g of 80%, 0.266 mol) and benzyltrimethylammonium chloride (2.46 g, 0.013 mmol). The resulting reaction mixture was allowed to stir at ambient temperature for 16 hours. The layers were separated. The aqueous fraction was extracted with additional dichloromethane. The organic fractions were combined, washed with water, dried over magnesium sulfate and then concentrated under reduced pressure. The resulting residue was combined with diethyl ether and the mixture was allowed to stir. An orange solid was isolated by filtration. This material was recrystallized from ethyl acetate to provide 19.8 g of 2-(lH-imidazo[4,5-c]quinolin-l- yfjethyl (2-propynyl) ether as a yellow crystalline solid, m.p. 124-126°C.
Analysis. Calculated for Cι5Ηι3N30: %C, 71.70; %H, 5.21; %N, 16.72. Found: %C, 71.85; %H, 5.25; %N, 16.90
!H NMR (300 MHz, DMSO) δ 9.21 (s, 1 H), 8.44 (m, 1 H), 8.36 (s, IH), 8.18 (m, 1 H), 7.71 (m, 2 H), 4.93 (t, J = 5.1 Hz, 2 H), 4.14 (d, J = 2.4 Hz, 2 H), 3.98 (t, J = 5.1 Hz, 2 H), 3.35 (t, J = 2.2 Hz, 1 H)
HRMS(ESI) Calculated for Cι5Hι4N30 (MH1") 252.1137, found 252.1141 Part B
2-(lH-Imidazo[4,5-c]quinolin-l-yl)ethyl (2-propynyl) ether (19.7 g, 78.4 mmol) and chloroform were combined and then cooled to 0°C. 3-Chloroperoxybenzoic acid (15.7 g of 57-86%) was added and the mixture was allowed to stir for 0.5 hour. The mixture was allowed to warm to ambient temperature by which time all material was in solution. Analysis by thin layer chromatography (TLC) indicated that some starting material was still present so more 3-chloroperoxybenzoic acid (two separate 4 g portions) was added. About 0.5 hour after the second portion was added, TLC showed no starting material. The reaction solution was extracted with 10% sodium hydroxide. The aqueous fraction was then extracted multiple times with dichloromethane. The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide 18.5 g of l-[2-(2-proρynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N- oxide as a yellow oil.
ΗRMS(ESI) Calculated for CιSHι4N302 (MH ) 268.1086, found 268.1098
Part C Under a nitrogen atmosphere trichloroacetyl isocyanate (15.5 g, 82.2 mmol) was added dropwise to a mixture of l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline- 5N-oxide (18.3 g, 68.5 mmol) and dichloromethane (300 mL). Vigorous carbon dioxide evolution was observed. After about 0.5 hour all of the material was in solution. The reaction solution was allowed to stir for about 1 hour at which time analysis by TLC indicated the presence of a small amount of starting material. More trichloroacetyl isocyanate (4.5 g) was added. After 1 hour, TLC analysis indicated that the reaction was complete. The volatiles were removed under reduced pressure to provide N-{l-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-yl}-2,2,2-trichloroacetamide as a pale yellow solid. Part D
Dichloromethane (150 mL) was added to a mixture of the solid from Part C and methanol (200 mL) and all of the material went into solution. Sodium methoxide (50 g of 25% in methanol) was added and the solution was allowed to stir at ambient temperature overnight. The resulting precipitate was isolated by filtration. The filtrate was concentrated to a volume of approximately 100 mL and a second crop of precipitate was isolated by filtration. The two crops were combined and dried in a vacuum oven at 60°C for 16 hours to provide 16.4 g of l-[2-(2-ρropynyIoxy)ethyl]-lH-imidazo[4,5-c]quinolin- 4-amine as an off-white solid, m.p. 225-227°C. Analysis. Calculated for C]5Ηι4N40 (H20)ι/ : %C, 66.53; %H, 5.40; %N, 20.69. Found: %C, 66.33; %H, 5.18; %N, 21.12
'HNMR (300 MHz, DMSO) δ 8.13 (s, 1 H), 8.08 (br d, J = 7.8 Hz, 1 H), 7.62 (br d, J = 8.3 Hz, 1 H), 7.44 (br t, J = 7.6 Hz, 1 H), 7.24 (br t, J = 7.5 Hz, 1 H), 6.54 (s, 2 H), 4.81 (t, J = 5.4 Hz, 2 H), 4.14 (d, J = 2.4 Hz, 2 H), 3.93 (t, J = 5.1 Hz, 2 H), 3.38 (t, J = 2.4 Hz, 1
H)
HRMS(ESI) Calculated for C15H15N4O (MET1) 267.1246, found 267.1253
Example 2
2-{3-[2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]-l-propynyl}benzonitrile
Figure imgf000050_0001
Part A
Under a nitrogen atmosphere l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5- c]quinoIin-4-amine (16 g, 60.1 mmol), di-tert-butyl dicarbonate (32.7 g, 150 mmol), triethylamine (21 mL, 150 mol), N,N-dimethylforrnamide (150 mL) and 4- (dimethylamino)pyridine (0.1 g) were combined and heated to 80-85°C. After about 1 hour the mixture became homogeneous and TLC analysis indicated that very little starting material remained. The solution was heated for an additional hour. The solution was diluted with ethyl acetate and water. The layers were separated and the aqueous fraction was extracted with ethyl acetate. The organic fractions were combined, washed with water and then with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a pale orange-yellow solid. This material was triturated with diethyl ether to provide 22.6 g of N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as an off-white solid, m.p. 139- 142°C.
Analysis. Calculated for C25Η30N4O5: %C, 64.36; %H, 6.48; %N, 12.01. Found: %C, 64.40; %H, 6.43; %N, 12.06 Η NMR (300 MHz, DMSO) δ 8.44 (m, 1 H), 8.35 (s, 1 H), 8.08 (m, 1 H), 7.73 (m, 2 H), 4.94 (t, J = 4.9 Hz, 2 H), 4.12 (d5 J = 2.4 Hz, 2 H), 3.98 (t, J = 5.1 Hz, 2 H), 3.31 (t, J = 2.4 Hz, I H), 1.34 (s, 18 H)
HRMS(ESI) calcd for C25H3ιN405 (MH+) 467.2294, found 467.2307 Part B
Under a nitrogen atmosphere 2-iodobenzonitrile (0.54 g, 2.35 mmol), dichlorobis(triphenylphosphine)palladium(II) (0.09 g, 0.13 mmol), and copper(I) iodide (0.05 g, 0.26 mmol) were added to a mixture of N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.14 mmol) and anhydrous N,N~dimethylformamide (25 mL). After 2 hours the reaction mixture was slowly poured into water. The resulting precipitate was collected and dried at 35°C for 16 hours to provide 1.18 g of 2-(3-{2-[ 4-(bis tert-butoxycarbonyl)amino-lH-imidazo[4,5--.]quinolin- l-yl]ethoxy}-l-propynyl)benzonitrile as a solid. Η NMR (300 MHz, DMSO) δ 8.47 (d, J = 6.8 Hz, 1 H), 8.39 (s, 1 H), 8.06 (d, J = 7.8 Hz, 1 H), 7.87 (d, J = 7.3 Hz, 1 H), 7.40 - 7.80 (m, 4 H), 7.34 (d, J = 7.3 z, 1 H), 5.00 (br s, 2
H), 4.47 (br s, 2 H), 4.13 (s, 2 H), 1.31 (s, 18 H)
HRMS(ESI) Calculated for C32H34N5θ5 (Mi?) 568.2560, found 568.2565 Part C
Trifluoroacetic acid (20 mL) was added to a solution of the material from Part B in dichloromethane (20 mL). After 4 hours the reaction mixture was diluted with dichloromethane containing a small amount of methanol and 20% sodium hydroxide. The layers were separated. The aqueous fraction was extracted with dichloromethane. The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a yellow powder. This material was purified by flash chromatography eluting with 9/1 dichloromethane/methanol to provide
0.48 g of2-{3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]-l- propynyl}benzonitrile as a white powder, m.p. 180-183°C.
Analysis. Calculated for C22Η N50 • (H20)2/5: %C, 70.54; %H, 4.79; %N, 18.70. Found: %C, 70.61; %H, 4.75; %N, 18.70 Η NMR (300 MHz, DMSO) δ 8.19 (s, 1 H), 8.12 (d, J *= 8.3 Hz, 1 H), 7.88 (d, J = 7.8 Hz,
1 H), 7.55 - 7.75 (m, 3 H), 7.40 - 7.50 (m, 2 H), 7.24 (br t, J = 7.5 Hz, 1 H), 6.68 (br s, 2 H), 4.87 (t, J = 5.1 Hz, 2 H), 4.50 (s, 2 H), 4.09 (t, J = 5.1 Hz, 2 H) Example 3 l-{2-[(3-Phenyl-2-propynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000052_0001
Under a nitrogen atmosphere, a mixture of l-[2-(2-propynyloxy)ethyl]-lH- imidazo[4,5-c]quinolin-4-amine (10 g, 37.6 mmol), anhydrous N,N-dimethyIformamide (150 mL) and potassium carbonate (6.23 g, 45.1 mmol) was heated to 70°C. lodobenzene (4.43 mL, 39.5 mmol), dichlorobis(triphenylphosphine)palladium(II) (0.53 g, 0.75 mol), and copper(I) iodide (0.29 g, 1.50 mmol) were added and the mixture was allowed to stir for 0.5 hour. The temperature was raised to about 85°C. After 1.5 hours analysis by ΗPLC (reverse phase, acetonitrile/water with 0.1% trifluoroacetic acid) indicated that the reaction was complete. The mixture was allowed to cool to ambient temperature and then it was filtered. The filtrate was concentrated under reduced pressure. The residue was purified twice by flash chromatography (95/5 dichloromethane/methanol) to provide 2.7 g of l-{2-[(3-ρhenyl-2-propynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 196-197°C.
Analysis. Calculated for C2IΗι8N40: %C, 73.67; %H, 5.30; %N, 16.36. Found: %C, 73.29; %H, 5.23; %N, 16.35 Η NMR (300 MHz, DMSO) δ 8.17 (s, 1 H), 8.12 (d, J = 7.4 Hz, 1 H), 7.63 (dd, J = 8.3,
0.9 Hz, 1 H), 7.44 (t, J = 7.5 Hz, 1 H), 7.15-7.40 (m, 6 H), 6.60 (s, 2 H), 4.86 (t, J = 5.1 Hz, 2 H), 4.39 (s, 2 H), 4.03 (t, J = 5.1 Hz, 2 H) HRMS(EI) Calculated for C2ιH]8N40 (M+) 342.1481, found 342.1490 Example 4 l-{2-[(3-Phenyl-2-propynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine
Hydrochloride
l-{2-[(3-Phenyl-2-propynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.92 mmol) was dissolved in a mixture of methanol (15 mL) and dichloromethane (5 L). Hydrogen chloride/diethyl ether (10 mL of IM) was added and the reaction solution was allowed to stir for 16 hours by which time a precipitate had formed. The mixture was concentrated under reduced pressure to provide a solid. This material was recrystallized from acetonitrile containing a small amount of methanol to provide 0.52 g of l-{2-[(3- phenyl-2-propynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine hydrochloride as an off-white crystalline solid, m.p. 231-236°C.
Analysis. Calculated for C2ιΗι9ClN40 • (H20)ι/4: %C, 65.79; %H, 5.13; %N, 14.61. Found: %C, 65.72; %H, 5.0; %N, 14.73
Η NMR (300 MHz, DMSO) δ 8.49 (s, 1 H), 8.34 (d, J = 8.3 Hz, 1 H), 7.81 (br d, J = 8.3 Hz, 1 H), 7.72 (t, J = 7.8 Hz, 1 H), 7.56 (t, J = 7.8 Hz, 1 H), 7.30 - 7.40 (m, 3 H), 7.14 (dd, J = 8.0, 1.5 Hz, 2 H), 4.94 (t, J = 4.8 Hz, 2 H), 4.38 (s, 2 H), 4.05 (t, J = 4.9 Hz, 2 H) HRMS (El) Calculated for C2ιHι8N40 (M ) 342.1481, found 342.1485
Example 5 1 - {2-[3-(4-Methoxyphenyl)proρoxy]ethyl} - lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000053_0001
Part A Under a nitrogen atmosphere, N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.14 mmol), triethylamine (0.8 mL, 5.56 mmol), 4-iodoanisole (0.51 g, 2.18 mmol) and anhydrous N,N- dimethylformamide (15 mL) were combined. Dichlorobis(triphenylphosphine)palladium(II) (0.09 g, 0.13 mol) and copper(I) iodide
(0.05 g, 0.26 mmol) were added and the reaction mixture was stirred for 1 hour at ambient temperature at which time analysis by ΗPLC (reverse phase, acetonitrile/water) indicated that the reaction was complete. The reaction mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate. The organic fraction was washed with water and then with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide 0.95 g of N,N-(bis tert-butoxycarbonyl)-l-(2-{[3-(4- methoxyphenyl)-2-propynyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine as an orange solid. ΗRMS(EI) Calculated for C32H36N406 (M+) 572.2635, found 572.2635 Part B
N,N-(Bis tert-butoxycarbonyl)-l-(2-{[3-(4-methoxyphenyl)-2- propynyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine (0.75 g, 1.31 mmol), ethyl acetate (25 mL) and catalyst (100 mg of 5% Pd/C with 50% water) were combined and then hydrogenated on a Parr apparatus at 40 psi (2.8 Kg/cm ). No reaction occurred. Platinum oxide (150 mg) and methanol (10 mL) were added and the mixture was hydrogenated at 45 psi (3.15 Kg/cm2) for 1 hour. Hydrogen consumption was observed immediately. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to provide N,N-(bis tert-butoxycarbonyl)-l-{2-[3-(4- methoxyphenyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine as a yellow-brown gum.
ΗRMS(EI) Calculated for C32H40N4O6 (M+) 576.2948, found 576.2965
Part C
Under a nitrogen atmosphere trifluoroacetic acid (10 mL) was added to a mixture of the material from Part B and dichloromethane (10 mL). The resulting solution was allowed to stir for 4 hours. The solution was concentrated under reduced pressure. The residue was partitioned between 50% aqueous sodium hydroxide and dichloromethane containing a small amount of methanol. The organic fraction was dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a tan foam. The foam was purified by flash chromatography (9/1 dichloromethane/methanol) to provide a light yellow glass. The glass was triturated with diethyl ether to provide a white powder. This material was dried in a vacuum oven for 4 hours at 60°C to provide 0.41 g of l-{2-[3- (4-methoxyphenyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 116-118°C.
Analysis. Calculated for C22Η24N402: %C, 70.19; %H, 6.43; %N, 14.88. Found: %C, 69.79; %H, 6.40; %N, 14.73
!H NMR (300 MHz, DMSO) δ 8.17 (s, 1 H), 8.12 (d, J= 8.3 Hz, 1 H), 7.64 (d, J = 8.3 Hz, 1 H), 7.45 (t, J = 7.8 Hz, 1 H), 7.24 (t, J = 7.6 Hz, 1 H), 6.80 (d, J = 8.8 Hz, 2 H), 6.66 (d, J = 8.8 Hz, 2 H), 6.60 (s, 2 H), 4.80 (t, J = 5.1 Hz, 2 H), 3.81 (t, J = 4.9 Hz, 2 H), 3.66 (s, 3 H), 3.27 (t, J = 6.1 Hz, 2 H), 2.32 (t, J = 7.3 Hz, 2 H), 1.60 m, 2 H)
Example 6 NI,4-Dimethyl-3-{3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}-l- benzensulfonamide
Figure imgf000055_0001
Part A Under a nitrogen atmosphere, l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5- c]quinolin-4-amine (1.7 g, 6.35 mmol), dibenzyl dicarbonate (4.55 g, 15.9 mmol), triethylamine (1.8 mL, 13.0 mmol), 4-(dimethylamino)pyridine and anhydrous N,N- dimethylformamide (20 mL) were combined. The reaction mixture was heated to 90°C at which time the reaction turned homogeneous. It was then heated to 130°C for 4 hours. The reaction mixture was allowed to cool and then it was partitioned between dichloromethane and water. The aqueous fraction was extracted with dichloromethane. The organic fractions were combined, dried over magnesium sulfate and then concentrated to a volume of ~10 mL. The concentrate was allowed to stand over the weekend and then it was diluted with toluene. The resulting precipitate was isolated by filtration and identified as starting material. The filtrate was diluted with diethyl ether. The resulting precipitate was isolated by filtration to provide 1.1 g of benzyl N-{l-[2- (propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-yl}carbamate as a white solid. ]Η NMR (300 MHz, DMSO) δ 9.98 (s, 1 H), 8.34 (d, J = 7.8 Hz, 1 H), 8.30 (s, 1 H), 7.97 (d, J = 7.3 Hz, 1 H), 7.70 (t, J = 7.8 Hz, 1 H), 7.58 (t, J = 7.8 Hz, 1 H), 7.15-7.50 (m, 5 H), 5.21 (s, 2 H), 4.90 (t, J = 5.1 Hz, 2 H), 4.14 (d, J = 2.4 Hz, 2 H), 3.96 (t, J = 4.9 Hz, 2 H),
3.38 (t, J = 2.4 Hz, 2 H) Part B
Under a nitrogen atmosphere benzyl N-{l-[2-(propynyloxy)ethyl]-lH- imidazo[4,5-c]quinolin-4-yl}carbamate (0.37 g, 0.91 mmol), 3-iodo-4-methyl-l- benzenesulfonamide (0.3 g, 0.96 mmol), triethylamine (0.2 mL, 1.36 mmol) and anhydrous acetonitrile (20 mL) were combined.
Dichlorobis(triphenylphosphine)palladium(II) (13 mg, 0.018 mol) and copper(I) iodide (7 mg, 0.036 mmol) were added and the reaction solution was heated to ~45°C. After 3 hours analysis by reverse phase HPLC indicated that the reaction was complete. The reaction solution was concentrated under reduced pressure and the residue was purified by flash chromatography (98/2 to 95/5 dichloromethane/methanol) to provide 0.33 g of benzyl N-( 1 - {2-[(3 - {2-methyl-5-[(methylamino)sulfonyl]phenyl} -2-propynyl)oxy]ethyl} - lH-imidazo[4,5-c]quinolin-4-yl)carbamate as a pale yellow solid. !H NMR (300 MHz, DMSO) δ 9.96 (s, 1 H), 8.36 (m, 2 H), 7.96 (d, J = 8.3 Hz, 1 H), 7.55-7.70 (m, 4 H), 7.48 (m, 2 H), 7.30-7.45 (m, 5 H), 5.21 (s, 2 H), 4.95 (t, J = 4.6 Hz, 2
H), 4.40 (s, 2 H), 4.06 (t, J = 5.1 Hz, 2 H), 2.54 (s, 3 H), 2.40 (d, J = 4.9 Hz, 3 H) MS (CI) 584, 476 Part C
Platinum on carbon (0.08 g of 10%) was added to a mixture of benzyl N-(l-{2-[(3- {2-methyl-5-[(methylamino)sulfonyl]phenyl}-2-propynyl)oxy]ethyl}-lH-imidazo[4,5- c]quinolin-4-yl)carbamate (0.3 g, 0.51 mmol) and methanol (10 mL). The mixture was hydrogenated on a Parr apparatus at 40 psi (2.8 Kg/cm ) for 16 hours. Analysis by LC- MS indicated alkyne reduction but no phenoxycarbonyl removal. Palladium on carbon (0.1 g of 10%) was added and the reaction mixture was hydrogenated at 40 psi (2.8 Kg/cm2) for 8 hours. Analysis by LC-MS indicated only a small amount of phenoxycarbonyl removal. Palladium black (0.1 g) was added and the reaction mixture was hydrogenated at 40 psi (2.8 Kg/cm2) for 16 hours. Analysis by LC-MS indicated one major product with a mass consistent with the desired product. The reaction mixture was filtered and the filtrate was washed with methanol and dichloromethane. The solvents were removed under reduced pressure to provide an off-white powder. This material was recrystallized from acetonitrile to provide 0.11 g of N1,4-dimethyl-3-{3-[2-(4-amino-lH- imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}-l-benzensulfonamide as a light yellow crystalline solid, m.p. 207-209°C.
Analysis. Calculated for C23Η27N503S: %C, 60.91; %H, 6.00; %N, 15.44. Found: %C, 60.87; %H, 5.75; %N, 15.51 !H NMR (300 MHz, DMSO) δ 8.16 (s, 1 H), 8.12 (d, J = 8.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 7.53 (d, J = 1.5 Hz, 1 H), 7.44 (br t, J = 7.6 Hz, 1 H), 7.38 (m, 1 H), 7.24 (br t, J =
7.6 Hz, 1 H), 7.16 (d, 7.8 Hz, 1 H), 7.02 (dd, J = 7.8, 2.0 Hz, 1 H), 6.58 (s, 2 H), 4.80 (t, 5.2 Hz, 2 H), 3.82 (t, 5.2 Hz, 2 H), 3.31 (t, 5.9 Hz, 2 H), 2.47 (s, 3 H), 2.37 (d, 4.4 Hz, 2 H), 1.65 (m, 2 H) HRMS(EI) Calculated for C23H27N503S (M+) 453.1835, found 453.1834
Example 7 l-(2-{[3-(2-Isopropylphenyl)-2-propynyl]oxy}ethyl)- lH-imidazo [4,5-c]quinolin-4-amine Hydrochloride
Figure imgf000058_0001
Under a nitrogen atmosphere l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5- c]quinolin-4-amine (0.50 g, 1.88 mmol), 2-iodoisopropylbenzene (0.65 g, 2.63 mmol), triethylamine (0.68 mL, 4.88 mmol) and N,N-dimethylformamide (10 mL) were combined and then heated to 60°C. Copper (I) iodide (0.04 g) and dichlorobis(triphenylphosphine)palladium(II) (0.08 g) were added. After 1.5 hours analysis by TLC (9/1 dichloromethane/methanol) indicated that the reaction was complete. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography eluting with 9/1 dichloromethane/methanol. The product fractions were combined and concentrated under reduced pressure. The residue was purified by column chromatography eluting with 9/1 dichloromethane/methanol containing 0.5% concentrated ammonium hydroxide. The product fractions were combined and concentrated under reduced pressure to provide -0.38 g of a solid. This material was combined with hydrogen chloride/diethyl ether (3.9 mL of 1.0 M), stirred overnight and then concentrated under reduced pressure. The residue was recrystallized from isopropanol/methanol, isolated by filtration and then dried to provide 0.24 g of l-(2-
{[3-(2-isopropylphenyl)-2-ρropynyl]oxy}ethyl)- lH-imidazo[4,5-c]quinolin-4-amine hydrochloride as a solid, m.p. 239-241°C. Analysis. Calculated for C24Η24N40 •HCl«(H20)ι/2: %C, 67.06; %H, 6.09; %N, 13.03. Found: %C, 67.07; %H, 6.00; %N, 13.09. Η NMR (300 MHz, DMSO-d6) δ 8.54 (s, IH), 8.39 (d, J= 8.1 Hz, IH), 7.85 (d, J= 8.2
Hz, IH), 7.76 (t, J= 7.2 Hz, 1 H), 7.59 (t, J= 8.0 Hz, IH), 7.30-7.38 (m, 2 H), 7.11-7.19
(m, 2 H), 5.00 (t, J= 4.7 Hz, 2 H), 4.47 (s, 2 H), 4.10 (t, j= 4.7 Hz, 2 H), 3.16 (m,lH),
1.13 (d, J= 6.9 Hz, 6 H)
IR(KBr) 3363, 3111, 2957, 1672, 753 cm"1
HRMS (El) Calculated for C24H24N40 (M+) 384.1950, found 384.1943
Example 8 l-(2-{[3-(2,6-Dimethylphenyl)-2-propynyl]oxy}ethyl)- 1 H-imidazo [4,5 -c] quinolin-4-amine
Figure imgf000059_0001
Using the general method of Example7, l-[2-(2-propynyloxy)ethyl]-lH- imidazo[4,5-c]quinolin-4-amine (0.50 g, 1.88 mmol) was reacted with 2,6-dimethyl iodobenzene (0.61 g, 2.63 mmol). The crude product was purified by column chromatography eluting with 95/5 dichloromethane/methanol to provide 0.056 g of l-(2- {[3-(2,6-dimethylphenyl)-2-prop3 yl]oxy}ethyl)-lΗ-imidazo[4,5-c]quinolin-4-amine as a solid, m.p. 200-201°C. Analysis. Calculated for C23H22N40 •(H20)2/5: %C, 73.29; %H, 6.07; %N, 14.86. Found: %C, 73.36; %H, 5.88; %N, 14.84.
*H NMR (300 MHz, DMSO-d6) δ 8.19 (s, IH), 8.13 (d, J= 8.1 Hz, 1 H), 7.62 (d, J= 7.9 Hz, 1 H), 7.44 (t, J= 8.0 Hz, IH), 7.23 (t, J= 7.9 Hz, 1 H), 7.09-7.14 (m, 1 H), 7.01-7.03 (m, 2 H), 6.76 (s, 2 H), 4.87 (t, J= 4.9 Hz, 2 H), 4.48 (s, 2 H), 4.05 (t, J= 4.9 Hz, 2 H), 2.15 (s, 6 H), IR(KBr) 3379, 3065, 1659, 1530, 1483, 1107, 751 cm HRMS (El) Calculated for C23H22N40 (M+) 370.1794, found 370.1789.
Example 9 1 -(2- {[3-(4-Phenoxyphenyl)-2-propynyl]oxy} ethyl)- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000060_0001
Using the general method of Example7, l-[2-(2-propynyloxy)ethyl]-lH- imidazo[4,5-c]quinolin-4-amine (0.50 g, 1.88 mmol) was reacted with 4-iodophenyl phenyl ether (0.78 g, 2.63 mmol). The crude product was purified by column chromatography eluting with 95/5 dichloromethane/methanol to provide a solid. The solid was slurried with aqueous sodium hydroxide to remove salts and then purified by column chromatography eluting with 9/1 ethyl acetate/methanol to provide a solid. This material was further purified by column chromatography eluting with 99/1 ethyl acetate/methanol to provide 24 mg of 1 -(2- {[3-(4-phenoxyphenyl)-2-propynyl]oxy}ethyl)-lH-imidazo[4,5- c]quinolin-4-amine as a solid, m.p. 146-148°C.
Analysis. Calculated for C27Η22N402 •(H20)45: %C, 72.24; %H, 5.30; %N, 12.48. Found: %C, 71.82; %H, 4.85; %N, 12.35. Η NMR (300 MHz, DMSO-d6) δ 8.18 (s, 1 H), 8.12 (d, J= 7.4 Hz, 1 H), 7.62 (d, J= 7.7 Hz, 1 H), 7.41-7.47 (m, 3 H), 7.18-7.27 (m, 4 H), 7.06 (dd, J= 7.6, 1.0 Hz, 2 H), 6.90 (dd,
J= 6.7 Hz, 2 H), 6.71 (s, 2 H), 4.85 (t, J= 5.1 Hz, 2 H), 4.37 (s, 2 H), 4.02 (t, J= 5.0 Hz, 2
H)
IR (KBr) 3444, 3070, 2928, 1500, 1230, cm-1 HRMS (El) Calculated for C27H22N402 (M+) 434.1743, found 434.1748.
Example 10 l-[2-({3-[2-(Trifluoromethyl)phenyl]-2-propynyl}oxy)ethyl]- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000061_0001
Using the general method of Example 7, l-[2-(2-propynyloxy)ethyl]-lH- imidazo[4,5-c]quinolin-4-amine (0.50 g, 1.88 mmol) was reacted with 2- iodobenzotrifluoride (0.71 g, 2.63 mmol). The reaction mixture was concentrated under reduced pressure. The resulting glassy solid was treated with aqueous sodium bisulfite (10 mL) and methanol (20 mL). A solid was removed by filtration. The filtrate was concentrated under reduced pressure to provide a white powder. This material was washed with water and dried for 4 days in an oven at 80°C to provide ~0.33 g of a solid. This material was partially dissolved in a mixture of dichloromethane (17 mL) and methanol (17 mL). Hydrogen chloride/diethyl ether (3.24 L of 1.0 M) was added and the mixture turned homogeneous. The mixture was concentrated under reduced pressure to provide a brown crystalline residue. The residue was combined with 50/50 acetonitrile/ethyl acetate containing a small amount of methanol. Sodium hydroxide (0.5 mL of 20%) was added. The mixture was concentrated under reduced pressure to provide a glassy solid. This glassy solid was purified by column chromatography eluting with 9/1 ethyl acetate/methanol to provide 14 mg of l-[2-({3-[2-(trifluoromethyl)phenyl]-2- prop} yl}oxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as a white crystalline solid, m.p. 154-155°C. Analysis. Calculated for C22HπF3N40: %C, 64.39; %H, 4.18; %N, 13.65. Found: %C,
64.39; %H, 4.19; %N, 13.71
Η NMR (300 MHz, DMSO-d6) δ 8.16 (s, 1 H), 8.11 (d, J= 7.4 Hz, 1 H), 7.74 (d, J= 7.3
Hz, 1 H), 7.56-7.64 (m, 3 H), 7.38-7.46 (m, 2 H), 7.22 (t, J= 1.6 Hz, 1 H), 6.59 (s, 2 H),
4.87 (t, J= 5.1 Hz, 2 H), 4.45 (s, 2 H), 4.04 (t, J= 5.1 Hz, 2 H)
IR (KBr) 3375, 3102, 1657, 1583, 1530, 1484, 1320, 1103, 765 cm"1
HRMS (El) Calculated for C22H17F3N40 (M+) 410.1354, found 410.1350.
Example 11 1 -(2- {3 -[4-(lH- 1 -Pyrrolyl)phenyl]ρropoxy} ethyl)- lH-imidazo[4,5-c]quinolin-4-amine trifluoroacetate
Figure imgf000062_0001
Part A
Under a nitrogen atmosphere dibenzyl dicarbonate (50 g, 174 mmol) was added to a mixture of l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (16.4 g, 61.6 mmol) and anhydrous N,N-dimethylformamide (200 mL). The reaction mixture was allowed to stir at ambient temperature for 16 hours and the reaction mixture turned homogeneous. The reaction mixture was partitioned between ethyl acetate and water. The layers were separated. The aqueous layer was extracted with ethyl acetate. The organic fractions were combined, washed with water, washed with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a semisolid. This material was triturated with diethyl ether to provide 27.4 g of N,N-(bis benzyloxycarbonyl)-l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as a white solid. Part B
Under a nitrogen atmosphere N,N-(bis benzyloxycarbonyl)- 1-[2-(2- propynyloxy)ethylj-lH-imidazo[4,5-c]quinolin-4-amine (0.5 g, 0.94 mmol), anhydrous acetonitrile (5 mL), triethylamine (0.34 mL, 2.43 mmol), and l-(4-iodophenyl)pyrrole (0.28 g, 1.03 mmol) were combined and the resulting homogeneous mixture was heated to
80°C. Copper (I) iodide (0.007 g) and dichlorobis(triphenylphosphine)palladium(II) (0.013 g) were added. The reaction was complete in 30 minutes. The product was purified by liquid chromatography using 4/6 hexane/ethyl acetate to provide a glassy solid. This material was purified on a second column using 9/1 hexane/ethyl acetate to provide 0.229 g of N,N-(bis benzyloxycarbonyl)- l-[2-({3-[4-(lH-pyrrol-l-yl)phenyl]prop-2- ynyl}oxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine.
!Η NMR (500 MHz, DMSO-d6) δ 8.49 (d, J= 7.7 Hz, 1 H), 8.44 (s, 1 H), 8.14 (d, J= 7.9 Hz, 1 H), 7.75-7.77 (m, 2 H), 7.54 (d, J= 5.1 Hz, 2 H), 7.40 (s, 2 H), 7.32 (d, J= 6.8 Hz, 2 H), 7.24-7.27 (m, 6 H), 7.14-7.16 (m, 4 H), 6.29 (s, 2 H), 5.18 (s, 4 H), 5.00 (t, J= 5.2 Hz, 2 H), 4.42 (s, 2 H), 4.10 (t, j= 5.1 Hz, 2 H)
MS (CI) for C4ιH33N505m/z 676 (MH4), 632, 524, 408 Part C
The material from Part B, palladium hydroxide (0.24 g of 20% on carbon) and methanol (5 mL) were combined in a Parr flask and hydrogenated at 45 psi (3.2 Kg/cm2) for 3-4 hours. The reaction mixture was filtered to remove catalyst, the filter cake was washed with additional methanol, and the filtrate was concentrated under reduced pressure. The residue was purified by semi-preparative HPLC using Method B to provide 36.6 mg of l-(2-{3-[4-(lH-l-pyrrolyl)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin- 4-amine trifluoroacetate as a solid, m.p. 179-181°C. Analysis. Calculated for C25Η25N50 •C2HF302: %C, 61.71 ; %H, 4.99; %N,13.33. Found:
%C, 61.49; %H, 4.89; %N, 13.23
JH NMR (500 MHz, DMSO-d6) δ 8.51 (s, 1 H), 8.38 (d, J= 8.4 Hz, 1 H), 7.84 (d, J= 8.4 Hz, 1 H), 7.73 (t, J= 7.3 Hz, 1 H), 7.56 (t, J= 7.8, 1 H), 7.33 (d, J= 8.4 Hz, 2 H), 7.26 (t, J= 2.1 Hz, 2 H), 6.96 (d, J= 8.4, 2 H), 6.24 (t, J= 2.1 H, 2 H), 4.91 (t, J = 5.0, 2 H), 3.85 (t, J= 5.0, 2 H), 3.3-3.4 (m, 2 H), 2.35 (t, J= 7.6, 2 H), 1.61 (m, 2 H), IR (KBr) 2949, 1705, 1523, 1204, 1123, 721 cm"1 HRMS (El) Calculated for C25H25N50 (M+) 411.2059, found 411.2060. Example 12 3-{3-[2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}benzoic acid
Bis(trifluoroacetate)
Figure imgf000064_0001
Part A
Under a nitrogen atmosphere N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (2.82 g g, 6.04 mmol), benzyl 3- iodobenzoate (2.245 g, 6.64 mmol), triethylamine (2.2 mL, 15.7 mmol), and anhydrous acetonitrile (20 mL) were combined and the resulting mixture was heated to 60°C. Copper (I) iodide (0.05 g) and dichlorobis(triphenylphosphine)palladium(II) (0.0.08 g) were added. The reaction was complete in 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography eluting initially with dichloromethane and then with 98/2 dichloromethane/methanol to provide 1.82 g of benzyl 3-{3-[2-(4-(bis tert-butoxycarbonyl)amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]prop- 1 -ynyl}benzoate.
!Η NMR (300 MHz, DMSO-d6) δ 8.46 (d, J= 9.6 Hz, 1 H), 8.39 (s, 1 H), 8.05 (d, J= 9.8 Hz, 1 H), 7.94-7.98 (m, 1 H), 7.84 (s, 1 H), 7.50-7.70 (m, 2 H), 7.36-7.49 (m, 7 H), 5.36 (s, 2 H), 4.98 (t, J= 4.6 Hz, 2 H), 4.37 (s, 2 H), 4.06-4.13 (m, 2 H), 1.30 (s, 18 H) MS (CI) for C39H40N4O7 m/z 677 (MH+), 577, 477
Part B
A solution of the material from Part A in methanol was combined with catalyst (1.0 g of 10% palladium on carbon) and the mixture was hydrogenated at 45 psi (3.2 Kg/cm ) at ambient temperature for ~2.25 hours. More catalyst (0.3 g) was added and the hydrogenation was continued for an additional 2 hours. The reaction mixture was filtered to remove the catalyst and the filter cake was rinsed thoroughly with methanol. The filtrate was concentrated under reduced pressure to provide ~1.2 g of N,N-(bis tert- butoxycarbonyl)- 3 - {3 -[2-(4-amino- lH-imidazo[4,5-c]quinolin- 1 - yl)ethoxy]propyl}benzoic acid. Η NMR (300 MHz, DMSO-d6) δ 8.50 (d, J= 9.5 Hz, 1 H), 8.40 (s, 1 H), 8.07-8.10 (m, 1
H), 7.70-7.75 (m, 3 H), 7.65 (s, 1 H), 1.29 (s, 18 H), 7.29 (t, J= 1.6 Hz, 1 H), 7.10 (d, J = 7.8 Hz, 1 H), 4.94 (t, J= 4.5 Hz, 2 H), 3.88 (t, J= 4.5 Hz, 2 H), 3.32 (t, J= 6.0 Hz, 2 H), 2.43 (t, J= 7.0 Hz, 2 H), 1.62 (m, 2 H) MS (CI) for C32H38N407m/z 591 (MH4), 491, 391 Part C
Under a nitrogen atmosphere the material from Part B was combined with anhydrous dichloromethane (10 mL) and trifluoroacetic acid (10 mL). The reaction mixture was stirred for 1.5 hours. The reaction mixture was concentrated under reduced pressure to provide an oil which was dried under high vacuum at ambient temperature to give a solid. This solid was triturated with ether. The resulting white powder was dried at
65°C in a vacuum oven overnight to provide 1.19 g of 3-{3-[2-(4-ammo-lH-imidazo[4,5- c]quinolin-l-l)ethoxy]propyl}benzoic acid bis(trifluoroacetate), m.p. 138-140°C. Analysis. Calculated for C22Η22N403»(C2ΗF302)2: %C, 50.49; %H, 3.91; %N, 9.06. Found: %C, 50.37; %H, 3.67; %N, 9.08 !H NMR (300 MHz, DMSO-d6) δ 9.07-7.14 (bs, 2 H), 8.51 (s, 1 H), 8.37 (d, J= 7.8 Hz, 1
H), 7.82 (d J= 8.0 Hz, 1 H), 7.74 (m, 2 H), 7.64 (s, 1 H), 7.56 (t, J= 7.1 Hz, 1 H), 7.30 (t, J= 7.7 Hz, 1 H), 7.15 (d, J= 7.6 Hz, 1 H), 4.91 (t, J = 4.5 Hz, 2 H), 3.86 (t, J= 4.4 Hz, 2 H), 3.34 (t, J= 5.9 Hz, 2 H), 2.44(t, J= 7.4 Hz, 2 H), 1.64 (m, 2 H) IR (KBr) 3367, 3104, 2372, 1685, 1204, 1146 cm"1 HRMS (El) Calculated for C22H22N403 (M+) 390.1692, found 390.1690.
Example 13 2- { 3 -[2-(4-Amino- 1 H-imidazo [4, 5 -cjquinolin- 1 -yl)ethoxy]propyl } benzoic acid trifluoroacetate
Figure imgf000066_0001
Part A
Using the general method of Example 12 Part A, N,N-(bis tert-butoxycarbonyl)- 1- [2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (2 g, 4.3 mmol) was coupled with benzyl 2-iodobenzoate (1.57 g, 4.71 mmol) to provide 1.79 g of a mixture of mono-and di-BOC protected benzyl 2-{3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]prop-l-ynyl}benzoate.
]Η NMR (300 MHz, DMSO-d6) δ 8.45 (d, J= 7.9 Hz, 1 H), 8.39 (s, 1 H), 8.06-8.09 (m, 1 H), 7.85-7.88 (m, 1 H), 7.70-7.73 (m, 2 H), 7.47-7.51 (m, 2 H), 7.40-7.43 (m, 2 H), 7.28- 7.37 (m, 3 H), 7.19 (m, 1 H), 5.23 (s, 2 H), 4.97 (t, J= 5.0 Hz, 2 H), 4.27 (s, 2 H), 4.07 (t, J = 4.9 Hz, 2 H), 1.30(s, 18 H)
MS (CI) for C39H40N4O7 m z 677 (MH+), 577, 477 Part B
Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide 0.041 g of a mixture of mono-and di-BOC protected 2-{3-[2-(4- amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}benzoic acid.
■H NMR (300 MHz, DMSO-d6) δ 8.50 (d, J= 7.3 Hz, 1 H), 8.39 (s, 1 H), 8.08 (d, J= 7.9 Hz, 1 H), 7.71-7.75 (m, 3 H), 7.22-7.28 (m, 2 H), 6.90 (d, J= 7.4 Hz, 1 H), 4.93 (t, J= 4.6 Hz, 2 H), 3.87 (t, J= 4.5 Hz, 2 H), 3.30 (t, J= 5.6 Hz, 2 H), 2.73 (t, J= 5.7 Hz, 2 H), 1.61 (m, 2 H), 1.28 (s, 18 H) MS (CI) for C32H38N407 m/z 591 (MH+), 491 , 391 Part C
Using the general method of Example 12 Part C, the material from Part B was hydrolyzed to provide 0.28 g of 2-{3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]propyl}benzoic acid as a solid, m.p. 186-188°C. Analysis. Calculated for C22Η22N403»C2ΗF302: %C, 57.14; %H, 4.59; %N, 11.11. Found: %C, 56.81; %H, 4.47; %N, 11.08 'H NMR (300 MHz, DMSO-d6) δ 8.90-9.20 (bs, 1 H), 8.50 (s, 1 H), 8.38 (d, J= 10.1 Hz,
1 H), 7.84 (d, J= 8.3 Hz, 1 H), 7.71-7.75 (m, 2 H), 7.56 (t, J= 7.6 Hz, 1 H), 7.21-7.32 (m,
2 H), 6.88 (d, J= 6.9 Hz, 2 H), 4.90 (t, J= 4.8 Hz, 2 H), 3.84 (t, J= 4.6 Hz, 2 H), 3.32 (m, 2 H), 2.72 (t, J= 6.9 Hz, 2 H), 1.62 (m, 2 H)
IR (KBr) 3212, 2929, 1709, 1204, 1124, 747 cm"1
HRMS (El) Calculated for C22H22N403 (M+) 390.1692, found 390.1693.
Example 14 4-{3-[2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}benzoic acid trifluoroacetate
Figure imgf000067_0001
Part A
Using the general method of Example 12 Part A, N,N-(bis tert-butoxycarbonyl)- 1- [2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (2.82 g, 6.04 mmol) was coupled with benzyl 4-iodobenzoate (2.25 g, 6.64 mmol) to provide 2.14 g of a mixture of mono-and di-BOC protected benzyl 4-[3-(2-{4-amino-lΗ-imidazo[4,5-c]quinolin-l- yl} ethoxy)prop- 1 -ynyl]benzoate. !H NMR (300 MHz, DMSO-d6) δ 8.47 (d, J=7.2 Hz, 1 H), 8.40 (s, 1 H), 8.06 (d, J= 6.5
Hz, 1 H), 7.87-7.89 (m, 2 H), 7.70-7.73 (m, 2 H), 7.36-7.49 (m, 5 H), 7.23-7.27 (m, 2 H),
5.35 (s, 2 H), 5.0 (t, J= 4.5 Hz, 2 H), 4.40 (s, 2 H), 4.09 (t, J*= 4.5 Hz, 2 H), 1.30 (s, 18 H)
MS (CI) for C39H40N4O7 m/z 677 (MH+), 577, 477 Part B
Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide 1.86 g of a mixture of mono-and di-BOC protected 4-{3-[2-(4- amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]propyl}benzoic acid.
Η NMR (300 MHz, DMSO-d6) δ 8.51 (d, J= 7.1 Hz, 1 H), 8.40 (s, 1 H), 8.07-8.10 (m, 1 H), 7.72-7.75 (m, 4 H), 7.01 (d, J= 8.4 Hz, 2 H), 4.94 (t, J= 4.7 Hz, 2 H), 3.88 (t, J= 4.6
Hz, 2 H), 3.30 (m, 2 H), 2.38 (t, J= 7.3 Hz, 2 H), 1.62 (m, 2 H), 1.29 (s, 18 H)
MS (CI) for C32H38N4θ7m/z 591 (MH+), 491, 391
Part C
Using the general method of Example 12 Part C, the material from Part B was hydrolyzed to provide 0.96 g of 4-{3-[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)ethoxy]propyl}benzoic acid trifluoroacetate, m.p. 235-237°C.
Analysis Calculated for C22Η22N403«C2ΗF302: %C, 57.14; %H, 4.59; %N, 11.11. Found:
%C, 57.06; %H, 4.47; %N, 11.03
!HNMR (300 MHz, DMSO-d6) δ 9.00-9.11 (bs, 2 H), 8.51 (s, 1 H), 8.37 (d, J= 8.4 Hz, 1 H), 7.83 (d, J= 6.0 Hz, 1 H), 7.71-7.76 ( , 3 H), 7.55 (tJ= 9.7 Hz, 1 H), 7.01 (d, J= 8.2
Hz, 2 H), 4.91 (t, J*= 5.0 Hz, 2 H), 3.84 (t, J= 4.7 Hz, 2 H), 3.32 (t, J= 5.8 Hz, 2 H), 2.38
(t, J= 7.1 Hz, 2 H), 1.62 (m, 2 H)
IR(KBr) 3266, 3014,2361, 1667, 1277, 1201, 1142 cm"1
HRMS (El) Calculated for C22H22N403 (M1") 390.1692, found 390.1697.
Example 15 1 -(2- {3-[3-(Dimethylamino)phenyl]ρropoxy} ethyl)- 1 H-imidazo [4, 5 -c] quinolin-4-amine dihydrochloride
Figure imgf000069_0001
Part A
Using the general method of Example 12 Part A, except that the reaction temperature was raised to 80°C, N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (3 g, 6.43 mmol) was coupled with 3-iodo-N,N-dimethylaniline (7.07 mmol) to provide 3.06 g of a mixture of mono protected and unprotected l-[2-({3-[3-(dimethylamino)phenyl]prop-2-ynyl}oxy)ethyl]- 1 H-imidazo [4, 5 -c] quinolin-4-amine . Part B
Using the general method of Example 12 Part B, the material from Part A was hydrogenated to provide -2.9 g of a mixture of mono Boc protected and unprotected l-(2- {3-[3-(dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine.
Part C
The material from Part B was combined with hydrogen chloride/methanol (30 mL of 3 M) and stirred at ambient temperature for 19 hours. A precipitate was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was dissolved in a small amount of methanol and then neutralized with concentrated ammonium hydroxide to pΗ ~11. The resulting precipitate was purified by column chromatography eluting with 95/5/1 dichloromethane/methanol/ammonium hydroxide. This material was combined with hydrogen chloride/diethyl ether. The resulting solution was concentrated under reduced pressure. The residue was triturated with diethyl ether. The resulting solid was isolated by filtration and then dried to provide 0.114 g of l-(2-{3- [3-(dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine dihydrochloride, m.p. 180-183°C.
Analysis. Calculated for C23Η27N5θ.(ΗCl)2.ι«(Η20)2.ι: %C, 54.82; %H, 6.66; %N, 13.89. Found: %C, 54.60; %H, 6.50; %N, 13.66 *H NMR (300 MHz, DMSO-d6) δ 8.71-8.73 (bs, 2 H), 8.44 (s, 1 H), 8.35 (d, J= 7.4 Hz, 1
H), 7.83 (d, J= 8.0 Hz, 1 H), 7.72 (t, J= 7.6 Hz, 1 H), 7.55 (t, J= 6.8 Hz, 1 H), 7.15 (m, 1 H), 7.05 (m, 1 H), 6.96 (s, 1 H), 6.66 (d, J= 8.1 Hz, IH), 4.88 (t, J= 5.3 Hz, 2 H), 4.02 (t, J- 3.7 Hz, 2 H), 3.37 (t, J= 6.4 Hz, 2 H), 2.94 (s, 6 H), 2.40 (t, J= 7.6 Hz, 2 H), 1.66 (m, 2 H), IR (KBr) 3426, 3138, 2928, 1693, 1113 cm"1
HRMS (El) Calculated for C23H27N50 (M+) 389.2216, found 389.2217
Example 16 2-(Ethoxymethyl)-l-[2-(3-phenylpropoxy)ethyl]- lH-imidazo[4,5-c]quinolin-4-amine Hydrochloride
Figure imgf000070_0001
Part A
2-[2-(Ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethanol (3.50 g, 12.9 mmol) was slowly added over a period of 20 minutes to a suspension of sodium hydride (0.67 g of 60% in mineral oil, 16.77 mmol) in anhydrous N,N-dimethylformamide. The reaction mixture was allowed to stir for 1 hour and then l-bromo-3-phenylpropane (2.16 mL, 14.19 mmol) was added. The reaction mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The residue was purified by column chromatography eluting with ethyl acetate to provide 2.38 g of 2-
(ethoxymethyl)-l-[2-(3-phenylpropxy)ethyl]-lH-imidazo[4,5-c]quinoline as a yellow oil. MS (CI) for C24H27N302 m z 390 (MH+), 346. Part B
The material from Part A was combined with chloroform (50 mL) and cooled to 0°C. 3-chloroperoxybenzoic acid (2.22 g of 57-86%) was added. After 1 hour the reaction mixture was allowed to warm to ambient temperature. The reaction mixture was partitioned between aqueous sodium bicarbonate and dichloromethane. The organic fraction was dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide 2-(ethoxymethyl)-l-[2-(3-phenylpropxy)ethyl]-lH-imidazo[4,5- c]quinoline-5N-oxide as a brown solid. Part C
Under a nitrogen atmosphere trichloroacetyl isocyanate (0.87 mL, 7.33 mmol) was slowly added to a mixture of the material from Part B and anhydrous dichloromethane (60 mL). After 1 hour the reaction mixture was concentrated under reduced pressure to provide 2,2,2-trichloro-N-{2-(ethoxymethyl)-l-[2-(3-phenylpropxy)ethyl]-lH- imidazo[4,5-c]quinolin-l-yl}acetamide.
Part D
Sodium methoxide (4.79 mL of 25% in methanol) was added to a mixture of the material from Part C and methanol (30 mL). The reaction mixture was allowed to stir overnight and then it was concentrated under reduced pressure to provide a dark oil. The dark oil was purified by column chromatography eluting with 5% methanol in dichloromethane to provide a light yellow oil. The oil was treated with 1.0 M hydrogen chloride to provide a white solid. The material was isolated by filtration and then dried overnight in a vacuum oven at 80°C to provide 0.79 g of 2-(ethoxymethyl)-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine hydrochloride as a white solid, m.p. 128-134°C. Analyzed for C24Η28N402 • 1.55 HCl: %C, 62.53; %H, 6.46; %N, 12.15;
Found: %C, 62.64; %H, 6.47; %N, 11.91.
Η-NMR (300 MHz, DMSO-d6) δ 8.14 (br d, J=8.3 Hz, 1 H), 7.63 (dd, J=8.3, 1.0 Hz, 1 H), 7.45 (m, 1 H), 7.24 (m, 1 H), 7.05-7.15 (m, 3 H), 6.90 (m, 2 H), 6.62 (s, 2 H), 4.80- 4.90 (m, 4 H), 3.83 (t, J=5.4 Hz, 2 H), 3.56 (q, J=7.0 Hz, 2 H), 3.27 (t, J=6.1 Hz, 2H), 2.37 (t, J=7.6 Hz, 2 H), 1.63 (m, 2H), 1.16 (t, J=6.8 Hz, 3 H)
IR ( Br) 3267, 3023, 1681, 1108 cm"1 HR S (El) Calculated for C24H28N402 (M+) 404.2212, found 404.2215. Example 17 l-(l-{[(3-Chlorobenzyl)oxy]methyl}propyl)-lH-imidazo[4,5-c]quinolin-4-amme
Figure imgf000072_0001
Part A
2-Ethyl-2-(lH-imidazo[4,5-c]quinolin-l-yl)-l-ethanol (3.0 g, 12.43 mmol), dichloromethane (40 mL), aqueous sodium hydroxide (40 mL of 50%), benzyltrimethylammonium chloride (0.01 g) and 3-chlorobenzyl bromide (2.81 g, 13.67 mmol) were combined and the resulting solution was stirred at ambient temperature overnight. Analysis by TLC (5% methanol in dichloromethane) indicated that the reaction was complete. The reaction was diluted with dichloromethane (100 mL) and water (100 mL). The layers were separated. The aqueous fraction was extracted with dichloromethane. The organic fractions were combined, washed with brine, dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel eluting with ethyl acetate) to provide 4.22 g of l-(l-{[(3-chlorobenzyl)oxy]methyl}propyl)-lH-imidazo[4,5-c]quinoline as a light orange oil.
Η-NMR (300 MHz, DMSO-d6) δ 9.22 (s, IH), 8.63 (s, IH), 8.55 (d, J = 7.8 Hz, IH), 8.17 (dd, J= 7.8, 1.5 Hz, IH), 7.69 (m, 2H), 7.23 (dd, J**= 4.9, 1.5 Hz, 2H), 7.08 (s, IH), 7.03 (m, IH), 5.40 (m, IH), 4.47 (s, 2H), 3.34-4.07 (m, 2H), 2.11 (m, 2H), 0.88 (t, 7.3 Hz,
3H)
MS (CI) for C2ιH20ClN3O m/z 366 (MH+), 332 Part B
3-Chloroperoxy benzoic acid (2.84 g of 77%) was added in portions to a solution of the material from Part A in chloroform (60 mL). After 2 hours analysis by TLC (10% methanol in dichloromethane) indicated that the reaction was complete. The reaction was diluted with chloroform, washed with saturated sodium bicarbonate, washed with brine, dried over magnesium sulfate and then concentrated under reduced pressure to provide crude l-(l-{[(3-chlorobenzyl)oxy]methyl}propyl)-lH-imidazo[4,5-c]quinolin-5N-oxide. Part C Ammonium hydroxide (20 mL) was added to a solution of the material from Part B in dichloromethane (80 mL). Tosyl chloride (2.42 g) was added in portions. Analysis by TLC (5% methanol in dichloromethane) indicated that the reaction went to completion immediately after the addition of the tosyl chloride. The reaction mixture was diluted with dichloromethane and saturated sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over magnesium sulfate and then concentrated under reduced pressure to provide a light brown oil. The oil was purified by flash chromatography (silica gel eluting with 5% methanol in dichloromethane) to provide an off-white gooey solid. This material was purified by flash chromatography (silica gel eluting with 5% methanol in dichloromethane) to provide a pinkish-white solid. This material was further purified by flash chromatography (silica gel eluting with ethyl acetate) to provide -1.0 g of l-(l-{[(3-chlorobenzyl)oxy]methyl}propyl)-lH-imidazo[4,5- c]quinolin-4-amine as an off-white solid, m.p. 60-62°C. Analysis: Calculated for C2ιΗ2ιClN40- '/4 H20: %C, 65.41: %H, 5.62; %N, 14.54; Found: %C, 65.5; %H, 5.62; %N, 14.61. !H-NMR (300 MHz, DMSO-d6) δ 8.37 (s, IH), 8.19 (d, J= 8.3 Hz, IH), 7.62 (dd, J= 8.3,
1.5 Hz, IH), 7.43 (dt, J- 8.3, 1.5 Hz, IH), 7.18-7.28 (m, 3H), 7.09 (m, IH), 6.52 (br s, 2H), 5.24 (m, IH), 4.48 (s, 2H), 4.01 (dd, J= 10.5, 6.6 Hz, 2H), 3.92 (dd, J= 10.3, 4.4 Hz, 2H), 2.10 (quintet, J= 7.3 Hz, 2H), 0.88 (t, 7.3 Hz, 3H) MS (CI) for C2ιH2ιClN40 m/z 381 (MH ), 185
Example 18 l-{2-[3-(2-Aminophenyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine trifluoroacetate
Figure imgf000074_0001
Part A
Under a nitrogen atmosphere, N,N-(bis tert-butoxycarbonyl)- 1-[2-(2- propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine (0.50 g, 1.07 mmol), triethylamine (0.39 mL, 2.79 mmol)) and anhydrous acetonitrile (10 mL) were combined. The resulting solution was heated to 80°C. As the reaction was heating, 2-iodoaniline (0.26 mL, 1.18 mmol), copper (I) iodide (0.012 g) and dichlorobis(triphenylphosphine)palladium(II) (0.023 g) were added. The reaction mixture was heated at 80°C overnight. The acetonitrile was removed under reduced pressure and the residue was purified by flash chromatography (silica gel eluting with 3% methanol in dichloromethane) to provide 0.47 g of N,N-(bis tert-butoxycarbonyl)-l-(2-{[3-(2- aminophenyl)prop-2-ynyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a brown solid.
Η-NMR (300 MHz, DMSO-d6, D20) δ 8.47 (d, J= 3.6 Hz, IH), 8.37 (s, IH), 8.10 (d, J= 9.6 Hz, IH), 7.75 (m, 2H), 7.04 (t, J= 7.2 Hz, IH), 6.80 (m, IH), 6.65 (d, J= 8.3 Hz, IH), 6.45 (t, J= 7.3 Hz, IH), 4.98 (t, J= 4.4 Hz, 2H), 4.36 (s, 2H), 4.08 (t, J= 4.9 Hz, 2H), 1.31 (s, 18H)
Part B
Catalyst (5% platinum on carbon) was added to a solution of N,N-(bis tert- butoxycarbonyl)-! -(2-{[3-(2-aminophenyl)prop-2-ynyl]oxy}ethyl)-lH-imidazo[4,5- c]quinolin-4-amine in methanol. The mixture was hydrogenated on a Parr apparatus at 50 psi (3.5 Kg.cm2) overnight. The reaction mixture was filtered through a layer of Celite® filter aid and the filter cake was washed with additional methanol. The filtrate was concentrated under reduced pressure to provide an off-white solid. This material was purified by flash chromatography (silica gel eluting with dichloromethane, then with 1% methanol in dichloromethane, then with 2% methanol in dichloromethane and finally with 3% methanol in dichloromethane) to provide -0.25 g of N,N-(bis tert-butoxycarbonyl)- 1-
{2-[3-(2-aminophenyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine as a light yellow oil.
!Η-NMR (300 MHz, DMSO-dό) δ 8.23 (dd, J= 8.4, 0.9 Hz, IH), 8.16 (dd, J= 8.4, 0.9 Hz, IH), 7.97 (s, IH), 6.96 (dt, J= 7.5, 1.6 Hz, 2H), 6.87 (dd, J= 7.5, 1.4 Hz, IH), 6.62 (dt, J= 7.3, 1.0 Hz, IH), 6.57 (dd, J= 8.3, 1.1 Hz, IH), 5.29 (s, IH), 4.71 (t, J= 5.3 Hz,
2H), 3.91 (t, J= 5.1 hZ, 2H), 3.38 (t, J= 6.0 Hz, 2H), 2.39 (t, J= 7.4 Hz, 2H), 1.76 (m, 2H), 1.41 (br s, 18H)
MS (CI) for C3iH39N505 m/z 562 (MH+), 462, 362, 229 Part C A solution of the material from Part B in anhydrous dichloromethane (4 mL) was added with stirring to a solution of trifluoroacetic acid (2mL) and anhydrous dichloromethane (2 mL) which had been cooled to 0°C. The reaction mixture was kept in an ice bath for about 2 hours and then it was allowed to warm to ambient temperature. The reaction mixture was stirred at ambient temperature overnight. The volatiles were removed under reduced pressure to provide a pink oil. The oil was dissolved in ethyl acetate (~ 3mL) and triethylamine (~ 1 mL) was added dropwise. The mixture was allowed to stir for about an hour. The resulting precipitate was isolated by filtration to provide 0.13 g of l-{2-[3-(2-aminophenyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4- amine trifluoroacetate as a white solid. Analysis: Calculated for C2ιΗ23N50 • C2HF302: %C, 58.10; %H, 5.09; %N, 14.73; Found: %C, 57.78; %H, 4.97; %N, 14.59.
!H-NMR (300 MHz, DMSO-d6) δ 8.87 (br s, IH), 8.49 (s, IH), 8.36 (d, J= 7.8 Hz, IH), 7.83 (d, J= 8.3 Hz, IH), 7.72 (t, J= 7.3 Hz, IH), 7.56 (t, J= 7.6 Hz, IH), 6.81 (t, J= 7.6 Hz, IH), 6.51 (m, 2H), 6.32 (t, J= 6.8 Hz, IH), 4.90 (t, J= 4.6 Hz, 2H), 3.85 (t, J= 4.9 Hz, 2H), 3.33 (t, J= 6.1 Hz, 2H), 2.22 (t, J= 7.3 Hz, 2H), 1.55 (m, 2H) IR (KBr) 3414, 3335, 3253, 3019, 1738, 1202, 1185, 1131 cm"'
HRMS (El) Calculated for C2ιH23N50 (M*) 361.1903, found 361.1903 Example 19 4- {[2-(4- Amino- lH-imidazo[4,5-c]quinolin- 1 -yl)ethoxy]methyl}benzonitrile
Figure imgf000076_0001
Part A
2-(lH-Imidazo[4,5-c]quinolin-l-yl)ethanol (1.5 g, 7.0 mmol) was added to a stirring mixture of α-bromo-p-tolunitrile (1.79 g, 9.1 mmol), sodium hydroxide (20 ml, 50%), dichloromethane (20 ml), and benzyltrimethylammonium chloride (0.06 g, 0.3 mmol). The reaction was maintained for 18 hours and then diluted with dichloromethane
(20 ml) and water (20 ml). The two phases were separated and the aqueous fraction was extracted with additional dichloromethane. The organic fractions were combined, washed with water, dried (MgS04), filtered, and concentrated. The residue was purified by flash column chromatography (silica gel, 9/1 dichloromethane/methanol) to provide 1.8 g of 4-
{[2-(lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]methyl}benzonitrile.
Η NMR (500 MΗz, DMSO-d6) δ 9.22 (s, 1Η), 8.41 (s, 1Η), 8.40 (d, J=l.l Ηz, 1Η), 8.17
(dd, 1=8.3,1.2 Ηz, 1Η), 7.72 (dt, J=7.6,1.3 Ηz, 1Η), 7.66 (dt, 1=7.6,1.3 Ηz, 1Η), 7.63 (d,
J=8. 3 Ηz, 2Η), 7.25 (d, J=8.2 Hz, 2H), 4.97 (t, J=5.1 Hz, 2H), 4.53 (s, 2H), 3.97 (t, J=5.5 Hz, 2H);
MS (CI) m/e 329 (M+H).
Part B
3-Chloroperoxybenzoic acid (1.6 g, 5.5 mmol, 60% by weight) was slowly added to a solution of 4-{2-(lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]methyl}benzonitrile (1.8 g, 5.5 mmol) in chloroform (50 ml). The reaction was maintained overnight and then sequentially washed with saturated sodium bicarbonate (200 ml), water (2 X 100 ml), dried (MgS04), filtered, and concentrated to provide 1.4 g of l-{2-[(4- cyanobenzyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide. Part C
Trichloroacetyl isocyanate (0.73 ml, 6.1 mmol) was added dropwise to a solution of l-{2-[(4-cyanobenzyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide (1.4 g, 4.1 mmol) and dichloromethane (25 ml). The reaction was maintained overnight and then concentrated. The resulting red solid was dissolved in methanol (100 ml) and sodium methoxide (4 ml, 25% in methanol) was added dropwise. The reaction was maintained overnight. The crude product formed as a precipitate and was isolated by filtration. Purification of the solid by recrystallization (isopropyl alcohol) followed by flash column chromatography (silica gel, 9/1 dichloromethane/methanol) provided 1.0 g of 4-{[2-(4- amino-lH-imidazo[4,5-c]quinolin-l-yl)ethoxy]methyl}benzonitrile as a white solid, m.p.
238.1-239.2 °C.
!ΗNMR (300 MHz, DMSO-d6) δ 8.19 (s, IH), 8.07 (dd, J=8.2,1.0 Hz, IH), 7.67 (d, J=8.4 Hz, 2H), 7.62 (dd, J=8.4,l.l Hz, IH), 7.43 (dt, J=7.6,1.3 Hz, IH), 7.30 (d, J=8.4 Hz, 2H), 7.21 (dt, J=7.6, 1.3 Hz, IH), 6.56 (s, 2H), 4.86 (t, J=5.1 Hz, 2H), 4.55 (s, 2H), 3.93 (t, J=5.1 Hz, 2H);
IR (KBr) 3456, 3285, 3117, 3069, 2228, 1637, 1583, 1526, 1481, 1397, 1372, 1353, 1252,
1097,884,822,760 cm"1;
MS (El) m/e 343.1440 (343.1433 Calculated for C20Hι7N5O);
Analysis: Calculated for C20Hι7N5O: %C, 69.96; %H, 4.99; %N, 20.39. Found: %C, 70.09; %H, 4.90; %N, 20.16.
Example 20
2-(Ethoxymethyl)-l-(2-{[6-(4-phenylbutoxy)hexyl]oxy}ethyl)- lH-imidazo[4,5-c]quinoline-4-amine
Figure imgf000077_0001
Part A
A solution of 2-[2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethanol (1.0 g, 3.7 mmol) in N,N-dimethylformamide (20 ml) was added dropwise to a suspension of sodium hydride (0.19 g of a 60% dispersion in mineral oil, 4.8 mmol) in N,N- dimethylformamide (10 ml). The reaction was maintained for 45 minutes followed by the dropwise addition of {4-[(6-bromohexyl)oxy]butyl}benzene (1.6 g, 5.1 mmol). The reaction was stirred overnight at room temperature and then partitioned between ethyl acetate and water. The two phases were separated and the aqueous fraction was extracted with additional ethyl acetate. The organic fractions were combined, washed with water, dried (MgS0 ), filtered, and concentrated. The crude product was purified by flash column chromatography (silica gel, 4:1 ethyl acetate/hexanes) to provide 0.81 g of 2- (ethoxymethyl)-l-(2-{[6-(4-phenylbutoxy)hexyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline as a brown oil.
Part B
3-Chloroperoxybenzoic acid (0.47 g, 1.6 mmol, 60% by weight) was slowly added to a solution of 2-(ethoxymethyl)-l-(2-{[6-(4-phenylbutoxy)hexyl]oxy}ethyl)-lH- imidazo[4,5-c]quinoline (0.81 g, 1.6 mmol) in chloroform (15 ml). The reaction was maintained overnight and then sequentially washed with saturated sodium bicarbonate and water, dried (MgS0 ), filtered, and concentrated to provide 0.7 g of 2-(ethoxymethyl)-l-
(2-{[6-(4-phenylbutoxy)hexyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-5N-oxide as an orange solid.
Part C Trichloroacetyl isocyanate (0.25 ml, 2.1 mmol) was added dropwise to a solution of2-(ethoxymethyl)-l-(2-{[6-(4-phenylbutoxy)hexyl]oxy}ethyl)-lH-imidazo[4,5- c]quinolin-5N-oxide (0.7 g, 1.4 mmol) and dichloromethane (20 ml). The reaction was maintained for 2 hours and sodium methoxide (2.5 ml, 25% in methanol) was added dropwise. The reaction was maintained overnight. The mixture was filtered and the filtrate concentrated. Purification of the filtrate by flash column chromatography (silica gel, 97:3 ethyl acetate/methanol) provided 0.22 g of 2-(ethoxymethyl)-l-(2-{[6-(4- phenylbutoxy)hexyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline-4-amine as a colorless oil. -H NMR (300 MHz, DMSO-d6) δ 8.10 (d, J=7.9 Hz, IH), 7.62 (d, J=7.9 Hz, IH), 7.43 (t, J=7.3 Hz, IH), 7.28-7.12 (m, 6H), 6.55 (s, 2H), 4.79 (broad s, 4H), 3.82 (t, J=5.3 Hz, 2H), 3.55 (q, J=7.0 Hz, 2H), 3.33-3.22 (m, 6H), 2.56 (t, J=7.2 Hz, 2H), 1.62-1.33 (m, 8H), 1.18- 1.10 (m, 7H); MS (El) m e 518.3263 (518.3256 Calculated for C3ιH42N403);
Analysis: Calculated for C3ιH42N403: %C, 71.78; %H, 8.16; %N, 10.80. Found: %C, 71.20; %H, 8.39; %N, 10.68.
Example 21 l-{2-[3-(Benzyloxy)propoxy]ethyl}-2-(ethox3πnethyl)-lH-imidazo[4,5-c]quinolin-4- amine
Figure imgf000079_0001
A solution of 2-[2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethanol (1.0 g, 3.7 mmol) in N,N-dimethylformamide was added dropwise to a suspension of sodium hydride (0.19 g of a 60% dispersion in mineral oil, 4.8 mmol) in N,N-dimethylformamide (20 ml). The reaction was maintained for 2 hours followed by the dropwise addition of benzyl 3-bromopropyl ether (0.72 ml, 4.1 mmol). The reaction was stirred overnight at 100°C, quenched by pouring over ice, and extracted with ethyl acetate. The organic fractions were washed with water, dried (MgS0 ), filtered, and concentrated. The crude product was purified by flash column chromatography (silica gel, 4: 1 ethyl acetate/hexanes) to provide 0.45 g of l-{2-[3-(benzyloxy)propoxy]ethyl}-2- (ethoxymethyl)-lH-imidazo[4,5-c]quinoline as a brown oil l-{2-[3-(benzyloxy)propoxy]ethyl}-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinoline was converted to l-{2-[3-(benzyloxy)propoxy]ethyl}-2-(ethoxymethyl)-lH-imidazo[4,5- c]quinolin-4-amine using the general methods described in Parts B and C of Example20. Purification by flash column chromatography (silica gel, 95/5 ethyl acetate/methanol) provided the desired product as a colorless oil. Η NMR (300 MHz, DMSO-d6) δ 8.11 (dd, J=8.2,0.8 Hz, IH), 7.62 (dd, J=8.3, 1.2 Hz, IH), 7.44 (dt, J=7.6,1.2 Hz, IH), 7.32-7.19 (m, 6H), 6.56 (s, 2H), 4.85-4.77 (m, 4H), 4.26 (s, 2H), 3.84 (t, J=5.4 Hz, 2H), 3.54 (q, J=7.0 Hz, 2H), 3.40 (t, J=6.2 Hz, 2H), 3.26 (t, J=6.2 Hz, 2H), 1.63 (pentet, J=6.3 Hz, 2H), 1.15 (t, J=7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 152.0, 149.5, 145.2, 138.5, 133.3, 128.1, 127.4, 127.3,
126.8, 126.3, 126.25, 121.0, 120.6, 114.8, 71.8, 69.0, 67.5, 66.3, 65.4, 64.4, 45.4, 29.4, 14.9;
IR (KBr) 3305, 174, 2970, 2925, 2864, 1633, 1583, 1533, 1481, 1437, 1386, 1099, 754, 737, 698 cm"1; MS (El) m/e 434.2318 (434.2317 Calculated for C25H30N4O3).
Example 22 l-[2-(3-Phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000080_0001
According to the general method of Example 20 (Parts A-C), 2-(lH-imidazo[4,5- c]quinolin-l-yl)ethanol and (3-bromopropyl)benzene were combined to provide l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as a white solid.
'ΗNMR (300 MHz, DMSO-d6) δ 8.17 (s, IH), 8.12 (d, J=7.2 Hz, IH), 7.64 (dd, J=8.3,1.0 Hz, IH), 7.45 (m, IH), 7.24 (m, IH), 7.16-7.08 (m, 3H), 6.92-6.89 (m, 2H), 6.60 (s, 2H), 4.81 (t, J=5.1 Hz, 2H), 3.82 (t, J=5.1 Hz, 2H), 3.29 (t, J=6.1 Hz, 2H), 2.38 (m, 2H), 1.63 (m, 2H), 1.56-1.25 (m, 8H), 0.88 (t, J=7.2 Hz, 3H); 13C NMR (75 MHz, CDC13) δ 151.5, 144.9, 142.6, 141.4, 132.6, 128.3, 128.2, 127.4,
127.1, 125.8, 122.2, 119.8, 115.4, 70.4, 68.6, 47.6, 32.0, 30.9; MS (El) m/e 347.1882(347.1872 Calculated for C2ιH22N40). Example 23 l-(2-{[3-(3,4-Dimethylρhenyl)-2-propynyl]oxy}ethyl]- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000081_0001
Under a nitrogen atmosphere, l-[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5- c]quinolin-4-amine (0.5 g, 1.9 mmol), copper (I) iodide (0.036 g, 0.2 mmol), 4-iodo-ortho- xylene (0.5 g, 2.1 mmol) and pyrrolidine (10 mL) were combined and stirred at ambient temperature. Dichlorobis(triphenylphosphine)palladium(II) (0.066 g, 0.1 mmol) was added and the reaction mixture was stirred at ambient temperature for 1 hour. Analysis by TLC
(30% methanol in chloroform) indicated that starting material was still present. The reaction mixture was heated at 65°C overnight. The pyrrolidine was removed under reduced pressure. The resulting residue was triturated with dichloromethane containing methanol. The insoluble material was isolated by filtration and then recrystallized from toluene (40 mL) to provide 0.1 g of l-(2-{[3-(3,4-dimethylphenyl)-2-propynyl]oxy}ethyl]- lH-imidazo[4,5-c]quinolin-4-amine as a solid, m.p. 214-216°C. Analysis: Calculated for C23Η22N40: %C, 74.57; %H, 5.99; %N, 15.12; Found: %C, 74.24; %H, 5.98; %N, 15.08. Η-NMR (300 MHz; DMSO-d6) δ (ppm) 8.167(s,lH), 8.112(d,J=7.3Hz,lH), 7.628(d,J=8.3Hz,lH), 7.44(t,J=7.3Hz,lH), 7.232(t,J*=6.8Hz,lH), 7.078(d,J=7.8Hz,lH), 7.024(s,lH), 6.952(d,J=7.9Hz,lH), 6.586(s,2H), 4.849(t,J=5Hz,2H), 4.365(s,2H),
4.015(t,J=5.6Hz,2H), 2.197(s,3H), 2.159(s,3H).
Examples 24 - 27 The compounds in the table below were prepared according to the synthetic method of Reaction Scheme I above using the following general method. 2-(4-Amino-lH~imidazo[4,5-c]quinolin-l-yl)-2-ethylethanol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.75 eq of 60% in mineral oil) and N,N- dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 10 minutes at ambient temperature to allow the alkoxide to form. The halide (1.75 eq) was added and the vial was placed back on the sonicator for about 30 to 60 minutes at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The reaction mixture was purified by semi-preparative ΗPLC. The semi-prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
Figure imgf000082_0001
Figure imgf000083_0001
Examples 28 - 41
The compounds in the table below were prepared according to the synthetic method of Reaction Scheme I above using the following general method.
The 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.2 eq of 60% in mineral oil) and N,N- dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 1 hour at 50°C to allow the alkoxide to form. The halide (1.2 eq) was added and the vial was placed back on the sonicator for about 1 to 2 hours at 50°C. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The reaction mixture was purified by semi-preparative ΗPLC. The semi-prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Examples 42 - 88
The compounds in the table below were prepared according to the synthetic method of Reaction Scheme I above using the following general method.
The 4-amino-lH-imidazo[4,5-c]quinolin-l-yl alcohol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.2 eq of 60% in mineral oil) and N,N- dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 15 to 30 minutes at ambient temperature to allow the alkoxide to form. The halide (1.2 eq) was added and the vial was placed back on the sonicator for about 15 to 120 minutes at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The reaction mixture was purified by semi-preparative ΗPLC. The semi-prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM) or nominal mass (NM).
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Examples 89 - 96
The compounds in the table below were prepared according to the synthetic method of Reaction Scheme V above using the following general method.
2-(4-Amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)ethanol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.2 eq of 60% in mineral oil) and N,N-dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 15 minutes at ambient temperature to allow the alkoxide to form. The halide (1.2 eq) was added and the vial was placed back on the sonicator for about 15 minutes at ambient temperature. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The reaction mixture was purified by semi-preparative ΗPLC. The semi-prep ΗPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product , which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Examples 97 - 100
The compounds in the table below were prepared according to the synthetic method of Reaction Scheme III above using the following general method.
A 1 mL portion of a solution prepared by dissolving 0.5 g of l-(4-amino-lH- imidazo[4,5-c]quinolin-l-yl)propan-2-ol in N,N-dimethylformamide (20 mL) was added to a 2 dram (7.4 mL) glass vial containing the phenol (2 eq.). Triphenylphosphine (54 mg, 2 eq.) dissolved in N,N-dimethylformamide (1 mL) was added to the vial. The resulting slurry was sonicated to dissolve the phenol. Diethyl azodicarboxylate (36 mg, 2 eq.) was added neat. The reaction mixture was sonicated for about 30 minutes and then shaken overnight at ambient temperature. The reaction mixture was purified by semi-preparative ΗPLC using Method A. The compounds of Examples 99 and 100 were provided as the trifluoroacetate salts The products were confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the nominal mass (NM).
Figure imgf000103_0002
Figure imgf000104_0001
Examples 101 - 104
The compounds in the table below were prepared according to the synthetic method of Reaction Scheme III above using the following general method.
A 1 mL portion of a solution prepared by dissolving 0.5 g of 2-(4-amino-lH- imidazo[4,5-c]quinolin-l-yl)-2-ethylethanol in N,N-dimethylformamide (20 mL) was added to a 4 dram (15 mL) glass vial containing the phenol (2 eq.). Triphenylphosphine (51 mg, 2 eq.) dissolved in N,N-dimethylformamide (1 L) was added to the vial. Diethyl azodicarboxylate (34 mg, 2 eq.) was added neat. The resulting solution was sonicated for about 2 minutes and then shaken overnight at ambient temperature. Analysis by HPLC indicated that the reaction was not complete. The solvent was removed under vacuum. The resulting oil was dissolved in 1 mL of tetrahydrofuran containing triphenylphosphine (2 eq.). Diethyl azodicarboxylate (2 eq.) was added neat. The reaction mixture was shaken at ambient temperature overnight. Analysis by HPLC indicated that the reaction was complete. The reaction mixture was purified by semi-preparative HPLC using Method B The semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the nominal mass (NM).
Figure imgf000105_0001
Figure imgf000106_0001
Example 105 l-(2-Phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000106_0002
2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)ethanol (25 mg, 0.108 mmol) and N,N-dimethylformamide (1 mL) were combined. Phenol (12 mg, 0.130 mmol) and triphenylphosphine (34 mg, 0.130 mmol) were added and the resulting slurry was sonicated for about 1 minute. Diethyl azodicarboxylate (23 mg, 0.130 mmol) was added and the reaction mixture was shaken at ambient temperature for 24 hours. Analysis by LC-MS showed that a major amount of starting material remained. An additional equivalent each of phenol, triphenylphosphine and diethyl azodicarboxylate were added. The reaction mixture was sonicated for 30 minutes. After 1 hour analysis by LC-MS showed product. The solvent was removed and the residue was purified by semi- preparative HPLC using Method A. Mass Measurement: TM = 304, NM[M+H]+1 = 305.
> Example 106 l-[(l-Phenoxymethyl)propyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000107_0001
2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)-2-ethylethanol (50 mg, 0.195 mmol) and N,N-dimethylformamide (2 mL) were combined. Phenol (37 mg, 0.390 mmol) and triphenylphosphine (102 mg) were added followed by diethyl azodicarboxylate (67 mg,
0.390 mmol). The resulting solution was sonicated for 1 hour. Analysis by LC-MS showed product and a small amount of starting material. The solvent was removed and the residue was purified by semi-preparative ΗPLC using Method A. Mass Measurement: TM = 332, NM[M+Η]+1 = 333.
Example 107 l-{(li?)-l-[(Prop-2-ynyloxy)methyl]propyl}-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000107_0002
Part A Crude 4-chloro-3-nitroquinoline (413.8 g, 1 eq.) was dissolved in dichloromethane
(1.65 L). The solution was heated to reflux and then filtered through a layer of Celite® filter agent. The filtrate was cooled to 5°C with stirring. Triethylamine (305.4 mL, 1.1 eq.) was added in a single portion. The reaction mixture was stirred for 15 minutes. (R)-(-)-2-Amino- 1-butanol (205 mL, 1.1 eq.) was added dropwise while maintaining the temperature of the reaction mixture below 40°C. The reaction mixture was allowed to stir at ambient temperature for several days. The reaction mixture was cooled to -30°C. A yellow precipitate was isolated by filtration, washed with very cold dichloromethane and then sucked dry. The solid was slurried for 1 hour with cold 80/20 water/methanol (1 L), isolated by filtration, washed with cool water, washed with very cold methanol (2 X 300 mL), and then sucked dry on the filter overnight to provide 475 g of (2R)-2-[(3- nitroquinolin-4-yl)amino]butan- 1 -ol. Part B (2R)-2-[(3-Nitroquinolin-4-yl)amino]butan-l-ol (238 g), isopropanol (5 L) and catalyst (23.8 g of 5% platinum on carbon) were combined in a stainless steel vessel and hydrogenated at 50 psi (3.5 Kg/cm2) for 16 hours. The reaction mixture was filtered through a layer of Celite® filter agent to remove the catalyst. The filtrate was concentrated under reduced pressure to provide 208.3 g of (2R)-2-[(3-aminoquinolin-4- yl)amino]butan-l-ol as an amber oil. The reaction was run a second time on the same scale. Part C
(2R)-2-[(3-Aminoquinolin-4-yl)amino]butan-l-ol (416.0 g, 1 eq.) and triethylorthoformate (1.2 L, 4 eq.) were combined and slowly heated to 145°C. Ethanol was distilled off as it formed during the reaction. After -500 mL of ethanol had been distilled off, the reaction mixture was allowed to cool to 50°C under a nitrogen atmosphere. Excess triethyLorthoformate was removed under reduced pressure to provide crude (2R)-2-( 1 H-imidazo [4, 5-c] quinolin- 1 -yl)butan- 1 -ol . Part D A mixture of (2R)-2-(lH-imidazo[4,5-c]quinolin-l -yl)butan-l -ol (434.3 g) and acetic anhydride (1.2 L) was slowly heated over a period of about 2 hours to 100°C. The reaction mixture was allowed to cool to ambient temperature overnight. Methanol (2.5 L) was added and the reaction mixture exothermed to produce a vigorous reflux. The reaction mixture was heated at reflux for an additional 2 hours, cooled to ambient temperature and then concentrated under reduced pressure. The residue was diluted with water and then made basic with sodium bicarbonate. Analysis of the resulting oil by TLC (20% methanol in ethyl acetate) showed two products and no starting material. The oil was extracted into ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide 359.3 g of a residue. This material was combined with acetic anhydride (1.6 L) and then heated to reflux for 1 hour. The reaction mixture was allowed to cool to ambient temperature overnight and then concentrated under reduced pressure. Analysis of the residue by TLC showed a single product spot. The residue was diluted with water (1 L), made basic (pH 8) with saturated sodium bicarbonate solution and then stirred for 1 hour. The resulting precipitate was isolated by filtration, washed with water and then dried in a vacuum oven overnight at 60°C to provide (2R)-2-(lH-imidazo[4,5-c]quinolin-l-yl)butyl acetate as a brown solid.
Part E
Sodium methoxide (163.0 g of 25% in methanol, 1.1 eq.) was added in a single portion to a solution of (2R)-2-(lH-imidazo[4,5-c]quinolin-l-yl)butyl acetate (194.0 g, 1 eq.) in methanol (970 mL). The reaction mixture was stirred at ambient temperature for 3 hours and then concentrated under reduced pressure. The residue was diluted with water
(1 L), neutralized (pΗ 6-7) with acetic acid and then stirred at ambient temperature overnight. The resulting precipitate was isolated by filtration, washed with water (2 X 200 mL), air dried on the filter and then dried in a vacuum oven overnight at 50°C to provide 145.5 g of (2R)-2-(lH-imidazo[4,5-c]quinolin-l-yl)butan-l-ol as a solid. Part F
(2R)-2-(lH-Imidazo[4,5-c]quinolin-l-yl)butan-l-ol (19 g, 78.8 mmol) was added to a mixture of sodium hydroxide (124 mL of 50%), dichloromethane (150 mL), benzyltrimethyl ammonium chloride (0.73 g), and propargyl bromide (11.4 mL, 102 mmol). The reaction mixture was allowed to stir at ambient temperature overnight. The reaction mixture was diluted with dichloromethane and water. The aqueous fraction was extracted multiple times with dichloromethane. The organic fractions were combined, washed with water, dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The residue was purified by column chromatography eluting with ethyl acetate to provide 20.9 g of l-{(lR)-l-[(prop-2-ynyloxy)methyl]propyl}-lH-imidazo[4,5- cjquinoline as a brown liquid. Part G
3-Chloroperoxybenzoic acid (15.0 g of 57-86%) was added to a chilled (0°) mixture of the material from Part F and chloroform (250 mL). After 0.5 hour the reaction mixture was allowed to warm to ambient temperature. The progress of the reaction was monitored by TLC and two additional portions of 3-chloroperoxybenzoic acid (3.75 g) were added. When the reaction was complete, it was washed with sodium bicarbonate. The aqueous fraction was extracted with ethyl acetate. The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide l-{(lR)-l-[(prop-2-ynyloxy)methyl]propyl}-lH-imidazo[4,5- c]quinoline-5N-oxide as a brown oil which solidified overnight.
Part Η
Trichloroacetyl isocyanate (10.7 mL) was added dropwise to a mixture of the material from Part G and anhydrous dichloromethane (300 mL). After 1 hour analysis by TLC indicated that the reaction was not complete so more trichloroacetyl isocyanate (2 mL) was added. After 1 hour the reaction mixture was concentrated under reduced pressure to provide 2,2,2-trichloro-N-(l-{(lR)-l-[(2-propynyloxy)methyl]propyl}-lH- imidazo[4,5-c]quinolin-4-yl)acetamide as a yellow solid.
Parti
Sodium methoxide (57.5 mL of 25% in methanol) was added to a mixture of the material from Part Η and methanol (250 mL). The reaction mixture turned homogeneous after 0.5 hour and was stirred overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography eluting with 80/20 dichloromethane/methanol to provide a solid. The solid was washed with diethyl ether, recrystallized from toluene and then dried in an oven at 60°C overnight to provide 9.77 g of l-{(lR)-l-[(prop-2-ynyloxy)methyl]propyl}-lH-imidazo[4,5-c]quinolin-4-amine as a crystalline solid.
Η-NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1 H), 8.19 (d, J=8.3 Hz, 1 H), 7.65 (dd, J=8.3, 1.5 Hz, 1 H), 7.44 (br t, J=7.6 Hz, 1 H), 7.25 (br t, J=7.6 Hz, 1 H), 6.65 (s, 2 H), 5.23 (m, 1 H), 4.17 (d, J=2.0 Hz, 2 H), 3.90-4.10 (m, 2 H), 3.46 (t, J=2.4 Hz, 1 H), 2.07 (m, 2 H), 0.88 (t, J=7.3 Hz, 3 H). Example 108 1 -(( IR)- 1 - { [(3-Phenylprop-2-ynyl)oxy]methyl}propyl)- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000111_0001
Part A
Under a nitrogen atmosphere l-{(lR)-l-[(prop-2-ynyloxy)methyl]propyl}-lH- imidazo[4,5-c]quinolin-4-amine (0.80 g, 1.25 mmol) and anhydrous N,N- dimethylformamide (60 mL) were combined and then heated to 40°C. Dibenzyl dicarbonate (3.98 g, 13.9 mmol) was added. The reaction was monitored by TLC and
ΗPLC. After 2 hours more dibenzyl dicarbonate (1 g) was added. After 1 hour the reaction went to completion. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide N,N-(bis benzyloxycarbonyl)-l-{(lR)-l- [(prop-2-ynyloxy)methyl]propyl}-lH-imidazo[4,5-c]quinolin-4-amine as a light brown oil. The oil was washed with hexane to remove excess dibenzyl dicarbonate. Part B
N,N-(Bis benzyloxycarbonyl)- 1 - {( IR)- 1 -[(prop-2-ynyloxy)methyl]propyl} - 1H- imidazo[4,5-c]quinolin-4-amine (1.91 g, 3.4 mmol), anhydrous acetonitrile (30 mL) and triethylamine (0.71 mL, 5.1 mmol) were combined and then heated to 70°C. Copper (I) iodide (0.026 g), dichlorobis(triphenylphosphine)palladium(II) (0.048 g) and iodobenzene (0.40 mL, 3.7 mmol) were added. The reaction was complete in 0.5 hour. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, dried over magnesium sulfate, filtered and then concentrated under reduced pressure to provide a brown liquid. This material was purified by column chromatography eluting with 39.5/59.5/1 ethyl acetate/hexane/triethylamine to provide 2.1 g of an oil. The oil was a mixture of mono and di benzyloxycarbonyl protected l-((lR)-l-{[(3-phenylprop-2- ynyl)oxy]methyl}propyl)-lH-imidazo[4,5-c]quinolin-4-amine. Part C
A portion of the material from Part B (0.8 g), methanol, and sodium methoxide (1.0 mL of 25% in methanol) were combined. After 16 hours analysis by TLC indicated that the reaction was complete. The reaction mixture was concentrated under reduced pressure. The resulting oil was purified by column chromatography eluting with 5 % methanol in dichloromethane to provide a glassy solid. This material was dried under high vacuum at ambient temperature overnight to provide 0.3 g of l-((lR)-l-{[(3-phenylprop- 2-ynyl)oxy]methyl } propyl)- 1 H-imidazo [4,5-c] quinolin-4-amine, m. . 63 -67°C . Analysis:. Calculated for C23Η22N40: %C, 74.57; %H, 5.99; %N, 15.12; Found: %C, 74.18; %H, 6.10; %N, 15.00.
Η-NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1 H), 8.21 (d, J=8.3 Hz, 1 H), 7.64 (dd, J=8.5, 1.2 Hz, 1 H), 7.43 (br t, J=7.6 Hz, IH), 7.25-7.40 (m, 5H), 7.22 (br t, J=7.6 Hz, 1 H), 6.61 (s, 2 H), 5.26 (m, 1 H), 4.41 (s, 2 H), 3.95-4.20 (m, 2 H), 2.10 (m, 2 H), 0.90 (t, J=7.3 Hz, 3 H)
IR (KBr) 3306, 3171, 1634, 1526, 1100, 755 cm"' HRMS (El) Calculated for C23H22N40 (M+) 370.1794, found 370.1798.
Example 109 l-{(lR)-l-[(3 -Phenylpropoxy)methyl]propyl } - lH-imidazo [4,5-c] quinolin-4-amine
Figure imgf000112_0001
Under a nitrogen atmosphere palladium hydroxide (0.72 g of 20% on carbon) was added to a solution of material from Example 108 Part B (1.3 g) in methanol (-20 mL).
Ill The mixture was hydrogenated at 50 psi (3.5 Kg/cm2) for 3.5 hours. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure.
The residue was purified by column chromatography eluting with 2.5% methanol in dichloromethane to provide an oil. The oil was triturated with diethyl ether to provide a solid which was isolated and dried to provide 0.4 g of l-{(lR)-l-[(3- phenylpropoxy)methyl]propyl}-lH-imidazo[4,5-c]quinolin-4-amine as a white crystalline solid, m.p. 118-120°C.
Analysis: Calculated for C23Η26N40: %C, 73.77; %H, 7.00; %N, 14.96. Found: %C,
73.68; %H, 7.17; %N, 14.72. Η-NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1 H), 8.22 (d, J=7.8 Hz, 1 H), 7.65 (dd, J=8.3,
1.0 Hz, 1 H), 7.44 (br t, J=7.7 Hz, IH), 7.05-7.30 (m, 4H), 6.95 (br d, J=6.8 Hz, 2 H), 6.62
(s, 2 H), 5.20 (m, IH), 3.88 (m, 2 H), 3.36 (m, 2 H), 2.37 (br t, J=7.6 Hz, 2 H), 2.08 (m, 2
H), 1.63 ( , 2 H), 0.89 (t, J=7.3 Hz, 3H)
IR (KBr) 3458, 3109 1639, 1528, 1392, 1250, 760 cm"' HRMS (El) Calculated for C23H26N40 (M÷) 374.2107, found 374.2104.
Examples 110 - 112 Part A Triethylamine (15 mL) and R-3-amino-2-methylpropan-l-ol (about 0.1 mole of crude) were added to a solution of 2,4-dichloro-3-nitroquinoline (24.3 g, 0.1 mole) in dichloromethane (250 mL). The reaction mixture was refluxed until analysis by TLC showed no change. The reaction mixture was evaporated to dryness. The solid yellow- brown residue was crushed and then extracted repeatedly with hexane containing a small amount of dichloromethane in order to remove the starting quinoline. The residue was then recrystallized from isopropanol to provide 19.0 g of R-3-[(2-chloro-3-nitroquinolin-4- yl)amino]-2-methylpropan-l-ol as a yellow solid. A sample (500 mg) was recrystallized from isopropanol to provide a yellow crystalline solid, m.p. 174-176°C. Part B R-3-[(2-Chloro-3-nitroquinolin-4-yl)amino]-2-methylpropan-l-ol (10 g, 33.8 mmol), isopropanol (350 mL) and catalyst (-1 g of 5% platinum on carbon) were combined and then hydrogenated on a Parr apparatus at 50 psi (3.5 Kg/cm2) initial hydrogen pressure. When hydrogen uptake had ceased, the reaction mixture was filtered to remove the catalyst. The filtrate was evaporated under reduced pressure to provide crude R-3-[(3-amino-2-chloroquinolin-4-yl)amino]-2-methylpropan-l-ol. Diethoxymethyl acetate (10.0 mL, 61.5 mmol) was added to the crude intermediate and a strong heat of reaction was observed. The resulting solution was heated on a steam bath for 20 minutes and then diluted with water and ammonium hydroxide. The resulting oil was extracted into ethyl acetate. The extracts were combined, dried over magnesium sulfate and then concentrated under reduced pressure. The resulting solid was slurried with ethyl acetate/hexane, isolated by filtration, washed with ethyl acetate/hexane and then dried to provide 6.0 g of R 3-(4-chloro-lH-imidazo[4,5-c]quinolin-l-yl)-2-methylpropan-l-ol as a yellow/tan solid. Part C
R 3-(4-Chloro-lH-imidazo[4,5-c]quinolin-l-yl)-2-methylpropan-l-ol (1.0 g, 3.6 mmol) and methanolic ammonia (30 mL of -15%) were combined and then heated in a steel bomb at 150°C. The container was allowed to cool to ambient temperature. Excess methanolic potassium hydroxide was added to the reaction mixture which was then concentrated under reduced pressure to decrease the volume. Water was added and then concentration was continued until a solid formed. The solid was isolated by filtration, washed with water and then dried to provide a near white solid. This material was recrystallized from methanol/dichloromethane to provide R 3-(4-amino-lH-imidazo[4,5- c]quinolin-l-yl)-2-methylpropan-l-ol as colorless solid, m.p. 258-261°C. Analysis: Calculated for C]4Ηι6N40: %C, 65.61, %H, 6.29; %N, 21.86; Found: %C, 65.50, %H, 6.3, %N, 21.7. Part D The compounds in the table below were prepared according to the synthetic method of Reaction Scheme I above using the following general method.
R 3-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)-2-methylpropan-l-ol (25 mg) was placed in a 2 dram (7.4 mL) vial. Sodium hydride (1.2 equivalents of 60% in mineral oil) and N,N-dimethylformamide (1 mL) were added. The vial was placed on a sonicator for about 15 minutes at 50°C to allow the alkoxide to form. The halide (1.2 equivalents) was added and the vial was placed back on the sonicator for about 2 hours at 50°C. The reaction mixture was analyzed by LC/MS to confirm the formation of the desired product. The reaction mixture was purified by semi-preparative HPLC. The semi-prep HPLC fractions were analyzed by LC-APCI/MS and the appropriate fractions were combined and lyophilized to provide the trifluoroacetate salt of the desired product, which was confirmed by accurate mass and Η NMR. The table below shows the structure of the free base and the theoretical mass (TM) and the measured mass (MM).
Figure imgf000115_0001
Example 113 l-[(Benzyloxy)methyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000116_0001
Sodium hydride (0.48 g of 60%, 11.9 mmol) was added to a suspension of 1H- imidazo[4,5-c]quinolin-4-amine (2.0 g, 10.9 mmol) in N,N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 3 hours and then chilled in an ice bath. Benzyl chloromethyl ether (1.5 mL, 10.9 mmol) was added. The reaction mixture was stirred at ambient temperature for 2 hours and then heated on a steam bath for 1 hour. A precipitate was isolated by filtration. The filtrate was diluted with water and an oil separated. The oil was seeded with the precipitated solid and 2.1 g of a gummy solid was obtained. This material was slurried with refluxing ethyl acetate (-5 mL). The mixture was cooled and a precipitate was isolated by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was slurried twice with ethyl acetate and then combined with the precipitate to provide 0.8 g of solid. This solid was recrystallized from ethanol (~5 mL) to provide 0.6 g of l-[(benzyloxy)methyl]-lH-imidazo[4,5-c]quinolin-4- amine, m.p. 168-172°C.
Analysis: Calculated for Cι8Ηι6N40: %C, 71.0; %H, 5.3; %N, 18.4; Found: %C, 70.9; %H, 5,3; %N, 18.4.
Example 114 l-(2-{3-[4-(Dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000117_0001
Part A Using the general method of Example 12 Part A, N,N-(bis tert-butoxycarbonyl)- 1 -
[2-(2-propynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine ( 2.5 g, 5.36 mmol) was reacted with 4-iodo-N,N-dimethylaniline (1.46 g, 5.89 mmol) at 70 °C. The reaction was judged complete at 30 minutes. The solution was diluted with ethyl acetate, washed with water (3x), saturated aqueous sodium bicarbonate (3x), brine (3x), dried with anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The resulting solid was purified by chromatography over silica gel (98/2 dichloromethane/methanol) to provide 0.883 g of tert-butyl l-[2-({3-[4-(dimethylamino)phenyl]prop-2-ynyl}oxy)ethyl]- lH-imidazo[4,5-c]quinolin-4-ylcarbamate as a brown solid. MS (CI) for C33Η39Ν505 m/z 586 (MH+), 486, 386, 229 Part B
Using the general method of Example 12 Part B, tert-butyl l-[2-({3-[4- (dimethylamino)phenyl]prop-2-ynyl}oxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-ylcarbamate (0.883 g, 1.507 mmol) was hydrogenated to provide 0.783 g of tert-butyl l-(2-{3-[4- (dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-ylcarbamate as a brown solid.
MS (CI) for C33Η-* 3N505 m z 590 (MH+), 490, 390, 229 Part C
Using the general method of Example 12 Part C, tert-butyl l-(2-{3-[4- (dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-ylcarbamate (0.783 g, 1.327 mmol) was reacted with trifluoroacetic acid (10 mL). The resulting material was triturated twice with ethyl ether to provide 0.634 g of l-(2-{3-[4-
(dimethylamino)phenyl]propoxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine
(trifluoroacetate)ι.5 as a white solid, m.p. 137-140°C.
Analysis. Calculated for C23H27N50 (C2HF302)ι.5: %C, 54.83; %H, 5.22; %N, 12.30.
Found: %C, 54.67; %H, 4.91; %N, 12.27
Η NMR (300 MHz, DMSO-d6) δ 9.04-9.11 (bs, 2 H), 8.49 (s, 1 H), 8.36 (d, J = 7.3 Hz, 1
H), 7.83 (d, J = 8.3, 1 H), 7.74 (t, J = 8.3 Hz, 1 H), 7.56 (t, J = 6.8 Hz, 1 H), 6.71 (d, J =
7.8 Hz, 2 H), 6.60 (m, 2 H), 4.90 (t, J = 4.9, 2 H), 3.83 (t, J = 4.9, 2 H), 3.27 (t, J = 5.9, 2
H), 2.28 (s, 6 H), 2.25 (t, J = 7.8, 2 H), 1.54 (p, J = 6.4, 6.8, 2 H)
MS (CI) for C23H27N50 m z 390 (MH+), 229
Example 115 l-(2-{[(2E)-3-Phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000118_0001
Part A
A dried round bottom flask was charged with a stir bar, sodium hydride (60% in mineral oil, 0.19 g, 4.65 mmol) and hexane (2 mL) under nitrogen. By syringe a solution of anhydrous dimethylformamide (10 mL) and 2-(lH-imidazo[4,5-c]quinolin-l-yl)ethanol (0.902 g, 4.23 mmol) was added to the flask and heated to 60 °C for 20 minutes. By syringe cinnamyl chloride (0.65 mL, 4.65 mmol) was added to solution. The reaction was judged complete at 50 minutes with -80% conversion to desired product. The volatiles were removed under reduced pressure and the resulting oil partitioned between dichloromethane and water. The aqueous layer was extracted with dichloromethane; the organic fractions were combined, dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting glassy solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) and dried in vacuum oven at 60 °C for 15 hours to provide 0.652 g of l-(2-{[(2E)-3-phenylprop-2- enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline as a glassy solid. MS (CI) for C2ιΗι9N30 m z 330 (MH+), 214 Part B
Using the general method of Example 1 Part B, l-(2-{[(2£)-3-phenylprop-2- enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline (0.652 g, 1.98 mmol) was oxidized to provide 0.67 g of l-(2-{[(2E)-3-phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5- c]quinoline-5N-oxide. The resulting brown solid was used without further purification. Part C
A round bottom flask was charged with a stir bar, l-(2-{[(2E)-3-phenylprop-2- enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (0.67 g, 1.98 mmol), dichloromethane (15 mL) and aqueous ammonium hydroxide (27%, 7 mL) at ambient temperature. -Toluenesulfonyl chloride (0.415 g, 2.18 mmol) was added in several portions as a solid and the resulting solution stirred. After 20 minutes the reaction was judged complete; the solution was partitioned between aqueous and organic and extracted with dichloromethane (3x). The organic layers were combined, extracted with 5%> aqueous sodium bicarbonate (3x), washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting white solid was purified by five successive recrystalizations from methanol/water to provide 0.086 g of 1-
(2-{[(2E)-3-phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a white fluffy solid, m.p. 183.7-184.3°C.
Analysis. Calculated for C2ιΗ20N O: %C, 73.23; %H, 5.85; %N, 16.27. Found: %C, 73.11; %H, 5.81; %N, 16.10 Η NMR (300 MHz, DMSO-d6) δ 8.19 (s, 1 H), 8.12 (d, J = 7.3 Hz, 1 H), 7.62 (d, J = 8.3
Hz, 1 H), 7.43 (t, J = 8.3 Hz, 1 H), 7.19-7.31 (m, 6 H), 6.61 (s, 2 H), 6.33 (d, J = 15.6 Hz, 1 H), 6.17 (dt, J = 16.0, 5.2 Hz, 1 H), 4.84 (t, J = 4.9, 2 H), 4.07 (d, J = 3.9, 2 H), 3.91 (t, J = 5.4, 2 H) MS (CI) for C21H20N4O m/z 345 (MH+), 270, 229 Example 116 2-Octyl-l - {2-[(3-phenylprop-2-ynyl)oxy]ethyl} - lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000120_0001
Part A
Using the general method of Example 1 Part A, 2-(2-octyl-lH-imidazo[4,5- c]quinolin-l-yl)ethanol (4.8 g, 14.75 mmol) was reacted with propargyl bromide (80% in toluene, 4.93 mL, 44.25 mmol) to provide 4.84 g of 2-octyl-l-[2-(prop-2-ynyloxy)ethyl]- lH-imidazo[4,5-e]quinoline as a brown solid.
Part B
Using the general method of Example 12 Part A, 2-octyl-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (4.84 g, 13.32 mmol) was reacted with iodobenzene (1.7 mL, 14.65 mmol) at 40 °C. After 45 minutes the reaction was judged complete. The volatiles were removed under reduced pressure and the resulting oil purified by chromatography over silica gel (98/2 (dichloromethane/methanol) to provide
4.2 g of 2-octyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline as a pale yellow solid.
MS (CI) for C29Η33N30 m/z 440 (MH+), 291 Part C
Using the general method of Example 1 Part B, 2-octyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (2.2 g, 5.004 mmol) was oxidized to provide
2.28 g of2-octyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N- oxide as an oil. Part D
Using the general method of Example 115 Part C, 2-octyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-<?]quinoline-5N-oxide (2.2 g, 4.83 mmol) was aminated. The resulting brown solid was purified by trituration with ethyl ether and recrystallization from 2-propanol to provide 1.23 g of 2-octyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH- imidazo[4,5-c]quinolin-4-amine as a white crystalline solid, m.p. 138-138.7°C. Analysis. Calculated for C29Η34N40: %C, 76.62; %H, 7.54; %N, 12.32. Found: %C, 76.6; %H, 7.49; %N, 12.19
Η NMR (300 MHz, DMSO-d6) δ 8.07 (d, J = 8.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 7.41 (t, J = 6.8 Hz, 1 H), 7.27-7.36 (m, 3 H), 7.18-7.24 (m, 3 H), 6.45 (s, 2 H), 4.78 (t, J = 4.9
Hz, 2 H), 4.34 (s, 2 H), 4.00 (t, J = 4.9, 2 H), 2.94 (t, J = 7.8 Hz, 2 H), 1.83 (p, J = 7.3, 7.3 Hz, 2 H), 1.22-1.43 (m, 10 H), 0.85 (t, J = 6.8 Hz, 3 H) MS (CI) for C29H34N40 m/z 455 (MH+), 283
Example 117
2-Octyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000121_0001
Part A Using the general method of Example 12 Part B, 2-octyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (2.0 g, 4.55 mmol) was hydrogenated to provide 1.78 g of 2-octyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline as a white solid.
'ΗNMR (300 MHz, DMSO-d6) δ 9.15 (s, 1 H), 8.41 (d, J = 9.78 Hz, 1 H), 8.16 (d, J = 9.8 Hz, 1 H), 7.63-7.71 (m, 2 H), 7.06-7.09 (m, 3 H), 6.81-6.84 (m, 2 H), 4.85 (t, J = 4.9 Hz, 2 H), 3.84 (t, J = 4.9, 2 H), 3.25 (t, J = 5.9 Hz, 2 H), 3.04 (t, J = 7.8 Hz, 2 H), 2.31 (t, J = 8.3
Hz, 2 H), 1.91 (p, J = 7.3, 7.3 Hz, 2 H), 1.59 (p, J = 8.8, 5.8 Hz, 2 H), 1.25-1.49 (m, 10 H),
0.85 (t, J = 7.3 Hz, 3 H)
Part B Using the general method of Example 1 Part B, 2-octyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline (1.78 g, 4.03 mmol) was oxidized to provide 1.8 g of 2-octyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N- oxide as an oil.
Part C Using the general method of Example 115 Part C, 2-octyl- 1 -[2-(3 - phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N-oxide (1.85 g 4.03 mmol) was aminated. The resulting brown solid was purified by trituration with ethyl ether and recrystallization from acetonitrile to provide 0.31 g of 2-octyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as a white crystalline solid, m.p. 103.8-104.5°C.
Analysis. Calculated for C29Η38N40: %C, 75.94; %H, 8.35; %N, 12.22. Found: %C,
75.71; %H, 8.46; %N, 12.22
Η NMR (300 MHz, DMSO-d6) δ 8.06 (d, J = 7.8 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 7.41
(t, J = 7.8 Hz, 1 H), 7.21 (t, J = 7.8 Hz, 1 H), 7.05-7.15 (m, 3 H), 6.90 (dd, J = 5.4, 1.9, 2 H), 6.45 (s, 2 H), 4.73 (t, J = 4.4 Hz, 2 H), 3.80 (t, J = 4.9, 2 H), 3.24 (t, J = 5.9 Hz, 2 H),
2.97 (t, J = 7.8 Hz, 2 H), 2.39 (t, J = 7.8 Hz, 2 H), 1.85 (p, J = 7.3, 7.8 Hz, 2 H), 1.62 (p, J
= 6.8, 6.3 Hz, 2 H), 1.24-1.44 (m, 10 H), 0.84 (t, J = 6.8 Hz, 3 H)
MS (CI) for C29H38N40 m/z 459 (MH"*"), 373, 285
Example 118 2-Methyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000123_0001
Part A
Using the general method of Example 1 Part A, 2-(2-methyl-lH-imidazo[4,5- c]quinolin-l-yl)ethanol (4.0 g, 17.6 mmol) was reacted with propargyl bromide (80% in toluene, 5.9 mL, 52.8 mmol) to provide 3.6 g of 2-methyl-l-[2-(prop-2-ynyloxy)ethyl]- lH-imidazo[4,5-c]quinoline as a dark brown oil.
MS (CI) for Cι6Η15N30 m z 266 (MH+), 184
Part B
Using the general method of Example 12 Part A, 2-methyl-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (3.6 g, 13.57 mmol) was reacted with iodobenzene (1.7 mL, 14.92 mmol) at ambient temperature. After 20 hours the reaction was judged complete. The solution was basified with 5% aqueous sodium bicarbonate and then extracted with dichloromethane (3x). The organics were combined, washed with water (3x), washed with brine, dried with anhydrous sodium sulfate, filtered and then concentrated under reduced pressure. Purification was completed by chromatography over silica gel (95/5 dichloromethane/methanol) and recrystallization from acetonitrile to provide 1.94 g of 2-methyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5- c]quinoline as a light yellow solid.
MS (CI) for C22Ηι9N30 m z 342 (MH+), 228 Part C
Using the general method of Example 1 Part B, 2-methyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (1.0 g, 2.93 mmol) was oxidized to provide
1.3 g of 2-methyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline- 5N-oxide as a tan solid.
Η NMR (300 MHz, DMSO-d6) δ 8.94 (s, 1 H), 8.78 (d, J = 8.3 Hz, 1 H), 8.48 (d, J = 7.8
Hz, 1 H), 7.79 (m, 2 H), 7.26-7.35 (m, 3 H), 7.09-7.18 (m, 2 H), 4.86 (t, J = 5.4 Hz, 2 H),
4.34 (s, 2 H), 4.04 (t, J = 4.9, 2 H), 2.66 (s, 3 H)
Part D Using the general method of Example 115 Part C, 2-methyl-l-{2-[(3-phenylprop-
2-ynyI)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide (1.05 g, 2.93 mmol) was aminated. The resulting tan solid was purified by trituration with ethyl ether, recrystalization from toluene, chromatography over silica gel (98/2 dichloromethane/methanol) to provide 0.261 g of 2-methyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl} -lH-imidazo[4,5-c]quinolin-4-amine as a white powder, m.p.
142.7-143.3°C.
Analysis. Calculated for C22Η20N4O: %C, 74.14; %H, 5.66; %N, 15.72. Found: %C,
73.97; %H, 5.77; %N, 15.77
Η NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 8.3 Hz, 1 H), 7.61 (d, J = 8.3 Hz, 1 H), 7.41 (t, J = 8.3 Hz, 1 H), 7.28-7.35 (m, 3 H), 7.12-7.24 (m, 3 H), 6.52 (s, 2 H), 4.77 (t, J = 4.9
Hz, 2 H), 4.36 (s, 2 H), 4.02 (t, J = 4.9, 2 H), 2.62 (s, 3 H)
MS (CI) for C22H20N4O m/z 357 (MH+), 243, 199
Example 119 2-Methyl- 1 - [2-(3 -phenylpropoxy)ethyl] - 1 H-imidazo [4, 5-c]quinolin-4-amine
Figure imgf000125_0001
Part A
Using the general method of Example 12 Part B, 2-methyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (0.9 g, 2.636 mmol) was hydrogenated to provide 0.845 g of 2-methyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline as a white solid. Η NMR (300 MHz, DMSO-d6) δ 9.12 (s, 1 H), 8.44 (d, J = 7.3 Hz, 1 H), 8.16 (d, J = 7.8
Hz, 1 H), 7.65-7.70 (m, 2 H), 7.04-7.08 (m, 3 H), 6.79-6.83 (m, 2 H), 4.85 (t, J = 4.9 Hz, 2 H), 3.85 (t, J = 5.4 Hz, 2 H), 3.23 (t, J = 6.4, 2 H), 2.70 (s, 3 H), 2.3 (t, J = 7.8 Hz, 2 H), 1.58 (p, J = 6.36, 6.36 Hz, 2 H) Part B Using the general method of Example 1 Part B, 2-methyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline (0.845 g, 2.45 mmol) was oxidized to provide 0.88 g of 2-methyl-l-[2-(3-phenylρropoxy)ethyl]-lH-imidazo[4,5-c]quinoline- 5N-oxide as a glassy solid. Material was used without further purification. Part C Using the general method of Example 115 Part C, 2-methyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N-oxide (0.88 g, 2.45 mmol) was aminated. The resulting brown solid was purified by trituration with ethyl ether and recrystallized from toluene to provide 0.596 g of 2-methyl-l-[2-(3-phenylpropoxy)ethyl]- lH-imidazo[4,5-c]quinolin-4-amine as a white powder, m.p. 129.7-130.7 °C. Analysis. Calculated for C22H24N40: %C, 73.31; %H, 6.71; %N, 15.54. Found: %C,
73.21; %H, 6.66; %N, 15.58
Η NMR (300 MHz, DMSO-d6) δ 8.07 (d, J = 8.3 Hz, 1 H), 7.62 (d, J = 7.3 Hz, 1 H), 7.41
(t, J = 7.3 Hz, 1 H), 7.22 (t, J = 8.3 Hz, 1 H), 7.05-7.14 (m, 3 H), 6.88 (dd, J = 6.8, 2.4 Hz,
2 H), 6.52 (s, 2 H), 4.73 (t, J = 4.9 Hz, 2 H), 3.80 (t, J = 4.9, 2 H), 3.24 (t, J = 6.4 Hz, 2 H),
2.64 (s, 3 H), 2.38 (t, J = 8.3 Hz, 2 H), 1.62 (p, J = 6.8, 6.4 Hz, 2 H)
MS (CI) for C22H24N40 m/z 361 (MH+), 347, 199
Example 120 2-(Methoxyethyl)- 1 - {2-[(3 -phenylprop-2-ynyl)oxy] ethyl} - lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000126_0001
Part A Using the general method of Example 1 Part 2-[2-(methoxyethyl)-lH-imidazo[4,5- c]quinolin-l-yl]ethanol (2.53 g, 9.33 mmol) was reacted with propargyl bromide (80% in toluene, 3.11 mL, 27.9 mmol) to provide 2.72 g of 2-(methoxyethyl)-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline as an oil. MS (CI) for Cι8Ηι9N302 m/z 310 (MH+), 278, 196 Part B
Using the general method of Example 12 Part A, 2-(methoxyethyl)-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (2.72 g, 1.79 mmol) was reacted with iodobenzene (1.1 mL, 9.67 mmol) at ambient temperature. After 45 minutes the reaction was judged complete. The volatiles were removed under reduced pressure and the resulting oil partitioned between dichloromethane and 5% aqueous sodium bicarbonate. The aqueous layer was extracted with dichloromethane. The organic fractions were combined, washed with brine, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to leave a brown solid. The solid was purified by cliromatography over silica gel (95/5 (dichloromethane/methanol) and trituration with hexane to provide 2.39 g of 2-(methoxyethyl)-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5- cjquinoline as a yellow solid. MS (CI) for C24Η23N3θ2 m z 386 (MH+), 354, 270 Part C
Using the general method of Example 1 Part B, 2-(methoxyethyl)-l-{2-[(3- phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (1.19 g, 3.097 mmol) was oxidized to provide 1.24 g of 2-(methoxyethyl)-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}- lH-imidazo[4,5-c]quinoline-5N-oxide as an glassy solid.
Part D
Using the general method of Example 115 Part C, 2-(methoxyethyl)-l-{2-[(3- phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide (1.243 g, 3.097 mmol) was aminated. The resulting brown oil was purified by chromatography over silica gel (98/2 dichloromethane/methanol), recrystallization from ethyl acetate and acetonitrile to provide 0.379 g of 2-(methoxyethyl)-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH- imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 134.5-135.5 °C. Analysis. Calculated for C24Η24N402: %C, 71.98; %H, 6.04; %N, 13.99. Found: %C,
72.21; %H, 5.98; %N, 14.29
Η NMR (300 MHz, DMSO-d6) δ 8.09 (d, J = 8.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 7.41 (t, J = 8.3 Hz, 1 H), 7.28-7.36 (m, 3 H), 7.18-7.24 (m, 3 H), 6.50 (s, 2 H), 4.82 (t, J = 4.9 Hz, 2 H), 4.36 (s, 2 H), 4.01 (t, J = 4.9, 2 H), 3.84 (t, J = 6.8 Hz, 2 H), 3.29 (s, 3 H), 3.23 (t, J = 6.8 Hz, 2 H)
MS (CI) for C24H24N402 m z 401 (MH+), 255, 183
Example 121 2-(2-Methoxyethyl)-l-[2-(3-phenylpropoxy)ethyl]- 1 H-imidazo [4,5-c] quinolin-4-amine
Figure imgf000128_0001
Part A
Using the general method of Example 12 Part B, 2-(2-methoxyethyl)-l-{2-[(3- phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (1.2 g, 3.11 mmol), was hydrogenated to provide 1.01 g of 2-(2-methoxyethyl)-l-[2-(3-phenylpropoxy)ethyl]-lH- imidazo[4,5-c]quinoline as an oil.
MS (CI) for C24Η27N302 m/z 390 (MH+), 235
Part B
Using the general method of Example 1 Part B, 2-(2-methoxyethyl)-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline (1.01 g, 2.60 mmol) was oxidized to provide 1.05 g of 2-(2-methoxyethyl)-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5- c]quinoline-5N-oxide as an brown oil.
Part C
Using the general method of Example 115 Part C, 2-(2-methoxyethyl)-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N-oxide (1.05 g, 2.601 mmol) was aminated. The resulting brown solid was purified by chromatography over silica gel (98/2 dichloromethane/methanol), recrystallization from ethyl acetate/hexane to provide 0.111 g of 2-(2-methoxyethyl)-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 103.8-104.5°C.
Analysis. Calculated for C24Η28N402 (H2O)0.2: %C, 70.63; %H, 7.01; %N, 13.73. Found: %C, 70.38; %H, 6.80; %N, 13.57 Η NMR (300 MHz, DMSO-d6) δ 8.09 (d, J = 7.3 Hz, 1 H), 7.63 (d, J = 8.3 Hz, 1 H), 7.42 (t, J = 6.8 Hz, 1 H), 7.22 (t, J = 7.8 Hz, 1 H), 7.08-7.15 (m, 3 H), 6.89 (d, J = 5.4 Hz, 2 H), 6.49 (s, 2 H), 4.78 (t, J = 4.9 Hz, 2 H), 3.86 (t, J = 6.8, 2 H), 3.80 (t, J = 5.4 Hz, 2 H), 3.30 (s, 3 H), 3.22-3.28 (m, 4 H), 2.39 (t, J = 8.3 Hz, 2 H), 1.62 (p, J = 8.3, 6.4 Hz, 2 H) MS (CI) for C24H28N402 m z 405 (MH+), 373, 235
Example 122 2-(Ethoxymethyl)-l-{2-[(3-phenylprop-2-3 ιyl)oxy]ethyl}- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000129_0001
Part A
Using the general method of Example 1 Part A 2-[2-(ethoxymethyl)-lH- imidazo[4,5-c]quinolin-l-yl]ethanol (1.39 g, 5.123 mmol) was reacted with propargyl bromide (80% in toluene, 1.7 mL, 15.37 mmol) to provide 1.6 g of 2-(ethoxymethyl)-l- [2-(prop-2-ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline as an oil. MS (CI) for Cι8Ηι9N302 m/z 310 (MH+), 371, 270 Part B Using the general method of Example 12 Part A, 2-(ethoxymethyl)-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (1.5 g, 4.13 mmol) was reacted with iodobenzene (0.51 mL, 4.54 mmol) at 40 °C. After 50 minutes the reaction was judged complete. The volatiles were removed under reduced pressure and the resulting oil was partitioned between dichloromethane and 5% aqueous sodium bicarbonate. The aqueous layer was extracted with dichloromethane. The organic fractions were combined, washed with brine, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to leave a brown oil. The oil was purified by chromatography over silica gel (98/2 dichloromethane/methanol) to provide 1.25 g of 2-(ethoxymethyl)-l-{2-[(3- phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline as a brown glassy solid. MS (CI) for C24Η23N302 m/z 386 (MH+), 342, 272
Part C
Using the general method of Example 1 Part B, 2-(ethoxymethyl)-l-{2-[(3- phenylprop-2-ynyI)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (0.655 g, 1.70 mmol) was oxidized to provide 0.68 g of 2-(ethoxymethyl)-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}- lH-imidazo[4,5-c]quinoline-5N-oxide as an oil.
Part D
Using the general method of Example 115 Part C 2-(ethoxymethyl)-l-{2-[(3- phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide (0.682 g, 1.700 mmol) was aminated. The resulting brown solid was purified by chromatography over silica gel (98/2 dichloromethane/methanol) to provide 0.297 g of 2-(ethoxymethyl)-l-{2-
[(3-phenylprop-2-ynyl)oxy]ethyl}-lΗ-imidazo[4,5-c]quinolin-4-amine as a white granular solid, m.p. 110.8-111.7 °C.
Analysis. Calculated for C24H24N402 (H2O)0.ι: %C, 71.66 ; %H, 6.06; %N, 13.93. Found: %C, 71.56; %H, 5.96; %N, 13.74 Η NMR (300 MHz, DMSO-d6) δ 8.13 (d, J = 7.8 Hz, 1 H), 7.63 (d, J = 8.3 Hz, 1 H), 7.44
(t, J = 6.8 Hz, 1 H), 7.28-7.36 (m, 3 H), 7.19-7.26 (m, 3 H), 6.67 (s, 2 H), 4.88 (t, J = 5.4 Hz, 2 H), 4.81 (s, 2H), 4.38 (s, 2 H), 4.03 (t, J = 5.9, 2 H), 3.55 (q, J = 6.8, 7.3 Hz, 2 H), 1.15 (t, J = 6.8 Hz, 3 H) MS (CI) for C24H24N402 m/z 401 (MH+), 371, 285
Example 123 2-Butyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}- lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000131_0001
Part A
Using the general method of Example 1 Part A, 2-(2-butyI-lH-imidazo[4,5- c]quinolin-l-yl)ethanol (5.0 g, 18.56 mmol) was reacted with propargyl bromide (80% in toluene, 6.3 mL, 55.62 mmol) to provide 4.02 g of 2-butyl-l-[2-(prop-2-ynyloxy)ethyl]- lH-imidazo[4,5-c]quinoline as a tan solid.
MS (CI) for C19Η2IN30 m/z 308 (MH+), 268, 220 PartB
Using the general method of Example 12 Part A, 2-butyl-l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (4.0 g, 13.08 mmol) was reacted with iodobenzene (1.6 mL, 14.38 mmol) at 90 °C. After 15 minutes the reaction was judged complete. The volatiles were removed under reduced pressure and the resulting oil was purified by chromatography over silica gel (98/2 dichloromethane/methanol) and recrystallization from mixture of ethyl acetate/hexane to provide 3.1 g of 2-butyl-l-{2- [(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline as a tan solid. Part C
Using the general method of Example 1 Part B, 2-butyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (1.0 g, 2.61 mmol) was oxidized to provide 1.0 g of 2-butyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N- oxide as an oil. Part D
Using the general method of Example 115 Part C, 2-butyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline-5N-oxide (1.04 g, 2.60 mmol) was aminated. The resulting brown solid was purified by trituration with ethyl ether, two times with chromatography over silica gel (8/2 dichloromethane/ethyl acetate, 98/2 dichloromethane/methanol) to provide 0.450 g of 2-butyl-l-{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine as a white powder, m.p. 133-140 °C. Analysis. Calculated for C25Η26N40 (H2O)0.2: %C, 74.67 ; %H, 6.62; %N, 13.93. Found: %C, 74.65; %H, 6.60; %N, 14.00 Η NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 7.8 Hz, 1 H), 7.61 (d, J = 7.3 Hz, 1 H), 7.41
(t, J = 7.3 Hz, 1 H), 7.29-7.36 (m, 3 H), 7.17-7.24 (m, 3 H), 6.45 (s, 2 H), 4.78 (t, J = 4.9 Hz, 2 H), 4.34 (s, 2 H), 4.01 (t, J = 4.9, 2 H), 2.95 (t, J = 8.3 Hz, 2 H), 1.81 (p, J = 7.3, 8.3 Hz, 2 H), 1.44 (sextet, J = 7.3, 7.3, 7.8 Hz, 2 H), 0.93 (t, J = 7.3 Hz, 3 H) MS (CI) for C25H26N 0 m/z 399 (MH+), 283, 267
Example 124 2-Butyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000132_0001
Part A Using the general method of Example 12 Part B, 2-butyl-l -{2-[(3-phenylprop-2- ynyl)oxy]ethyl}-lH-imidazo[4,5-c]quinoline (2.4 g, 6.26 mmol) was hydrogenated to provide 1.67 g of 2-butyl-l-[2-(3-phenylp opoxy)ethyl]-lH-imidazo[4,5-c]quinoline as a white solid.
MS (CI) for C25Η29N30 m/z 388 (MH+), 279 Part B Using the general method of Example 1 PartB, 2-butyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline (1.68 g, 4.34 mmol) was oxidized to provide 1.75 g of 2-butyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N- oxide as glassy solid. MS (CI) for C25Η29N302 m/z 404 (MH+), 388
Part C
Using the general method of Example 115 Part C, 2-butyl-l-[2-(3- phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N-oxide (1.75 g, 4.34 mmol) was aminated. The resulting tan solid was purified by recrystallization from acetonitrile to provide 0.572 g of 2-butyl-l-[2-(3-phenylpropoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4- amine as tan crystalline solid, m.p. 80.8-81.3 °C.
Analysis. Calculated for C25Η3oN40 (H2O)0.3: %C, 73.61 ; %H, 7.56; %N, 13.73. Found: %C, 73.3; %H, 7.65; %N, 13.67 Η NMR (300 MHz, DMSO-d6) δ 8.07 (d, J = 8.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H), 7.41 (t, J = 7.3 Hz, 1 H), 7.21 (t, J = 7.3 Hz, 1 H), 7.05-7.14 ( , 3 H), 6.89 (d, J = 7.3 Hz, 2 H),
6.45 (s, 2 H), 4.74 (t, J = 4.4 Hz, 2 H), 3.80 (t, J = 4.9, 2 H), 3.24 (t, J = 5.9 Hz, 2 H), 2.98 (t, J = 7.8 Hz, 2 H), 2.39 (t, J = 7.8 Hz, 2 H), 1.84 (p, J = 7.3, 8.3 Hz, 2 H), 1.62 (p, J = 7.8, 5.9 Hz, 2 H), 1.48 (sextet, J = 7.3, 7.3, 7.8 Hz, 2 H), 0.95 (t, J = 7.3 Hz, 3 H) MS (CI) for C25H30N4O m/z 403 (MH+), 213
Example 125 l-[2-(Benzyloxy)ethyl]-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000133_0001
Part A Using the general method of Example 1 Part B, l-[2-(benzyloxy)ethyl]-2-
(ethoxymethyl)-lH-imidazo[4,5-c]quinoline (0.324 g, 0.897 mmol) was oxidized to provide 0.338 g of l-[2-(benzyloxy)ethyl]-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinoline-
5N-oxide as a brown oil.
Part B
Using the general method of example 115 Part C, l-[2-(benzyloxy)ethyl]-2- (ethoxymethyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (0.339 g, 0.897 mmol) was aminated. The resulting tan solid was purified by recrystallized from acetonitrile to provide 0.187 g of l-[2-(benzyloxy)ethyl]-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-
4-amine as a white powder, m.p. 144.5-146.0 °C.
Analysis. Calculated for C22Η24N402: %C, 70.19; %H, 6.43; %N, 14.88. Found: %C, 69.96; %H, 6.29; %N, 15.09
'HNMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 7.8 Hz, 1 H), 7.61 (d, J = 8.3 Hz, 1 H), 7.43
(t, J = 6.8 Hz, 1 H), 7.19-7.24 (m, 4 H), 7.11-7.14 (m, 2 H), 6.6 (s, 2 H), 4.87 (t, J = 5.4, 2
H), 4.79 (s, 2 H), 4.44 (s, 2 H), 3.90 (t, J = 5.4, 2 H), 3.52 (q, J = 6.8, 6.8 Hz, 2 H), 1.13 (t,
J = 6.8 Hz, 3 H) MS (CI) for C22H24N402 m/z 377 (Ml-f), 331, 241
Example 126 l-[2-(Benzyloxy)ethyl]-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000134_0001
Part A
Using the general method of Example 1 Part B, l-[2-(benzyloxy)ethyl]-2-butyl- lH-imidazo[4,5-c]quinoline (2.3 g, 6.39 mmol) was oxidized to provide 2.4 g of l-[2- (benzyloxy)ethyl]-2-butyl-lH-imidazo[4,5-c]quinoline-5N-oxide as a brown oil. MS (CI) for C23Η25N302 m/z 376 (MH+), 360, 270 Part B Using the general method of example 1 Part C, l-[2-(benzyloxy)ethyl]-2-butyl-lH- imidazo[4,5-c]quinoline-5N-oxide (2.4 g, 6.39 mmol) was reacted with trichloroacetyl isocyanate (1.45 g, 7.678 mmol) to provide 3.3 g of N-{l-[2-(benzyloxy)ethyl]-2-butyl- lH-imidazo[4,5-c]quinolin-4-yl}-2,2,2-trichloroacetamide as a brown oil. Part C
Using the general method of example 1 Part D, N-{l-[2-(benzyloxy)ethyl]-2-butyl- lH-imidazo[4,5-c]quinolin-4-yl}-2,2,2-trichloroacetamide (3.3 g, 6.39 mmol) was hydrolyzed with sodium methoxide (5 mL of 25% in methanol). The resulting tan solid was purified by chromatography over silica gel (98/2 dichloromethane/methanol), recrystallized from methanol and dried under vacuum at 60 °C for 18 hours to provide
0.174 g of l-[2-(benzyloxy)ethyl]-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 133-135 °C.
Analysis. Calculated for C23Η26Ν40: %C, 73.77; %H, 7.00; %N, 14.96. Found: %C, 73.51; %H, 7.06; %N, 14.92 Η NMR (300 MHz, DMSO-d6) δ 8.03 (d, J = 7.3 Hz, 1 H), 7.60 (d, J = 8.3 Hz, 1 H), 7.39
(t, J = 6.8 Hz, 1 H), 7.17-7.24 (m, 4 H), 7.10-7.12 (m, 2 H), 6.45 (s, 2 H), 4.76 (t, J = 5.4, 2 H), 4.41 (s, 2 H), 3.89 (t, J = 4.9, 2 H), 2.94 (t, J = 8.3 Hz, 2 H), 1.77 (p, J = 7.8, 7.8 Hz, 2 H), 1.40 (sextet, J = 7.8, 7.3, 6.8 Hz, 2 H), 0.91 (t, J = 7.3 Hz, 3 H) MS (CI) for C23H26N40 m/z 375 (MH+), 242, 183
Example 127 l-[2-(Benzyloxy)ethyl]-2-methyl-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000135_0001
Part A Using the general method of Example 1 Part B,l-[2-(benzyloxy)ethyl]-2-methyl- lH-imidazo[4,5-c]quinoline (6 g, 18.9 mmol) was oxidized to provide 6.3 g of l-[2- (benzyloxy)ethyl]-2-methyl-lH-imidazo[4,5-c]quinoline-5N-oxide as a brown solid. Part B Using the general method of example 1 Part C, l-[2-(benzyloxy)ethyl]-2-methyl- lH-imidazo[4,5-c]quinoline-5N-oxide (6.3 g, 18.9 mmol) was reacted with trichloroacetyl isocyanate (4.95 g, 26.27 mmol) to provide 10.4 g of N-{l-[2-(benzyloxy)ethyl]-2-methyl- lH-imidazo[4,5-c]quinolin-4-yl}-2,2,2-trichloroacetamide as a brown solid. Part C Using the general method of example 1 Part D, N- { 1 -[2-(benzyloxy)ethyl]-2- methyl-lH-imidazo[4,5-c]quinolin-4-yl}-2,2,2-trichloroacetamide (10.46 g, 21.89 mmol) was hydrolyzed with sodium methoxide (20 mL of 25% in methanol). The resulting brown solid was purified by chromatography over silica gel (98/2 dichloromethane/methanol) and dried under vacuum at 60 °C for 18 hours to provide 1.036 g of l-[2- (benzyloxy)ethyl]-2-methyl-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p.
159-160°C.
Analysis. Calculated for C20Η20Ν4O: %C, 72.27; %H, 6.06; %N, 16.85. Found: %C, 72.17; %H, 5.96; %N, 16.81 Η NMR (300 MHz, DMSO-d6) δ 8.04 (d, J = 7.3 Hz, 1 H), 7.59 (d, J = 8.3 Hz, 1 H), 7.39 (t, J = 8.3 Hz, 1 H), 7.15-7.27 (m, 4 H), 7.08-7.13 (m, 2 H), 6.49 (s, 2 H), 4.75 (t, J = 5.4, 2 H), 4.43 (s, 2 H), 3.90 (t, J = 5.4, 2 H), 2.61 (s, 3 H) MS (CI) for C2oH2oN40 m/z 333 (MH+), 243, 199
Example 128 l-[2-(Benzyloxy)ethyl]-2-octyl-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000137_0001
Part A Using the general method of Example 1 Part B, l-[2-(benzyloxy)ethyl]-2-octyl- lH-imidazo[4,5-c]quinoline (2.4 g, 5.8 mmol) was oxidized to provide 2.5 g of l-[2- (benzyloxy)ethyl]-2-octyl-lH-imidazo[4,5-c]quinoline-5N-oxide as a brown oil. Part B
Using the general method of example 115 Part C, l-[2-(benzyloxy)ethyl]-2-octyl- lH-imidazo[4,5-c]quinoline-5N-oxide (2.50 g, 5.80 mmol) was aminated. The resulting oil was purified by chromatography over silica gel (98/2 dichloromethane/methanol) and recrystallized from acetonitrile to provide 0.75 g l-[2-(benzyloxy)ethyl]-2-octyl-lH- imidazo[4,5-c]quinolin-4-amine as a white powder, m.p. 110-111 °C. Analysis. Calculated for C27Η34N40: %C, 75.31; %H, 7.96; %N, 13.01. Found: %C, 75.20; %H, 7.88; %N, 13.00
Η NMR (300 MHz, DMSO-d6) δ 8.03 (d, J = 7.8 Hz, 1 H), 7.60 (d, J = 8.3 Hz, 1 H), 7.40 (t, J *= 7.3 Hz, 1 H), 7.17-7.26 (m, 4 H), 7.10-7.13 (m, 2 H), 6.45 (s, 2 H), 4.76 (t, J = 4.9, 2 H), 4.41 (s, 2 H), 3.88 (t, J = 4.9, 2 H), 2.93 (t, J = 7.8 Hz, 2 H), 1.79 (p, J = 7.3, 7.3 Hz, 2 H), 1.20-1.38 (m, 10 H), 0.85 (t, J = 6.3 Hz, 3 H) MS (CI) for C27H34N40 m/z 431 (MH"1"), 291 , 214
Example 129 2-(2-Methoxyethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000138_0001
Part A
Under a nitrogen atmosphere, 2-phenoxyethylamine (17.6 ml, 0.13 mol) was added dropwise to a chilled (ice bath) solution of 4-chloro-3-nitroquinoline (21.5 g, 0.1 mol), triethylamine (21.5 ml, 0.16 mol) in dichloromethane (500 ml). The reaction was maintained at ambient temperature overnight. Water was added and the phases were separated. The organic phase was dried (MgS0 ), filtered, and the bulk of the solvent was removed under vacuum. Hexane was added and the solution was chilled in a refrigerator. The resulting precipitate was recovered by vacuum filtration to provide 19.1 g of 3-nitro- N-(2-phenoxyethyl)quinolin-4-amine as a yellow solid.
Part B
3-Nitro-N-(2-phenoxyethyl)quinolin-4-amine (6.0 g, 19 mmol), 5% platinum on carbon (1.5 g) and ethyl acetate (300 ml) were placed in a hydrogenation flask. The mixture was shaken overnight under a hydrogen pressure of 40 psi (2.8 Kg/cm2). The reaction mixture was filtered and the catalyst was washed with ethyl acetate. The filtrate was dried (MgS0 ), filtered, and concentrated under vacuum to near dryness. Hexane was added and the resulting precipitate was collected by vacuum filtration to provide 4.9 g of N4-(2-phenoxyethyl)quinoline-3,4-diamine as a pale yellow solid.
Part C
3-methoxypropanoyl chloride (0.86 ml, 7.9 mmol) was added dropwise over a 30 minute period to a chilled (ice bath) solution of N4-(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) in dichloromethane (100 ml). After a few hours, a precipitate formed. The solvent volume was reduced under vacuum to near dryness and hexane (100 ml) was added. Vacuum filtration provided 2.9 g of 3-methoxy-N-{4-[(2- phenoxyethyl)amino]quinolin-3-yl}propanamide as a hydrochloride salt.
Part D
The product from Part C (2.9 g) and a 7.5% solution of ammonia in methanol (200 ml) were placed in a pressure vessel. The vessel was sealed and then heated at 160 °C for 6 hours. After the mixture was cooled to ambient temperature, it was concentrated under vacuum. The residue was partitioned between dichloromethane (150 ml) and water (150 ml). The fractions were separated and the aqueous fraction was extracted with dichloromethane (100 ml). The organic fractions were combined, dried (MgS0 ), and filtered. The bulk of the solvent was removed under vacuum and hexane was added to yield a white precipitate. Vacuum filtration provided 1.8 g of 2-(2-methoxyethyl)-l-(2- phenoxyethyl)-lH-imidazo[4,5-c]quinoline as a white solid.
Part E
3-Chloroperoxybenzoic acid (1.5 g, 8.7 mmol, 60% by weight) was added in three portions over a period of 20 minutes to 2-(2-methoxyethyl)-l-(2-phenoxyethyl)-lH- imidazo[4,5-c]quinoline (1.8 g, 5.2 mmol) in chloroform (100 ml). The reaction mixture was maintained at ambient temperature overnight and then washed with saturated sodium bicarbonate followed by water. The organic fraction was dried (MgS04) and concentrated under vacuum to near dryness. Hexane was added and the resulting precipitate was recovered by vacuum filtration to yield 1.6 g of 2-(2-methoxyethyl)-l-(2-phenoxyethyl)- lH-imidazo[4,5-c]quinoline-5N-oxide as a light yellow powder.
Part F
Under a nitrogen atmosphere, trichloroacetyl isocyanate (0.8 ml, 6.6 mmol) was added dropwise to a solution of 2-(2-methoxyethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5- c]quinoline-5N-oxide (1.6 g, 4.4 mmol) in dichloromethane (100 ml) and the reaction was maintained at ambient temperature for 2 hours. Ammonium hydroxide (5 drops, 7% by weight in methanol) was added and the reaction was maintained at ambient temperature for an additional 2.5 days. Sodium hydroxide (10%) was added and the two phases were separated. The organic phase was concentrated and purified by flash column chromatography (silica gel, 9:1 dichloromethane/methanol). Fractions containing product were combined, concentrated in vacuo, dissolved in boiling toluene, and treated with activated charcoal. The mixture was filtered to remove the charcoal and the filtrate was cooled. The resulting precipitate was recovered by filtration and dried in a vacuum oven (80 °C) to provide 0.68 g of 2-(2-methoxyethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5- c]quinolin-4-amine as a tan powder, m.p. 171.0-174.0°C.
Η NMR (300 MHz, DMSO-d6) δ 8.19 (d, J = 8.1 Hz, IH), 7.64 (d, J = 8.3 Hz, IH), 7.44 (t, J = 7.5 Hz, IH), 7.29-7.20 (m, 3H), 6.90 (t, J = 7.4 Hz, IH), 6.82 (d, J = 8.2 Hz, 2H),
6.58 (s, 2H), 5.01 (t, J = 5.0 Hz, 2H), 4.43 (t, J = 5.0 Hz, 2H), 3.87 (t, J = 6.9 Hz, 2H), 3.34 (s, 3H), 3.30 (t, J = 6.9 Hz, 2H);
MS (CI) m/e 363.1820 (363.1821 calcd for C2ιH23N 02, M+H);
Anal calcd for C2ιH22N402: C, 69.59; H, 6.12; N, 15.46. Found: C, 69.32; H, 6.17; N, 15.48.
Example 130 2-Isobutyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000140_0001
N4-(2-Phenoxyethyl)quinoline-3,4-diamine (1.5 g, 5.4 mmol) and isovaleryl chloride (0.8 ml, 6.4 mmol) were combined and treated according to the general procedures of Parts C-E of Example 129. The resulting product, 2-isobutyl-l-(2- phenoxyethyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (1.6 g, 4.5 mmol) was dissolved in dichloromethane (200 ml) and ammonium hydroxide (50 ml) was added. The reaction was chilled (ice bath) and -toluenesulfonyl chloride (0.85 g, 4.5 mmol) was slowly added over a period of 20 minutes. The cooling bath was removed and the reaction was maintained at ambient temperature overnight. The phases were separated and the organic phase was sequentially washed with 1% aqueous sodium carbonate (3X), water, brine; dried (Na2S0 ); and concentrated to near dryness in vacuo. Hexane was added to provide a precipitate. The solid was collected and purified by recrystallization from acetonitrile to yield 0.96 g of 2-isobutyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a tan powder, m.p. 176.6-177.8 °C. Η NMR (300 MHz, DMSO-d6) δ 8.16 (d, J = 8.2 Hz, IH), 7.63 (d, J = 8.3 Hz, IH), 7.43
(t, J = 7.6 Hz, IH), 7.28-7.20 (m, 3H), 6.89 (t, J = 7.3 Hz, IH), 6.81 (d, J = 8.6 Hz, 2H), 6.49 (s, 2H), 4.98 (t, J = 4.8 Hz, 2H), 4.42 (t, J = 4.8 Hz, 2H), 2.89 (d, J = 7.2 Hz, 2H), 2.40-2.22 (m, IH), 1.02 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz, DMSO-d6) 158.6, 153.9, 152.4, 145.5, 132.9, 130.1, 127.1, 126.9, 121.5, 120.8, 115.3, 114.7, 66.6, 44.4, 35.3, 27.1, 22.4;
MS (CI) m/e 361.2017 (361.2028 calcd for C22H25N40, M+H);
Anal calcd for C22H24N40: C, 73.31; H, 6.71; N, 15.54. Found: C, 73.33; H, 6.56; N,
15.79.
Example 131
2-Isopropyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000141_0001
N4-(2-Phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and isobutyryl chloride (0.9 ml, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 0.82 g of 2- isopropyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 229-231°C.
Η NMR (300 MHz, DMSO-d6) δ 8.17 (d, J = 7.5 Hz, IH), 7.65-7.62 (dd, J = 8.3, 1.1 Hz, IH), 7.46-4.40 (dt, J = 8.2, 1.1 Hz, IH), 7.29-7.20 (m, 3H), 6.90 (t, J = 7.3 Hz, IH), 6.81 (d, J = 7.8 Hz, 2H), 6.46 (s, 2H), 5.01 (t, J = 4.9 Hz, 2H), 4.42 (t, J = 4.9 Hz, 2H), 3.54
(septet, J = 6.8 Hz, IH), 1.41 (d, J = 6.8 Hz, 6H);
13C NMR (75 MHz, DMSO-d6) 159.3, 158.5, 152.3, 145.4, 132.6, 130.1, 126.84, 126.78, 121.5, 120.7, 115.3, 114.6, 66.5, 44.1, 25.2, 21.8; MS (CI) m/e 347.1872 (347.1872 calcd for C21H23N40, M+H); Anal calcd for C2ιH22N40: C, 72.81; H, 6.40; N, 16.17. Found: C, 72.48; H, 6.59; N,
16.50.
Example 132 2-Butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000142_0001
N4-(2-Phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol), xylenes (150 ml), and trimethylorthovalerate (2.5 ml, 14.3 mmol) were combined under an atmosphere of nitrogen and heated at reflux temperature for 4 days. The external heat was increased and approximately 35 ml of xylenes was removed by distillation. The reaction was slowly cooled to room temperature and a precipitate formed. The solid was recovered by vacuum filtration to yield 2.4 g of 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinoline as a light tan crystalline solid. 2-Butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinoline was treated according to the general procedures described in Parts E and F of Example 129. A final recrystallization from acetonitrile provided 0.93 g of 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5- c]quinolin-4-amine as white needles, m.p. 168.3-169.5 °C.
Η NMR (300 MHz, DMSO-d6) δ 8.16 (d, J = 8.1 Hz, IH), 7.63 (d, J = 8.3 Hz, IH), 7.43 (t, J = 7.6 Hz, IH), 7.28-7.20 (m, 3H), 6.90 (t, J = 7.4 Hz, IH), 6.82 (d, J = 8.5 Hz, 2H), 6.47 (s, 2H), 4.97 (t, J = 4.8 Hz, 2H), 4.43 (t, J = 4.8 Hz, 2H), 3.00 (t, J = 7.7 Hz, 2H), 1.86
(m, 2H), 1.47 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H);
13C NMR (75 MHz, DMSO-d6) 158.5, 154.6, 152.3, 145.6, 132.9, 130.1, 126.8, 121.5, 120.7, 115.2, 114.6, 66.7, 44.4, 29.3, 26.2, 21.9, 13.6; MS (CI) m/e 361.2032 (361.2028 calcd for C22H25N40, M+H); Anal calcd for C22H24N40: C, 73.31; H, 6.71; N, 15.54. Found: C, 73.15; H, 6.69; N,
15.57.
Example 133 l-(2-Phenoxyethyl)-2-(phenoxymethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000143_0001
According to the general procedure described in Part C of Example 129, phenoxyacetyl chloride (1.2 ml, 8.6 mmol) was reacted with N4-^- phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol). The product of this reaction was treated according to the general procedures described in Parts D-F of Example 129. Recrystallization from acetonitrile provided 0.65 g of the final product, l-(2- phenoxyethyl)-2-(phenoxymethyl)-lH-imidazo[4,5-c]quinolin-4-amine, as a tan powder, m.p. 168.5-170.0°C. Η NMR (300 MHz, DMSO-d6) δ 8.25 (d, J = 7.9 Hz, IH), 7.64 (dd, J = 8.3, 1.0 Hz, IH),
7.47 (m, IH), 7.38-7.14 (m, 7H), 7.01 (t, J = 7.3 Hz, IH), 6.89 (t, J = 7.3 Hz, IH), 6.81 (d, J = 7.8 Hz, 2H), 6.69 (s, 2H), 5.53 (s, 2H), 5.29 (t, J = 5.0 Hz, 2H), 4.48 (t, J = 5.0 Hz, 2H);
13C NMR (75 MHz, DMSO-d6) 158.5, 152.7, 149.2, 146.1, 134.1, 130.2, 130.1, 127.6, 127.0, 126.9, 122.0, 121.6, 121.5, 121.4, 115.3, 115.1, 114.7, 66.6, 62.7, 45.0; MS (CI) m/e 411.1813 (411.1821 calcd for C25H23N402, M+H);
Anal calcd for C25H22N402: C, 73.15; H, 5.40; N, 13.65. Found: C, 73.36; H, 5.30; N, 13.66.
Example 134 2-(4-Methoxybenzyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine.
Figure imgf000144_0001
According to the general procedure described in Part C of Example 129, 4- methoxyphenylacetyl chloride (1.2 ml, 7.9 mmol) was reacted with N4-(2- phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol). The product of this reaction was treated according to the general procedures described in Parts D-F of Example 129. Recrystallization from acetonitrile provided 1.1 g of the final product, 2-(4- methoxybenzyl)-l-(2-phenoxyethyI)-lH-imidazo[4,5-c]quinolin-4-amine, as a tan solid, m.p. 201.0-203.6°C.
Η NMR (300 MHz, DMSO-d6) δ 8.15 (d, J = 8.1 Hz, IH), 7.63 (d, J = 8.3 Hz, IH), 7.43 (t, J = 7.6 Hz, IH), 7.26-7.18 (m, 5H), 6.93-6.87 (m, 3H), 6.74 (d, J = 8.2 Hz, 2H), 6.58 (s, 2H), 4.89 (t, J = 5.1 Hz, 2H), 4.40 (s, 2H), 4.24 (t, J = 5.1 Hz, 2H), 3.70 (s, 3H); MS (CI) m/e 425.1948 (425.1978 calcd for C26H25N402, M+H); Anal calcd for C26H24N402: C, 73.57; H, 5.70; N, 13.20. Found: C, 73.25; H, 5.93; N,
13.06. Example 135 2-Cyclopentyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000145_0001
N4-(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and cyclopentanecarbonyl chloride (1.1 ml, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 1.4 g of 2-cyclopentyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 216.0-217.9°C.
Η NMR (300 MHz, DMSO-d6) δ 8.17 (d, J = 8.1 Hz, IH), 7.63 (d, J = 8.2 Hz, IH), 7.43 (t, J = 7.6 Hz, IH), 7.28-7.20 (m, 3H), 6.90 (t, J = 7.3 Hz, IH), 6.81 (d, J *= 8.5 Hz, 2H), 6.46 (s, 2H), 5.02 (t, J = 4.9 Hz, 2H), 4.42 (t, J = 4.9 Hz, 2H), 3.60 (pentet, J = 8.2 Hz, IH), 2.18-1.67 (m, 8H); 13C NMR (75 MHz, DMSO-d6) 158.5, 158.3, 152.9, 144.6, 133.0, 130.1, 126.8, 121.5,
120.8, 115.3, 114.7, 66.5, 44.2, 36.1, 32.3, 25.3; MS (CI) m e 373.2030 (373.2028 calcd for C23H25N40, M+H); Anal calcd for C23H24N40: C, 74.17; H, 6.49; N, 15.04. Found: C, 74.18; H, 6.59; N, 15.08.
Example 136 2-[(2-Methoxyethoxy)methyl]-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000146_0001
N4-(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol) and 2-(2- methoxyethoxy)acetyl chloride (1.3 g, 8.6 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from methanol provided 1.6 g of 2-[(2-methoxyethoxy)methyl]-l-(2-phenoxyethyl)-lH-imidazo[4,5- c]quinolin-4-amine as white needles, m.p. 170.0-171.5°C.
Η NMR (300 MHz, CDC13) δ 8.06 (dd, J = 8.3, 1.0 Hz, IH), 7.82 (dd, J = 8.4, 1.0 Hz, IH), 7.55-7.50 (m, IH), 7.35-7.29 (m, IH), 7.26-7.18 (m, 2H), 6.92 (t, J = 7.4 Hz, IH), 6.79 (dd, J = 8.7, 0.9 Hz, 2H), 5.57 (s, 2H), 5.07 (t, J = 5.9 Hz, 2H), 5.00 (s, 2H), 4.47 (t, J = 5.9 Hz, 2H), 3.71 (m, 2H), 3.55 (m, 2H), 3.31 (s, 3H); 13C NMR (75 MHz, CDC13) 158.9, 152.3, 150.3, 146.2, 135.2, 130.3, 128.3, 128.2, 127.6,
123.1, 122.2, 120.6, 116.1, 115.1, 72.1, 70.2, 66.6, 66.3, 59.3, 45.6; MS (CI) m/e 393.1912 (393.1927 calcd for C22H25N403, M+H); Anal calcd for C22H2 N403: C, 67.33; H, 6.16; N, 14.27. Found: C, 67.62; H, 6.24; N, 14.37.
Example 137 2-(Cyclopropylmethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000147_0001
N4-(2-phenoxyethyl)quinolme-3,4-diamine (1.7 g, 6.1 mmol) and cyclopropylacetyl chloride (0.86 ml, 7.3 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from methanol provided 0.86 g of 2-(cyclopropylmethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin- 4-amine as a white solid, m.p. 191.7-192.6°C.
Η NMR (300 MHz, DMSO-d6) δ 8.17 (d, J = 7.5 Hz, IH), 7.63 (dd, J = 8.3, 1.1 Hz, IH), 7.46-7.41 (m, IH), 7.28-7.19 (m, 3H), 6.89 (t, J = 7.3 Hz, IH), 6.79 (d, J = 7.8 Hz, 2H), 6.49 (s, 2H), 4.98 (t, J = 5.0 Hz, 2H), 4.42 (t, J = 5.0 Hz, 2H), 2.99 (d, J = 6.7 Hz, 2H), 1.40-1.26 (m, IH), 0.55 (m, 2H), 0.32 (m, 2H);
13C NMR (75 MHz, DMSO-d6) 158.6, 154.1, 152.4, 145.5, 133.1, 130.1, 127.0, 126.9, 121.5, 120.8, 115.2, 114.7, 72.1, 66.6, 44.5, 31.1, 9.0, 4.6;
Anal calcd for C22H22N4O*0.1 H20: C, 73.35; H, 6.21; N, 15.55. Found: C, 73.23; H, 6.31; N, 15.57.
Example 138 2-(2-Cyclopentylethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000148_0001
According to the general procedure described in Part C of Example 129, 3- cyclopentylpropionyl chloride (1.3 ml, 8.6 mmol) was reacted with N4-(2- phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol). The product of this reaction was treated according to the general procedures described in Parts D-F of Example 129. Recrystallization from acetonitrile provided 0.44 g of the final product, 2-(2- cyclopentylethyl)-l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine, as a white powder, m.p. 165.0°C.
Η NMR (300 MHz, DMSO-d6) δ 8.17 (d, J = 8.0 Hz, IH), 7.64 (dd, J = 8.3, 0.80 Hz, IH), 7.44 (t, J = 7.3 Hz, IH), 7.29-7.20 (m, 3H), 6.90 (t, J = 7.3 Hz, IH), 6.81 (d, J = 7.9 Hz, 2H), 6.60 (s, 2H), 4.97 (t, J = 4.6 Hz, 2H), 4.44 (t, J = 4.6 Hz, 2H), 3.00 (t, J = 7.6 Hz,
2H), 1.91-1.77 (m, 5H), 1.64-1.48 (m, 4H), 1.20-1.14 (m, 2H);
13C NMR (75 MHz, CDC13) 158.2, 155.0, 151.5, 144.7, 133.6, 129.9, 127.5, 127.4, 127.0, 122.6, 121.9, 119.5, 115.5, 114.5, 66.0, 45.7, 39.8, 33.9, 32.3, 26.4, 24.9; MS (CI) m e 401.2336 (401.2341 calcd for C25H29N40, M+H); Anal calcd for C25H28N40: C, 74.97; H, 7.05; N, 13.99. Found: C, 74.67; H, 7.11; N, 13.97.
Example 139 l-(2-Phenoxyethyl)-2-tetrahydrofuran-3-yl-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000149_0001
N4-(2-phenoxyethyl)quinoline-3,4-diamine (1.6 g, 5.7 mmol) and tetrahydrofuran- 3-carbonyl chloride (0.98 ml, 7.3 mmol) were combined and treated according to the general procedure described in Example 130. Recrystallization from acetonitrile provided 0.3 g of l-(2-phenoxyethyl)-2-tetrahydrofuran-3-yl-lH-imidazo[4,5-c]quinolin-4-amine as a tan solid, m.p. 235.9-236.3°C.
Η NMR (300 MHz, DMSO-d6) δ 8.18 (d, J = 7.8 Hz, IH), 7.63 (dd, J = 8.3, 1.0 Hz, IH), 7.44 (dd, J = 7.6, 1.0 Hz, IH), 7.29-7.20 (m, 3H), 6.90 (t, J = 7.3 Hz, IH), 6.81 (d, J = 7.9 Hz, 2H), 6.49 (s, 2H), 5.05 (t, J = 4.9 Hz, 2H), 4.42 (t, J = 4.9 Hz, 2H), 4.24 (m, IH), 4.04- 3.98 (m, 3H), 3.92-3.87 (m, lH),2.50-2.30 (m, 2H); 13C NMR (75 MHz, DMSO-d6) 158.6, 155.2, 152.4, 145.5, 133.2, 130.1, 127.0, 126.9,
121.6, 120.3, 115.2, 114.7, 72.1, 68.0, 66.5, 44.4, 36.0, 32.4; MS (CI) m/e 375.1808 (375.1821 calcd for C22H23N4O2, M+H);
Anal calcd for C22H22N4O2*0.25 H20: C, 69.73; H, 5.98; N, 14.78. Found: C, 69.90; H, 5.91; N, 14.90.
Example 140 l-(2-Phenoxyethyl)-2-phenyl-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000150_0001
According to the general procedure described in Part C of Examplel29, benzoyl chloride (1.0 ml, 8.5 mmol) was reacted with N4-(2-phenoxyethyl)quinoline-3,4-diamine (2.0 g, 7.2 mmol). The product of this reaction was treated according to the general procedures described in Parts D-F of Example 129. Recrystallization from methanol provided 0.74 g of the final product, l-(2-ρhenoxyethyl)-2-phenyl-lH-imidazo[4,5- c]quinolin-4-amine, as a tan solid, m.p. 182.5-184.6°C.
Η NMR (300 MHz, DMSO-d6) δ 8.21 (d, J = 7.9 Hz, IH), 7.83-7.79 (m, 2H), 7.68-7.58 (m, 4H), 7.48 (t, J = 7.3 Hz, IH), 7.29 (t, J = 7.3 Hz, IH), 7.16 (m, 2H), 6.85 (t, J = 7.3 Hz, IH), 6.68 (m, 4H), 5.02 (t, J = 5.1 Hz, 2H), 4.33 (t J = 5.1 Hz, 2H); 13C NMR (75 MHz, DMSO-de) 158.2, 153.6, 152.9, 146.0, 133.6, 131.1, 130.8, 130.3,
130.1, 129.3, 127.9, 127.5, 127.1, 121.9, 121.6, 121.2, 115.4, 114.7, 66.1, 45.6; MS (CI) m/e 381.1703 (381.1715 calcd for C24H2ιN40, M+H); Anal calcd for C24H20N4O*0.25 H20: C, 74.88; H, 5.37; N, 14.55. Found: C, 74.42; H, 5.10; N, 14.48.
Example 141 4- {[2-(4-Amino- lH-imidazo[4,5-c]quinolin- 1 -yl)butoxy]methyl}benzonitrile
Figure imgf000151_0001
Part A
2-(lH-imidazo[4,5-c]quinolin-l-yl)-l-butanol (3.0 g, 12.4 mmol) was added to a stirring mixture of α-bromo- ?-tolunitrile (3.0 g, 15.3 mmol), sodium hydroxide (40 ml, 50%)), dichloromethane (40 ml), and benzyltrimethylammonium chloride (0.02 g, 0.11 mmol). The reaction was maintained for 72 hours and then diluted with dichloromethane
(100 ml) and water (100 ml). The phases were separated and the aqueous phase was extracted with additional dichloromethane (100 ml). The organic fractions were combined, washed with water, dried (MgS04), filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 9/1 dichloromethane/methanol, Rf 0.48) to provide 2.66 g of 4-{[2-(lH-imidazo[4,5- c]quinolin- 1 -yl)butoxy]methyl}benzonitrile.
Part B
3-Chloroperoxybenzoic acid (2.2 g, 7.5 mmol, 60% by weight) was slowly added to a solution of 4-{[2-(lH-imidazo[4,5-c]quinolin-l-yl)butoxy]methyl}benzonitrile (2.6 g,
7.3 mmol) in chloroform (70 ml). The reaction was maintained for 2 hours and then sequentially washed with saturated sodium bicarbonate (200 ml), water (2 X 100 ml); dried (MgS04); filtered; and concentrated to provide 2.7 g of the 5N-oxide product. Part C >-Toluenesulfonyl chloride (1.43 g, 7.5 mmol) was slowly added over a 20 minute period to a chilled (0 °C) mixture of the product from Part B (2.7 g, 7.3 mmol), concentrated ammonium hydroxide (10 ml) and dichloromethane (20 ml). Monitoring by thin layer chromatography (9:1 dichloromethane/methanol) indicated that the reaction was complete within minutes. The reaction was wanned to ambient temperature and the phases were separated. The organic phase was sequentially washed with sodium carbonate (3X), water, and brine; dried (Na2S04); and concentrated in vacuo. Purification of the resulting brown oil by flash column chromatography (silica gel, 92/8 dichloromethane/methanol) followed by multiple recrystallizations from ethyl acetate/hexane yielded 0.45 g of 4-{[2-(4-amino-lH-imidazo[4,5-c]quinolin-l- yl)butoxy]methyl}benzonitrile as a tan powder, m.p. 160.0-161.0°C. Η NMR (300 MHz, DMSO-d6) δ 8.41 (s, IH), 8.20 (d, J = 7.3 Hz, IH), 7.67 (m, 3H), 7.44 (t, J = 7.3 Hz, IH), 7.31-7.21 (m, 3H), 6.72 (s, 2H), 5.26 (broad s, IH), 4.54 (s, 2H), 4.02-3.91 (m, 2H), 2.07 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H);
13C NMR (125 MHz, DMSO-de) 152.2, 145.2, 143.8, 140.1, 132.4, 132.0, 127.5, 126.6,
126.4, 121.0, 120.5, 118.7, 115.0, 110.0;
MS (El) m/e 371.1754 (371.1746 calcd for C22H2ιN50);
Anal calcd for C22H2ιN50: C, 71.14; H, 5.70; N, 18.85. Found: C, 70.78; H, 5.65; N, 18.51.
Example 142 4-({[(2R)-2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)butyl]oxy}methyl)benzonitrile
Figure imgf000153_0001
(2R)-2-(lH-imidazo[4,5-c]quinolin-l-yl)butan-l-ol (1.36 g, 5.3 mmol) was reacted according to the general procedures described in Parts A and B of Example 141 to provide 1.60 g of the 5N-oxide product.
Trichloroacetyl isocyanate (0.77 ml, 6.5 mmol) was added dropwise to a solution of the 5N-oxide (1.60 g) and dichloromethane (25 ml). The reaction was maintained overnight and then concentrated in vacuo. The resulting red oil was dissolved in methanol (25 ml) and sodium methoxide (4.0 ml, 21% in methanol) was added dropwise. The reaction was maintained for 2.5 days. The solvent was removed in vacuo and the crude product was purified by flash column chromatography (silica gel, 92/8 dichloromethane/methanol) followed by recrystallization from methyl acetate to yield 4-
({[(2R)-2-(4-amino-lH-imidazo[4,5-c]quinolin-l-yl)butyl]oxy}methyl)benzonitrile as a white solid. The enantiomeric excess (ee) of the final product was determined to be greater than 99% based on liquid chromatography (column: CΗIRALCEL® OD-RΗ; eluent: 90/10/0.2 pentane/methanol/triethylamine; flow rate 2 ml/min, Rt 7.8 minutes). Η NMR (500 MHz, DMSO-d6) δ 8.39 (s, IH), 8.20 (d, J = 7.8 Hz, IH), 7.69 (d, J = 8.1
Hz, 2H), 7.63 (dd, J = 8.3, 1.1 Hz, IH), 7.45-7.42 (m, IH), 7.31 (d, J = 8.1 Hz, 2H), 7.23 (m, IH), 6.58 (s, 2H), 5.27 (broad s, IH), 4.57 (s, 2H), 4.03 (dd, J = 10.3, 6.8 Hz, IH), 3.93 (dd, J =10.3, 3.9 Hz, IH), 2.09 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H); Anal calcd for C22H2ιN50: C, 71.14; H, 5.70; N, 18.85. Found: C, 71.00; H, 5.66; N, 18.64. Example 143 4-({[(2S)-2-(4-Amino-lH-imidazo[4,5-c]quinolin-l-yl)butyl]oxy}methyl)benzonitrile
Figure imgf000154_0001
(2S)-2-(lH-imidazo[4,5-c]quinolin-l-yl)butan-l-ol (1.3 g) was reacted according to the general procedure described in Example 142. Recrystallization of the final product from ethyl acetate/hexanes provided 0.2 g of 4-({[(2S)-2-(4-amino-lH-imidazo[4,5- c]quinolin-l-yl)butyl]oxy}methyl)benzonitrile as a white solid. The enantiomeric excess
(ee) of the final product was determined to be greater than 99% based on liquid chromatography (column: CΗIRALCEL® OD-RΗ; eluent: 90/10/0.2 pentane/methanol/triethylamine; flow rate 2 ml/min, Rt 8.7 minutes). Η NMR (500 MHz, DMSO-d6) δ 8.40 (s, IH), 8.20 (d, J = 8.0 Hz, IH), 7.70 (d, J = 8.2 Hz, 2H), 7.63 (dd, J = 8.3, 1.1 Hz, IH), 7.46-7.41 (m, IH), 7.31 (d, J = 8.2 Hz, 2H), 7.23
(m, IH), 6.62 (s, 2H), 5.27 (broad s, IH), 4.57 (s, 2H), 4.04 (dd, J = 10.3, 6.7 Hz, IH), 3.93 (dd, J =10.3, 3.9 Hz, IH), 2.10 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H); Anal calcd for C22H2ιN50: C, 71.14; H, 5.70; N, 18.85. Found: C, 71.10; H, 5.98; N, 18.96.
Example 144 2-(2-Methoxyethyl)-l-[2-(prop-2-ynyloxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine
Figure imgf000155_0001
Part A
Propargyl bromide (10.0 ml, 89.8 mmol, 80 % in toluene) and benzyltrimethylammonium chloride (0.60 g, 3.2 mmol) were dissolved in dichloromethane (130 ml). The solution was treated with sodium hydroxide (130 ml, 50 % w/w in water). 2-[2-(2-Methoxyethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethanol (20.0 g, 73.7 mmol) was added and the mixture was vigorously stirred for 18 hours. Thin layer chromatography
(9/1 chloroform/methanol) indicated complete conversion. The mixture was diluted with water (200 ml) and the phases were separated. The aqueous fraction was extracted with additional dichloromethane (3 x 150 ml). The combined organic fractions were washed with brine (100 ml), dried (Na2S04), filtered and concentrated to yield 22.7 g of 2-(2- methoxyethyl)-l-[2-(prop-2-ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline as an orange solid.
'Η MR (300 MHz, DMSO-d6) δ 9.15 (s, IH), 8.40 (m, IH), 8.15 (m, IH), 7.73-7.64 (m, 2H), 4.89 (t, J = 5.3 Hz, 2H), 4.10 (d, J = 2.4 Hz, 2H), 3.95 (t, J = 5.1 Hz, 2H), 3.89 (t, J = 6.9 Hz, 2H), 3.36 (t, J = 2.4 Hz, IH), 3.32 (s, 3H), 3.27 (t, J = 6.9 Hz, 2H). Part B
2-(2-Methoxyethyl)-l-[2-(prop-2-ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline (22.7 g, 73.4 mmol) was dissolved in chloroform (300 ml) and chilled in an ice water bath. 3-Chloroperoxybenzoic acid (17.0 g, 127.9 mmol, 77 % max) was added in small portions over 30 minutes. Analysis by thin layer chromatography (9/1 chloroform/methanol) at 30 minutes indicated that there was still starting material present. Additional 3- chloroperoxybenzoic acid (7.00 g, 52.7 mmol, 77 % max) was added. After 2 hours, the reaction was warmed to ambient temperature and quenched by the addition of saturated sodium bicarbonate (100 ml). The aqueous and organic fractions were separated and the aqueous fraction was extracted with additional chloroform (2 x 50 ml). The combined organic fractions were washed with water (100 ml), brine (100 ml); dried (Na2S04); filtered; and concentrated in vacuo to provide a dark orange solid. Η NMR indicated less than 5 % 3-chlorobenzoic acid in the crude product. The material was used without further purification.
Η NMR (300 MHz, DMSO-d6) δ 8.56 (s, IH), 8.33 (d, J = 7.7 Hz, IH), 7.99 (d, J = 7.3 Hz, IH), 7.38-7.30 (m, 2H), 4.40 (t, J = 4.8 Hz, 2H), 3.63 (d, J = 2.1 Hz, 2H), 3.47 (t, J = 4.9 Hz, 2H), 3.40 (t, J = 6.9 Hz, 2H), 2.88 (t, J = 2.0 Hz, IH), 2.84 (s, 3H), 2.78 (t, J = 6.3 Hz, 2H).
Part C
Under an atmosphere of nitrogen, 2-(2 -methoxyethyl)- l-[2-(prop-2- ynyloxy)ethyl]-lH-imidazo[4,5-c]quinoline-5N-oxide (1.57 g, 4.83 mmol) was dissolved in dichloromethane (25 ml). Trichloroacetyl isocyanate (0.80 ml, 6.71 mmol) was added dropwise via syringe. The reaction was stirred for 1 hour and then the volatiles were removed in vacuo. The resulting residue was treated with methanol (15 ml) forming an orange suspension. A solution of sodium methoxide (25 % in methanol) was added slowly via syringe. The reaction became a dark orange solution. After 1.5 hours the reaction was quenched by the slow addition of saturated ammonium chloride solution (10 ml). The methanol was removed in vacuo. The aqueous residue was extracted with dichloromethane (3 x 10 ml) and the organic fractions were combined and washed with water (10 ml) and brine (10 ml). The solution was dried (Na2S04), filtered and concentrated in vacuo to yield the crude product as an orange solid. Recrystallization from propyl acetate provided 0.78 g of 2-(2-methoxyethyl)-l-[2-(prop-2-ynyloxy)ethyl]- 1 H-imidazo [4, 5 -c]quinolin-4-amine as off-white crystals.
Η NMR (300 MHz, DMSO-d6) δ 8.05 (d, J = 7.3 Hz, IH), 7.61 (d, J = 7.2 Hz, IH), 7.42 (t, J = 7.8 Hz, IH), 7.23 (t, J = 7.3 Hz, IH), 6.44 (bs, 2H), 4.78 (t, J = 5.2 Hz, 2H), 4.11 (d, J = 2.5 Hz, 2H), 3.91 (t, J = 5.5 Hz, 2H), 3.83 (t, J = 6.7 Hz, 2H), 3.37 (t, J = 2.6 Hz, IH), 3.30 (s, 3H), 3.20 (t, J = 6.8 Hz, 2H); MS (CI) m/e 325 (M + H);
Anal calcd for Cι8H20N4O2: C, 66.65; H, 6.21; N, 17.27. Found: C, 66.34; H, 6.05; N, 16.96. Example 145 2-methyl-l-(2-{[(2E)-3-phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4- amine
Figure imgf000157_0001
Part A
Using the general method of Example 1 Part B, 2-(2-methyl-lH-imidazo[4,5- c]quinolin-l-yl)ethyl acetate (12.0 g, 44.56 mmol) was oxidized to provide 8.7 g of 2-(2- methyl-5-oxido-lH-imidazo[4,5-c]quinolin-l-yι)ethyl acetate as a brown solid. Material was used without further purification.
PartB
A dried round bottom flask was charged with a stir bar, 2-(2-methyl-5-oxido-lH- imidazo[4,5-c]quinolin-l-yl)ethyl acetate (8.7 g, 30.49 mmol), anhydrous dimethylformamide (80 mL), and anhydrous toluene (100 mL) under nitrogen. To this brown mixture was added phosphorus oxychloride (3.1 mL) by syringe at ambient temperature. The reaction solution cleared in a couple of minutes and a slight exotherm was observed. The reaction was judged to be complete after 30 minutes. The volatiles were removed under reduced pressure. The resulting brown solid was partitioned between dichloromethane and 4% aqueous sodium bicarbonate to a pΗ of -8. The aqueous layer was extracted with dichloromethane (5x). The organic fractions were combined, dried with anhydrous sodium sulfate, concentrated under reduced pressure and dried overnight at ambient temperature under reduced pressure to provide 9.2 g of 2-(4-chloro-2-methyl- lH-imidazo[4,5-c]quinolin-l-yl)ethyl acetate as a brown oil. MS (CI) for Cι5Ηι4ClN302 m/z 304 (MH+), 262, 218 Part C
A round bottom flask was charge with a stir bar, 2-(4-chloro-2-methyl-lH- imidazo[4,5-c]quinolin-l-yl)ethyl acetate (9.2 g, 30.5 mmol), methanol (200 mL) and potassium carbonate (0.4 g, 3.0 mmol). The reaction was judged complete after stirring for 5 hours at 26 °C. The solution was partitioned between chloroform and brine. The organic layer was removed and the aqueous fraction extracted with chloroform (6x). The organic fractions were combined, dried with anhydrous sodium sulfate and concentrated under reduced pressure to approximately 200 mL when crystallization was observed. The solution was stoppered and maintained at ambient temperature for 24 hours. The resulting fine white crystals were collected by filtration to provide 4.49 g of 2-(4-chloro-2-methyl-
1 H-imidazo [4, 5 -c] quinolin- 1 -yl)ethanol. MS (CI) for Cι3Ηι2ClN30 m/z 262 (MH+), 218 Part D
A round bottom flask was charge with a stir bar, 2-(4-chloro-2-methyl-lH- imidazo[4,5-c]quinolin-l-yl)ethanol (3.9 g, 14.9 mmol), dichloromethane (125 mL), aqueous sodium hydroxide (50%, 125 mL), benzyltrimethylammonium chloride (0.55 g, 0.003 mmol) and stirred vigorously at ambient temperature. To this mixture was added cinnamyl bromide (8.8 g, 44.71 mmol) as a solid. After 45 minutes the solution was clear and the reaction was judged complete. The solution was poured into ice water (200 mL), the organic layer separated and was drawn off. The aqueous solution was extracted with dichloromethane (4x). The organic layers were combined, washed with brine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting orange oil was purified by chromatography over silica gel (dichloromethane, followed by 98/2 dichloromethane/methanol). The resulting oil was triturated with ethyl ether and the resulting solid was collected by filtration and dried to provide 4.22 g of 4-chloro-2- methyl-l-(2-{[(2E)-3-phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinoline as a white solid.
MS (CI) for C22Η20ClN3O m/z 378 (MH+), 262, 228
Part E 4-Chloro-2-methyl-l-(2-{[(2E)-3-phenylprop-2-enyl]oxy}ethyl)-lH-imidazo[4,5- c]quinoline (2.12 g, 5.61 mmol), was combined with an ammonia/methanol solution (7%, 70 mL) in a bomb and heated to 150 °C for 16.5 hours and cooled to ambient temperature. Analysis indicated that the reaction was incomplete. The solution was concentrated under reduced pressure to - 10 mL, diluted with ammonia/methanol (7%, 50 mL) and reacted in a bomb at 150 °C for 8.5 hours to complete the reaction. The solution was partitioned between dichloromethane and saturated aqueous sodium bicarbonate and the organic layer removed. The aqueous layer was saturated with sodium chloride and extracted with dichloromethane (3x). The organic fractions were combined, dried with anhydrous sodium sulfate and concentrated under reduced pressure. The resulting brown solid was recrystalized from methanol to provide 0.963 g of 2-methyl-l-(2-{[(2E)-3-phenylprop-2- enyl]oxy}ethyl)-lH-imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 111.8-112.5 °C.
Analysis. Calculated for C22Η22N40: %C, 73.72; %H, 6.19; %N, 15.63. Found: %C, 73.48; %H, 6.25; %N, 15.57
Η NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 7.5 Hz, 1 H), 7.61 (d, J = 8.1 Hz, 1 H), 7.40 (t, J = 5.6 Hz, 1 H), 7.18-7.30 (m, 6 H), 6.51 (s, 2 H), 6.31 (d, J = 16.2 Hz, 1 H), 6.17 (dt, J=15.6, 5.3 Hz, 1 H), 4.76 (t, J = 5.0 Hz, 2 H), 4.05 (d, J = 3.9 Hz, 2 H), 3.91 (t, J = 5.6, 2
H), 2.64 (s, 3 H) MS (CI) for C22H22N40 m/z 259 (MH+), 243, 199
Example 146 2-methyl- 1 - {2-[(3-phenylprop-2-ynyl)oxy]ethyl} -6,7,8,9-tetrahydro- lH-imidazo[4,5- c] quinolin-4-amine
Figure imgf000159_0001
Part A
Using the general method of Example 115 Part C, the 4-amino group was introduced to 2-(2-methyl-5-oxido-lH-imidazo[4,5-c]quinolin-l-yl)ethyl acetate (8.47 g, 29.71 mmol). The resulting brown oil was purified by trituration with acetonitrile and dried to yield 3.583 g of 2-(4-amino-2-methyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl acetate as a tan solid.
MS (CI) for Ci5Η16ClN4θ2 m/z 285 (MH+), 270, 199 Part B
A Parr flask was charged with 2-(4-amino-2-methyl-lH-imidazo[4,5-c]quinolin-l- yl)ethyl acetate (3.61 g, 12.64 mmol), trifluoroacetic acid (50 mL) and purged with nitrogen. To this solution was added platinum(IV) oxide (0.5 g). The reaction was judged to be complete after 13 days of hydrogenation at ambient temperature. The solution was filtered and the volatiles removed under reduced pressure. The resulting brown oil was partitioned between dichloromethane and saturated aqueous sodium bicarbonate to a pΗ of ~ 8. The layers were separated. The aqueous layer was extracted with dichloromethane
(4x). The organic fractions were combined, dried with anhydrous sodium sulfate and concentrated under reduced pressure. The resulting white solid was purified by recrystallization from ethyl acetate/methanol (9/1) and dried to provide 0.98 g of 2-(4- amino-2-methyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)ethanol as a white solid.
MS (CI) for Cι3Ηι8N40 m/z 247 (MH+), 203 Part C
Using the general method of Example 1 Part A, 2-(4-amino-2-methyl-6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl)ethanol (0.763 g, 3.098 mmol) was reacted with propargyl bromide (80% in toluene, 1.1 mL, 9.29 mmol) to provide 0.42 g of 2- methyl-l-[2-(prop-2-ynyloxy)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4- amine as a brown oil.
MS (CI) for Cι6Η20N4O m/z 285 (MH+), 247, 183 Part D Using the general method of Example 12 Part A, 2-methyl-l-[2-(prop-2- ynyloxy)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (0.396 g, 1.392 mmol) was reacted with iodobenzene (0.17 mL, 1.532 mmol) at ambient temperature. After 18 hours the reaction was incomplete. The solution was heated to 50 °C for 3 hours to complete the reaction. The volatiles were removed under reduced pressure. The resulting oil was partitioned between dichloromethane and 4% aqueous sodium carbonate and the organic layer removed. The aqueous layer was extracted with dichloromethane (3x). The organic fractions were combined, dried with anhydrous sodium sulfate and the volatiles were removed under reduced pressure. The resulting oil was purified by chromatography over silica gel (95/5 dichloromethane/methanol). The resulting white solid was dissolved in dichloromethane (2 mL) and reacted with IM HCl in ether (2 mL). The volatiles were removed under reduced pressure and the resulting solids recrystallized from methanol to provide 0.1089 g of 2-methyl-l-{2-[(3-phenylprop-2-ynyl)oxy]ethyl}-
6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (hydrochloride) 1.9 as a tan solid. Analysis. Calculated for C22Η24N40 (HC1) 9 (H2O)0.7: %C, 59.74; %H, 6.22; %N, 12.67; %C1, 15.23. Found: %C, 59.72; %H, 6.04; %N, 12.65; %C1, 14.99 Η NMR (300 MHz, DMSO-d6) δ 7.93 (s, 2 H), 7.36-7.40 (m, 3 H), 7.28-7.30 (m, 2 H), 4.56 (t, J = 5.0 Hz, 2 H), 4.35 (s, 2 H), 3.88 (t, J = 5.3 Hz, 2 H), 2.92 (s, 2 H), 2.69 (s, 2 H),
2.60 (s, 3 H), 1.73 (s, 4 H) MS (CI) for C22H24N40 m/z 361 (MH+), 247, 199
CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system is used to assess cytokine induction. Activity is based on the measurement of interferon and tumor necrosis factor (α) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995).
Blood Cell Preparation for Culture
Whole blood from healthy human donors is collected by venipuncture into EDTA vacutainer tubes. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque®-1077. The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 106 cells/mL in RPMI complete. The PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park,
NJ) containing an equal volume of RPMI complete media containing test compound.
Compound Preparation
The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells.
Incubation
The solution of test compound is added at 60 μM to the first well containing RPMI complete and serial 3 fold dilutions are made in the wells. The PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (0.12 to 30 μM). The final concentration of PBMC suspension is 1.5-2 X
106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5%> carbon dioxide atmosphere.
Separation Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm
(-200 x g) at 4°C. The cell-free culture supernatant is removed with a sterile polypropylene pipet and transfened to sterile polypropylene tubes. Samples are maintained at -30 to -70°C until analysis. The samples are analyzed for interferon ( ) and for tumor necrosis factor (α) by ELISA Interferon (α and Tumor Necrosis Factor (α) Analysis by ELISA
Interferon (α) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
Tumor necrosis factor (α) concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San
Diego, CA. Results are expressed in pg/mL.
The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound. A "*" indicates that no induction was seen at any of the tested concentrations; generally the highest concentration tested was 10 or 30 μM.
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001

Claims

WHAT IS CLAIMED IS:
A compound of the formula (I):
Figure imgf000169_0001
(I) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of:
-alkenyl;
-aryl; and
-R-v-aryl; R2 is selected from the group consisting of:
-hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl- Y- alkenyl;
-alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2;
-CO-C O alkyl;
-CO-0-Cι-ιo alkyl; -N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
Ri is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of C1-10 alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
2. A compound or salt of claim 1 wherein Ri is -alkyl-aryl.
3. A compound or salt of claim 1 wherem Ri is -(CH2)o-3-phenyl.
4. A compound or salt of claim 1 wherein Ri is -(CH2)o-3-substituted phenyl.
5. A compound or salt of claim 1 wherein X is -CH(alkyl)(alkyl)- wherein the alkyl groups can be the same or different.
6. A compound or salt of claim 1 wherein X is -CH2-CH2-.
7. A compound or salt of claim 1 wherein X is -CH(C2H5)(CH2)-.
8. A compound or salt of claim 1 wherein R2 is H.
9. A compound or salt of claim 1 wherein R2 is alkyl.
10. A compound or salt of claim 1 wherein R2 is -alkyl-O-alkyl.
11. A compound of the formula (II)
Figure imgf000171_0001
(II)
wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Rio is selected from the group consisting of:
-H; -alkyl;
-alkenyl; and
-aryl; R2 is selected from the group consisting of:
-hydrogen; -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -alkyl-Y-alkyl;
-alkyl-Y- alkenyl;
-alkyl-Y-aryl; and -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2; -CO-CMO alkyl; -CO-O-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; n is 0 to 4; each Y is independently -O- or -S(0)o-2-; each R3 is independently H or CMO alkyl; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
12. A compound of claim 11 wherein Rio is aryl.
13. A compound or salt of claim 11 wherein Rio is — (CH2)0-3— phenyl.
14. A compound or salt of claim 11 wherein R10 is — (CH2)o-3-substituted phenyl.
15. A compound or salt of claim 11 wherein X is -CH(alkyl)(alkyl)-, wherein the alkyl groups can be the same or different.
16. A compound or salt of claim 11 wherein X is -CH2-CH2-
17. * A compound or salt of claim 11 wherein X is -CH(C2H5)(CH2)-.
18. A compound or salt of claim 11 wherein R2 is H.
19. A compound or salt of claim 11 wherein R2 is alkyl.
20. A compound or salt of claim 11 wherein R2 is alkyl-O-alkyl.
21. A compound of the formula (III)
Figure imgf000173_0001
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of:
-aryl; -alkenyl; and
-R-r-aryl; R2 is selected from the group consisting of:
-hydrogen;
-alkyl; -alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl; . -alkyl-Y-aryl;
- alkyl- Y- alkenyl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen; -N(R3)2;
-CO-N(R3)2; -CO-CMO alkyl; -CO-O-Ci-io alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; Rj is alkyl or alkenyl, which may be interrupted by one or more
-O- groups; each Rj is independently H or CMO alkyl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
22. A compound or salt of claim 21 wherein R[ is -(CH2)o-3— substituted phenyl.
23. A compound or salt of claim 21 wherein R2 is H or alkyl.
24. A compound or salt of claim 21 wherein R2 is -alkyl-O-alkyl.
25. A compound of the formula (IV):
Figure imgf000175_0001
(IN)
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-; Rio is selected from the group consisting of: -H; -alkyl;
-alkenyl; and -aryl; R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl- Y-aryl; -alkyl- Y- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-Ν(R3)2;
-CO-N(R3)2;
-CO-Ci-io alkyl; -CO-O-CMO alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; each R3 is independently H or CMO alkyl; each Y is independently -O- or - S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO • alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 11 and a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 21 and a pharmaceutically acceptable carrier.
29. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
30. The method of claim 29 wherein the cytokine is IFN-α.
31. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 11 to the animal.
32. The method of claim 31 wherein the cytokine is IFN-α.
33. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
34. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
35. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 11 to the animal.
36. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 11 to the animal.
37. A method of inducing cytokine biosynthesis in an animal comprising administering a theraputically effective amount of a compound or salt of claim 21 to the animal.
38. The method of claim 37 wherein the cytokine is IFN-α.
39. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.
40. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.
41. A compound of the formula (V):
Figure imgf000177_0001
(V) wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl; -R4-aryl; and
Figure imgf000178_0001
R2 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl;
• -aryl; -heteroaryl; -heterocyclyl; -alkyl-Y-al yl; -alkyl-Y- alkenyl;
-alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen;
-N(R3)2; -CO-N(R3)2; -CO-CMO alkyl; -CO-O-CMO alkyl; -N3;
-aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl;
R> is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of C O alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
42. A compound of the formula (VI):
Figure imgf000179_0001
(VI)
wherein X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-
Ri is selected from the group consisting of: -aryl;
-alkenyl;
Figure imgf000179_0002
-(CH2)MO-C≡C-R10; R2 is selected from the group consisting of: -hydrogen;
-alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH;
-halogen; -N(R3)2; -CO-N(R3)2; -CO-CMO alkyl; -CO-O-CMO alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; Rt is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl; Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or-S(0)o-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
43. A compound of the formula (VII):
Figure imgf000181_0001
(VII)
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl; -R -aryl; and
Figure imgf000181_0002
RJ is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or CMO alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
44. A compound of the formula (VIII):
Figure imgf000181_0003
Figure imgf000181_0004
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl;
Figure imgf000182_0001
-(CH2),-ιo-C≡C-Rι0; R2 is selected from the group consisting of: -hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl: -alkyl- Y-alkyl;
-alkyl- Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH;
-halogen; -N(R3)2; -CO-N(R3)2; -CO-CMO alkyl; -CO-O-CMO alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; j is alkyl or alkenyl, which may be interrupted by one or more
-O- groups; each R3 is independently H or CMO alkyl;
Rio is selected from the group consisting of H, alkyl, alkenyl and aryl; each Y is independently -O- or -S(0)o-2-; n is 0 to 4; each R present is independently selected from the group consisting of C O alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; and
R7 is tert-butyl or benzyl; or a pharmaceutically acceptable salt thereof.
45. A compound of the formula (IX)
Figure imgf000183_0001
(LX)
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Ri is selected from the group consisting of: -aryl; -alkenyl;
-R4-aιyl; and -(CH2)MO-C≡CH; R2 is selected from the group consisting of: -hydrogen; -alkyl;
-alkenyl; -aryl; -heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2; -CO-CMO alkyl; -CO-0-Cι-ιo alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl;
Rj is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 is independently H or C O alkyl; * each Y is independently -O- or -S(O)0-2-; n is 0 to 4; and each R present is independently selected from the group consisting of CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
PCT/US2001/046581 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines WO2002046189A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
UA2003065277A UA75622C2 (en) 2000-12-08 2001-06-12 Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
HU0700062A HUP0700062A2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines and pharmaceutical compositions thereof
NZ526105A NZ526105A (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines as immunomodulators, for inducing cytokine biosynthesis
AU3951602A AU3951602A (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
BRPI0116052-4A BR0116052A (en) 2000-12-08 2001-12-06 imidazoquinolines substituted by aryl ether
AU2002239516A AU2002239516B2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
CA002430844A CA2430844A1 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
JP2002547926A JP2004523498A (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinoline
EEP200300270A EE200300270A (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
PL01366115A PL366115A1 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
KR10-2003-7007538A KR20040028691A (en) 2000-12-08 2001-12-06 Aryl Ether Substituted Imidazoquinolines
SK684-2003A SK6842003A3 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
IL15604301A IL156043A0 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
EP01987282A EP1341789A2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
MXPA03004973A MXPA03004973A (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines.
NO20032452A NO20032452L (en) 2000-12-08 2003-05-28 Aryl ether substituted imidazole quinolines
HR20030462A HRP20030462A2 (en) 2000-12-08 2003-06-06 Aryl ether substituted imidazoquinolines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25421800P 2000-12-08 2000-12-08
US60/254,218 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002046189A2 true WO2002046189A2 (en) 2002-06-13
WO2002046189A3 WO2002046189A3 (en) 2003-03-20

Family

ID=22963391

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2001/046582 WO2002046190A2 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines
PCT/US2001/046697 WO2002046192A2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
PCT/US2001/046359 WO2002046188A2 (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
PCT/US2001/046696 WO2002046191A2 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
PCT/US2001/046704 WO2002046193A2 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines
PCT/US2001/046581 WO2002046189A2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines

Family Applications Before (5)

Application Number Title Priority Date Filing Date
PCT/US2001/046582 WO2002046190A2 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines
PCT/US2001/046697 WO2002046192A2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
PCT/US2001/046359 WO2002046188A2 (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
PCT/US2001/046696 WO2002046191A2 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
PCT/US2001/046704 WO2002046193A2 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines

Country Status (32)

Country Link
US (8) US6670372B2 (en)
EP (6) EP1341792A2 (en)
JP (7) JP2004521092A (en)
KR (6) KR20030070049A (en)
CN (6) CN1297554C (en)
AR (6) AR035665A1 (en)
AT (3) ATE319711T1 (en)
AU (12) AU3248202A (en)
BR (6) BR0116032A (en)
CA (6) CA2431151A1 (en)
CY (2) CY1105586T1 (en)
CZ (6) CZ20031562A3 (en)
DE (3) DE60117859T2 (en)
DK (3) DK1343784T3 (en)
EE (6) EE200300275A (en)
ES (3) ES2281456T3 (en)
HK (3) HK1064383A1 (en)
HR (6) HRP20030467B1 (en)
HU (6) HUP0600605A2 (en)
IL (6) IL156044A0 (en)
MX (6) MXPA03004972A (en)
NO (6) NO20032452L (en)
NZ (6) NZ526105A (en)
PL (7) PL365907A1 (en)
PT (2) PT1341791E (en)
RU (6) RU2003116063A (en)
SI (1) SI1341790T1 (en)
SK (6) SK6842003A3 (en)
TW (3) TW584633B (en)
UA (2) UA74852C2 (en)
WO (6) WO2002046190A2 (en)
ZA (6) ZA200305275B (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6534654B2 (en) 1996-06-21 2003-03-18 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6699878B2 (en) 1997-12-11 2004-03-02 3M Innovative Properties Company Imidazonaphthyridines
US6780873B2 (en) 1999-06-10 2004-08-24 3M Innovative Properties Company Urea substituted imidazoquinolines
US6784188B2 (en) 1999-06-10 2004-08-31 3M Innovative Properties Company Urea substituted imidazoquinolines
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
US6825350B2 (en) 1999-06-10 2004-11-30 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers
EP1545597A2 (en) * 2002-08-15 2005-06-29 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6921826B2 (en) 2000-12-08 2005-07-26 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6953804B2 (en) 2000-12-08 2005-10-11 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
EP1653959A2 (en) * 2003-08-14 2006-05-10 3M Innovative Properties Company Lipid-modified immune response modifiers
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
JP2007521317A (en) * 2003-08-14 2007-08-02 スリーエム イノベイティブ プロパティズ カンパニー Lipid-modified immune response modifier
US7299453B2 (en) 2001-12-20 2007-11-20 International Business Machines Corporation Testing measurements
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
US20090030030A1 (en) * 2003-12-29 2009-01-29 Bonk Jason D Arylalkenyl and arylalkynyl substituted imidazoquinolines
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US7696159B2 (en) 2003-03-25 2010-04-13 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
WO2010111485A1 (en) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
US7968562B2 (en) 2001-11-29 2011-06-28 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
WO2013013055A1 (en) 2011-07-21 2013-01-24 Rubigo Therapeutics, Inc. System for drug delivery and monitoring
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
EP4051270A4 (en) * 2019-10-29 2024-02-28 Prime Reach Trading Ltd 4-amino-imidazoquinoline compounds and use thereof

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
IL147953A (en) * 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
MXPA04008023A (en) * 2002-02-22 2004-11-26 3M Innovative Properties Co Method of reducing and treating uvb-induced immunosuppression.
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
CA2491680C (en) * 2002-07-02 2012-04-17 Southern Research Institute Inhibitors of ftsz and uses thereof
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006517974A (en) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Methods and compositions for IRM compounds and Toll-like receptor 8
US20040176367A1 (en) * 2003-03-07 2004-09-09 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
CN1852711A (en) * 2003-08-05 2006-10-25 3M创新有限公司 Infection prophylaxis using immune response modifier compounds
TW200524927A (en) * 2003-08-12 2005-08-01 3M Innovative Properties Co Hydroxylamine substituted imidazo-containing compounds
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658035A4 (en) 2003-08-25 2007-08-22 3M Innovative Properties Co Delivery of immune response modifier compounds
WO2005020999A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
MXPA06002408A (en) * 2003-09-02 2006-06-20 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions.
JP2007504269A (en) * 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
US20050059072A1 (en) * 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
SG149829A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
CA2543685A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
CN1906192A (en) 2003-11-14 2007-01-31 3M创新有限公司 Hydroxylamine substituted imidazo ring compounds
ATE400573T1 (en) * 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1H-IMIDAZOCINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
AR046845A1 (en) * 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
JP2007513165A (en) 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Concomitant drugs containing IRM compounds and methods of treatment
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
JP4991520B2 (en) * 2004-03-15 2012-08-01 スリーエム イノベイティブ プロパティズ カンパニー Immune response modulator formulation and method
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (en) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー Methods, compositions and preparations for delivering immune response modifiers
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
ATE555786T1 (en) * 2004-09-02 2012-05-15 3M Innovative Properties Co 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
EP1819364A4 (en) * 2004-12-08 2010-12-29 3M Innovative Properties Co Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP5543068B2 (en) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー Chiral fused [1,2] imidazo [4,5-c] cyclic compound
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005321912B2 (en) 2004-12-30 2012-04-05 3M Innovative Properties Company Treatment for cutaneous metastases
WO2006073939A2 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
WO2006091394A2 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
ATE552267T1 (en) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic IMMUGENES OF UROPATHOGENS ESCHERICHIA COLI
WO2006091647A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
RU2007137960A (en) 2005-03-14 2009-04-20 Меда Аб (Se) METHOD FOR TREATING ACTIN KERATOSIS (OPTIONS) AND 2-METHYL-1- (2-METHYL PROPYL) -1H-IMIDAZO [4,5-c]] 1,5] NAPHTIRIDIN-4-AMINE AS A MEANS OF TREATMENT OF ACTINIC KERO
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008539252A (en) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
JP2009501546A (en) 2005-07-18 2009-01-22 ノバルティス アーゲー A small animal model for HCV replication
BRPI0615788A2 (en) 2005-09-09 2011-05-24 Coley Pharm Group Inc n- {2- [4-amino (ethoxymethyl) -1h-imidazo [4,5-c] quinolin-1-yl] -1,1-dimethylethyl} methanesulfonamide amide and carbamate derivatives, pharmaceutical composition of these and their uses
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
JP2009514839A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant influenza vaccine containing cytokine inducer
ES2792398T3 (en) 2005-11-04 2020-11-11 Seqirus Uk Ltd Non-virion antigen-adjuvanted vaccines prepared from influenza viruses grown in cell culture
KR20080083270A (en) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
JP2009514850A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
PL2185191T3 (en) 2007-06-27 2013-02-28 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EA018579B1 (en) * 2008-01-15 2013-09-30 Меда Аб Method of treatment of polypes/polyposis and precancerous colorectal changes
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
FR2949344A1 (en) 2009-04-27 2011-03-04 Novartis Ag FLU PROTECTIVE VACCINES
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
AR077757A1 (en) 2009-07-15 2011-09-21 Novartis Ag COMPOSITIONS OF FUSION PROTEINS OF RESPIRATORY SINCICIAL VIRUS (RSV) AND METHODS FOR PREPARATION
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
PL2606047T3 (en) 2010-08-17 2017-07-31 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
ES2575688T3 (en) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy
EP4144368A1 (en) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
ES2782119T3 (en) 2011-05-13 2020-09-10 Glaxosmithkline Biologicals Sa RSV prefusion F antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
MX355623B (en) * 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN112587658A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
DK2941233T3 (en) 2013-01-07 2020-10-19 Univ Pennsylvania Compositions and methods for treating cutaneous T-cell lymphoma
JP6446054B2 (en) 2013-11-05 2018-12-26 スリーエム・イノベイティブ・プロパティーズ・カンパニー Sesame oil-based injection formulation
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
SG11201605455YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for treating egfr expressing tumors
EA037818B1 (en) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Mutant staphylococcal antigens
CN105233291A (en) 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
AU2015286043B2 (en) 2014-07-09 2020-08-20 Birdie Biopharmaceuticals Inc. Anti-PD-L1 combinations for treating tumors
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugate for treating tumors
CN105461767B (en) * 2014-08-07 2019-03-12 富力 A kind of chemical synthesis process of forsythin
KR102161364B1 (en) * 2015-09-14 2020-09-29 화이자 인코포레이티드 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
CN108770357B (en) * 2015-09-29 2022-10-28 芝加哥大学 Polymer conjugate vaccines
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019166937A1 (en) * 2018-02-28 2019-09-06 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
RU2020128440A (en) 2018-02-28 2022-03-28 Пфайзер Инк. IL-15 OPTIONS AND THEIR APPLICATIONS
JP7384835B2 (en) 2018-05-23 2023-11-21 ファイザー・インク Antibodies specific to CD3 and their uses
TWI816396B (en) 2018-05-23 2023-09-21 美商輝瑞大藥廠 Antibodies specific for gucy2c and uses thereof
EP3802536B1 (en) 2018-05-24 2022-07-13 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20210213010A1 (en) * 2018-07-24 2021-07-15 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
WO2020109898A1 (en) * 2018-11-26 2020-06-04 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN114616234B (en) * 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 Phosphorus imidazoquinoline amine derivative, pharmaceutical composition and application thereof
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP4077387A1 (en) 2019-12-17 2022-10-26 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
PE20231565A1 (en) 2020-07-17 2023-10-04 Pfizer THERAPEUTIC ANTIBODIES AND THEIR USES
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
WO1995002598A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135210A (en) * 1937-03-13 1938-11-01 John R Farrar Golf ball
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3819190A (en) * 1972-10-02 1974-06-25 D Nepela Golf ball
US4284276A (en) * 1980-02-13 1981-08-18 Worst Joseph C Grooved golf ball
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5054153A (en) * 1989-12-01 1991-10-08 Silliman Paul D Golf club cleaner
DK0553202T3 (en) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Process for the preparation of imidazo (4,5-c) quinoline-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2692159B1 (en) * 1992-06-10 1996-10-11 Vartan Berberian BALL FOR BALL GAMES AND METHODS OF OBTAINING SUCH A BALL.
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1995002597A1 (en) 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09116911A (en) * 1995-10-20 1997-05-02 Canon Inc Image pickup system
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5759109A (en) * 1996-09-09 1998-06-02 Martini; Byron Rocco Simulated golf ball instructional device
ES2290969T3 (en) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company AMENDING COMPOUNDS OF THE IMMUNE RESPONSE FOR THE TREATMENT OF DISEASES MEDIATED BY TH2 AND RELATED.
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
CN1220997C (en) * 1998-05-22 2005-09-28 松下电器产业株式会社 Electrolytic condenser and its manufacturing method
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (en) * 1999-01-08 2009-12-07 3M Innovative Properties Company Use of immune response modifiying compound for cervical dysplasias treatment
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
WO2002102377A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
MXPA04001972A (en) 2001-08-30 2005-02-17 3M Innovative Properties Co Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules.
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003043572A2 (en) 2001-11-16 2003-05-30 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
AU2004220469B2 (en) 2001-11-29 2010-07-29 3M Innovative Properties Company Methods of improving skin quality
RU2327460C2 (en) 2001-11-29 2008-06-27 3М Инновейтив Пропертиз Компани Immunomodulator-containing pharmaceutical formulations
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
MXPA04008023A (en) 2002-02-22 2004-11-26 3M Innovative Properties Co Method of reducing and treating uvb-induced immunosuppression.
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CA2488801A1 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
DE60335010D1 (en) 2002-08-15 2010-12-30 3M Innovative Properties Co IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003301052A1 (en) * 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (en) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー Combination immunostimulant
JP2006517974A (en) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Methods and compositions for IRM compounds and Toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
JP2006519866A (en) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Prophylactic treatment of UV-induced epidermal neoplasia
US20040176367A1 (en) 2003-03-07 2004-09-09 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
CA2518082C (en) 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
WO1995002598A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613902B2 (en) 1996-06-21 2003-09-02 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6534654B2 (en) 1996-06-21 2003-03-18 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6624305B2 (en) 1996-06-21 2003-09-23 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6897314B2 (en) 1996-06-21 2005-05-24 3M Innovative Properties Company Process for preparing imidazoquinolinamines
US6894165B2 (en) * 1997-12-11 2005-05-17 3M Innovative Properties Company Imidazonaphthyridines
US6699878B2 (en) 1997-12-11 2004-03-02 3M Innovative Properties Company Imidazonaphthyridines
US6797716B2 (en) 1997-12-11 2004-09-28 3M Innovative Properties Company Imidazonaphthyridines
US6747040B2 (en) 1997-12-11 2004-06-08 3M Innovative Properties Company Imidazonaphthyridines
US6825350B2 (en) 1999-06-10 2004-11-30 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers
US6784188B2 (en) 1999-06-10 2004-08-31 3M Innovative Properties Company Urea substituted imidazoquinolines
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
US6780873B2 (en) 1999-06-10 2004-08-24 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6989389B2 (en) 2000-12-08 2006-01-24 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US6720334B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Urea substituted imidazopyridines
US6720422B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Amide substituted imidazopyridines
US6720333B2 (en) 2000-12-08 2004-04-13 3M Innovative Properties Company Amide substituted imidazopyridines
US6696465B2 (en) 2000-12-08 2004-02-24 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6953804B2 (en) 2000-12-08 2005-10-11 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US6716988B2 (en) 2000-12-08 2004-04-06 3M Innovative Properties Company Urea substituted imidazopyridines
US6949649B2 (en) 2000-12-08 2005-09-27 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US7078523B2 (en) 2000-12-08 2006-07-18 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6921826B2 (en) 2000-12-08 2005-07-26 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US7968562B2 (en) 2001-11-29 2011-06-28 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US7299453B2 (en) 2001-12-20 2007-11-20 International Business Machines Corporation Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6924293B2 (en) 2001-12-21 2005-08-02 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
EP1545597A2 (en) * 2002-08-15 2005-06-29 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
EP1545597A4 (en) * 2002-08-15 2006-08-30 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
EP2269632A2 (en) 2002-08-15 2011-01-05 3M Innovative Properties Co. Immunostimulatory compositions and methods of stimulating an immune response
AU2003299863B2 (en) * 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US7112677B2 (en) 2002-09-26 2006-09-26 3M Innovative Properties Company 1H-imidazo dimers
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US8329197B2 (en) 2002-12-30 2012-12-11 3M Innovative Properties Company Ex vivo uses of immunostimulatory combinations
US10105426B2 (en) 2002-12-30 2018-10-23 Trustees Of Dartmouth College Immunostimulatory combinations
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US8835394B2 (en) 2003-03-25 2014-09-16 Medicis Pharmaceutical Corporation Treatment for basal cell carcinoma
US7696159B2 (en) 2003-03-25 2010-04-13 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007521317A (en) * 2003-08-14 2007-08-02 スリーエム イノベイティブ プロパティズ カンパニー Lipid-modified immune response modifier
EP2939693A1 (en) * 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1653959A4 (en) * 2003-08-14 2009-04-08 3M Innovative Properties Co Lipid-modified immune response modifiers
EP1653959A2 (en) * 2003-08-14 2006-05-10 3M Innovative Properties Company Lipid-modified immune response modifiers
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8802853B2 (en) * 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20090030030A1 (en) * 2003-12-29 2009-01-29 Bonk Jason D Arylalkenyl and arylalkynyl substituted imidazoquinolines
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9186400B2 (en) 2009-03-25 2015-11-17 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9504742B2 (en) 2009-03-25 2016-11-29 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010111485A1 (en) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US10722573B2 (en) 2009-03-25 2020-07-28 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2013013055A1 (en) 2011-07-21 2013-01-24 Rubigo Therapeutics, Inc. System for drug delivery and monitoring
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
EP4051270A4 (en) * 2019-10-29 2024-02-28 Prime Reach Trading Ltd 4-amino-imidazoquinoline compounds and use thereof
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis

Also Published As

Publication number Publication date
US20020193396A1 (en) 2002-12-19
CN1252070C (en) 2006-04-19
KR20030070049A (en) 2003-08-27
WO2002046190A2 (en) 2002-06-13
IL155884A0 (en) 2003-12-23
SK7122003A3 (en) 2003-11-04
TWI222972B (en) 2004-11-01
NZ526089A (en) 2004-11-26
JP2004521092A (en) 2004-07-15
MXPA03004975A (en) 2003-09-05
PL365995A1 (en) 2005-01-24
US20040092545A1 (en) 2004-05-13
CZ20031591A3 (en) 2003-11-12
US6670372B2 (en) 2003-12-30
ZA200305274B (en) 2004-10-18
AR035664A1 (en) 2004-06-23
HRP20030466A2 (en) 2004-06-30
NO20032596D0 (en) 2003-06-06
IL156044A0 (en) 2003-12-23
PL366330A1 (en) 2005-01-24
US20030212091A1 (en) 2003-11-13
NO20032452L (en) 2003-07-16
NZ526088A (en) 2004-12-24
PL365907A1 (en) 2005-01-10
AU3249702A (en) 2002-06-18
SK287732B6 (en) 2011-07-06
CZ20031561A3 (en) 2004-04-14
HRP20030463A2 (en) 2004-04-30
IL155950A0 (en) 2003-12-23
ATE353895T1 (en) 2007-03-15
HUP0600338A2 (en) 2006-08-28
HK1069166A1 (en) 2005-05-13
ES2260323T3 (en) 2006-11-01
WO2002046192A2 (en) 2002-06-13
SK7132003A3 (en) 2003-10-07
BR0116032A (en) 2006-02-21
US7612083B2 (en) 2009-11-03
ZA200305272B (en) 2005-01-26
JP2004515501A (en) 2004-05-27
AU2002239530B2 (en) 2006-09-28
PT1341791E (en) 2005-09-30
CN1479739A (en) 2004-03-03
CN1537111A (en) 2004-10-13
AU3951602A (en) 2002-06-18
CZ303462B6 (en) 2012-09-26
BR0116052A (en) 2006-02-21
NZ526087A (en) 2004-11-26
AU2002232497B2 (en) 2006-11-02
WO2002046193A3 (en) 2003-02-27
EP1341790B1 (en) 2007-02-14
CY1105586T1 (en) 2010-07-28
WO2002046191A3 (en) 2003-03-13
DK1343784T3 (en) 2006-07-10
SK6842003A3 (en) 2003-12-02
EE200300274A (en) 2003-10-15
WO2002046188A3 (en) 2003-03-13
HK1066005A1 (en) 2005-03-11
CN1247575C (en) 2006-03-29
JP4437189B2 (en) 2010-03-24
HRP20030461A2 (en) 2004-06-30
JP2004532810A (en) 2004-10-28
AU2002230618B2 (en) 2006-11-02
SK7152003A3 (en) 2003-09-11
TW584633B (en) 2004-04-21
US7132429B2 (en) 2006-11-07
DE60117859T2 (en) 2006-11-23
CZ20031592A3 (en) 2004-01-14
DK1341790T3 (en) 2007-06-04
DE60126645D1 (en) 2007-03-29
ZA200305275B (en) 2004-10-08
ES2281456T3 (en) 2007-10-01
AU3953002A (en) 2002-06-18
AU3248202A (en) 2002-06-18
CN1894244A (en) 2007-01-10
US20050148619A1 (en) 2005-07-07
DE60111076T2 (en) 2006-05-04
AR035667A1 (en) 2004-06-23
DE60111076D1 (en) 2005-06-30
WO2002046189A3 (en) 2003-03-20
AU2002239516B2 (en) 2006-11-09
CN1487939A (en) 2004-04-07
AU2002239517B2 (en) 2006-11-02
CZ20031562A3 (en) 2004-03-17
RU2315049C2 (en) 2008-01-20
RU2003116649A (en) 2005-02-10
AU3951702A (en) 2002-06-18
PL392462A1 (en) 2010-11-22
TWI293300B (en) 2008-02-11
IL156043A0 (en) 2003-12-23
JP2004529078A (en) 2004-09-24
ATE319711T1 (en) 2006-03-15
NO20032596L (en) 2003-06-06
NZ526106A (en) 2004-11-26
WO2002046188A2 (en) 2002-06-13
US6656938B2 (en) 2003-12-02
EE200300275A (en) 2003-10-15
EE200300270A (en) 2003-10-15
CA2436984A1 (en) 2002-06-13
CN1479738A (en) 2004-03-03
NO20032451L (en) 2003-07-16
NO20032595D0 (en) 2003-06-06
US20040077678A1 (en) 2004-04-22
US20040106640A1 (en) 2004-06-03
NO20032451D0 (en) 2003-05-28
JP2004523498A (en) 2004-08-05
NZ526105A (en) 2004-11-26
EP1339715A2 (en) 2003-09-03
PL366115A1 (en) 2005-01-24
EE200300268A (en) 2003-10-15
EP1341791B1 (en) 2005-05-25
KR20040047733A (en) 2004-06-05
DE60126645T2 (en) 2007-11-22
MXPA03005011A (en) 2003-09-05
RU2302418C2 (en) 2007-07-10
NO20032473D0 (en) 2003-05-30
CA2436846A1 (en) 2002-06-13
EP1341789A2 (en) 2003-09-10
SK7112003A3 (en) 2003-12-02
BR0116047A (en) 2003-09-30
CA2436980C (en) 2011-03-29
CN1297554C (en) 2007-01-31
NO20032473L (en) 2003-05-30
AU2002232482B2 (en) 2006-10-19
CN1253452C (en) 2006-04-26
CN1511155A (en) 2004-07-07
CA2436846C (en) 2010-11-16
WO2002046190A3 (en) 2003-07-17
US20050234088A1 (en) 2005-10-20
EP1341792A2 (en) 2003-09-10
DE60117859D1 (en) 2006-05-04
UA74852C2 (en) 2006-02-15
PL365883A1 (en) 2005-01-10
HK1064383A1 (en) 2005-01-28
RU2003116123A (en) 2004-11-20
MXPA03004972A (en) 2004-01-29
CZ295848B6 (en) 2005-11-16
HRP20030467B1 (en) 2009-04-30
EP1343784A2 (en) 2003-09-17
EP1343784B1 (en) 2006-03-08
HRP20030462A2 (en) 2004-04-30
AU3061802A (en) 2002-06-18
PT1341790E (en) 2007-05-31
KR20030070050A (en) 2003-08-27
RU2003116059A (en) 2005-02-10
RU2003116063A (en) 2004-12-10
BR0116026A (en) 2004-12-21
CA2431151A1 (en) 2002-06-13
AR035668A1 (en) 2004-06-23
NO20032452D0 (en) 2003-05-28
CA2436980A1 (en) 2002-06-13
PL207340B1 (en) 2010-12-31
HRP20030467A2 (en) 2004-04-30
BR0116470A (en) 2005-08-16
ATE296301T1 (en) 2005-06-15
IL155904A0 (en) 2003-12-23
WO2002046191A2 (en) 2002-06-13
US7049439B2 (en) 2006-05-23
EP1341790A2 (en) 2003-09-10
ZA200305270B (en) 2004-08-26
JP2004515500A (en) 2004-05-27
RU2308456C2 (en) 2007-10-20
MXPA03004973A (en) 2004-01-29
SK287264B6 (en) 2010-04-07
MXPA03005012A (en) 2003-09-05
US6953804B2 (en) 2005-10-11
KR20040023576A (en) 2004-03-18
US6683088B2 (en) 2004-01-27
WO2002046193A2 (en) 2002-06-13
US20030158192A1 (en) 2003-08-21
HUP0600600A2 (en) 2006-11-28
HUP0600605A2 (en) 2006-11-28
ES2242782T3 (en) 2005-11-16
HRP20030464A2 (en) 2004-06-30
HUP0400704A2 (en) 2004-06-28
ZA200305271B (en) 2004-10-08
AR035669A1 (en) 2004-06-23
PL361948A1 (en) 2004-10-18
AR035666A1 (en) 2004-06-23
IL155903A0 (en) 2003-12-23
WO2002046192A3 (en) 2003-02-13
KR20040028691A (en) 2004-04-03
CA2436983A1 (en) 2002-06-13
UA75622C2 (en) 2006-05-15
NO326159B1 (en) 2008-10-13
AR035665A1 (en) 2004-06-23
CA2430844A1 (en) 2002-06-13
NZ526086A (en) 2005-11-25
NO20032595L (en) 2003-06-06
JP2010031040A (en) 2010-02-12
BR0116464A (en) 2006-02-21
DK1341791T3 (en) 2005-09-19
HUP0400710A2 (en) 2004-06-28
ZA200305273B (en) 2004-10-08
SI1341790T1 (en) 2007-06-30
NO20032449L (en) 2003-05-28
NO20032449D0 (en) 2003-05-28
EE200300272A (en) 2003-10-15
SK7102003A3 (en) 2003-10-07
EP1341791A2 (en) 2003-09-10
CZ20031560A3 (en) 2004-05-12
EE200300271A (en) 2003-10-15
MXPA03004974A (en) 2003-09-05
KR20040028690A (en) 2004-04-03
RU2351598C2 (en) 2009-04-10
HUP0700062A2 (en) 2007-05-02
CZ20031563A3 (en) 2004-02-18
CY1106569T1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
US6670372B2 (en) Aryl ether substituted imidazoquinolines
US6677348B2 (en) Aryl ether substituted imidazoquinolines
AU2002239516A1 (en) Aryl ether substituted imidazoquinolines
US6664260B2 (en) Heterocyclic ether substituted imidazoquinolines
US6660747B2 (en) Amido ether substituted imidazoquinolines
US7276515B2 (en) Thioether substituted imidazoquinolines
AU2002230618A1 (en) Heterocyclic ether substituted imidazoquinolines
US20040102471A1 (en) Thioether substituted imidazoquinolines
AU2002232482A1 (en) Amido ether substituted imidazoquinolines
AU2002239517A1 (en) Sulfonamido ether substituted imidazoquinolines
AU2002232497A1 (en) Urea substituted imidazoquinoline ethers
EP1451187A1 (en) Amide substituted imidazopyridines
AU2002315009B2 (en) Thioether substituted imidazoquinolines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2003-500461

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 156043

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526105

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2430844

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004973

Country of ref document: MX

Ref document number: 6842003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020037007538

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20030462A

Country of ref document: HR

Ref document number: PV2003-1591

Country of ref document: CZ

Ref document number: 888/CHENP/2003

Country of ref document: IN

Ref document number: 2002239516

Country of ref document: AU

Ref document number: 018201725

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002547926

Country of ref document: JP

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 2001987282

Country of ref document: EP

Ref document number: 2003/05275

Country of ref document: ZA

Ref document number: 200305275

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2001987282

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1591

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037007538

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 526105

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526105

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: PI0116052

Country of ref document: BR